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African animal trypanosomosis or nagana is a tsetse fly-transmitted disease, caused by 
Trypanosoma congolense, T. vivax and to a lesser extent T. brucei brucei. The disease causes 
major losses in revenue in many livestock-producing African countries. The available control 
methods, including chemotherapeutic drugs and insecticidal spraying, have become 
environmentally unacceptable. Antigenic variation displayed by the parasites has hindered 
vaccine development efforts. In this context, rather than focusing solely on the parasite itself, 
efforts in vaccine development have shifted towards targeting pathogenic factors released by the 
parasites during infection.  
 
Congopain, the major cysteine protease of T. congolense, has been shown to act as a pathogenic 
factor in the disease process. Analysis of the immune response of trypano-tolerant cattle revealed 
that these animals have the ability to control congopain activity in vivo. Therefore, congopain is 
an attractive vaccine candidate. To test the protective potential of congopain, immunisation 
studies had been conducted in cattle using the baculovirus-expressed catalytic domain of 
congopain (C2) in RWL, a saponin-based proprietary adjuvant from SmithKline-Beecham. 
Immunised animals were partially protected against a disease caused by an infection with T. 
congolense. Unfortunately, subsequent attempts to reproduce these results were disappointing. It 
was hypothesised that this failure could be due to the different expression system (P. pastoris) 
used to produce the antigen (C2), or the different adjuvant, ISA206 (Seppic), used, thus hinting 
towards an epitope presentation problem. Congopain had been shown to dimerise at 
physiological pH in vitro. Sera from trypano-tolerant cattle preferentially recognised the dimer 
conformation, advocating for protective epitopes to be dimer associated. For that reason, the 
present study aimed at improving the antigenicity of congopain through firstly, the elucidation of 
the protective epitopes associated with the dimer, secondly, the determination of the 3-D 
structure of the protease in order to map protective epitopes to later design mimotopes, and 
thirdly improve the delivery of congopain to the immune cells while maintaining the 
conformation of the protease by using a molecular adjuvant, BiP.  
 
A dimerisation model was proposed, identifying the amino acid residues forming the 




the dimerisation motif were mutated by PCR-based site-directed mutagenesis to generate 
mutants with different dimerisation capabilities. The congopain mutants were expressed in yeast 
and their dimerisation capability was assessed by PhastGel® SDS-PAGE. The mutations altered 
both the electrophoretic mobility of the mutants and their enzymatic characteristics compared to 
wild-type congopain. This advocated for the involvement of these amino acid residues in the 
dimerisation process, although they seem not to be the only partakers.  
 
Wild-type C2 and mutant forms of C2 were heterologously expressed in P. pastoris and purified 
to crystallisation purity levels. Crystallisation of these proteins is currently underway, but the 
results are still unknown. While awaiting the crystallisation results, in silico homology modelling 
was employed to gain insight into the 3-D structure, using cruzipain crystal structure as a 
template. The modelled 3-D structure of congopain followed the common framework of 
cathepsin L-like cysteine proteases. Due to time constraints and awaiting the crystal-derived 3-D 
structure, the 3-D model of congopain was not exploited to design mimotopes with the potential 
to provide protection against the disease.  
 
As it was shown that protective epitopes are likely to be dimer-specific, maintaining the native 
conformation of congopain is essential for stimulating a protective immune response in animals. 
Chemically formulated adjuvants usually contain high salt concentration, at acidic or basic pH, 
thus might change the conformation of the protease. Adjuvants capable of efficiently delivering 
the antigen to immune cells while maintaining the conformation of the protease were sought. 
Proteins belonging to the HSP70 family are natural adjuvants in higher eukaryotes. A protein 
belonging to the HSP70 family was previously identified in T. congolense lysates and is 
homologous to mammalian BiP. Congopain was genetically fused with T. congolense BiP in 
order to improve antigen delivery and production of congopain activity-inhibiting antibodies. 
The chimeric proteins were successfully expressed in both bacteria and yeasts. The low yields of 
recombinantly expressed chimeras in yeast and problems associated with renaturation and 
purification of bacteria-expressed chimeras prevented immunisation studies in mice. However, 
the groundwork was laid for producing BiP-congopain chimeras for use in an anti-disease 
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Bis-Tris  2-bis(2-hydroxyethyl)amino-2-(hydroxymethyl)-1,3-propanediol 
BMGY  buffered media glycerol yeast extract 
BMM   buffered minimal media 
BSA   bovine serum albumin 
C2   catalytic domain of congopain 
CP   cysteine protease 
dNTP   deoxynucleotide triphosphate 
DTT   dithiothreitol 
E-64   trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane 
g   relative centrifugal force 
HRPO   horse radish peroxidase 
IgG   immunoglobulin G 
IPTG   isopropyl-beta-D-thiogalactopyranoside 
kDa   kilodalton 
MEC   molecular exclusion chromatography 
Mr   relative molecular mass 
OD600   optical density at 600 nm 
ORF   open reading frame 
PAGE   polyacrylamide gel electrophoresis 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PEG   polyethylene glycol 
RT   room temperature 
SAP   shrimp alkaline phosphatase 




TBS   tris buffered saline 
TPP   three phase partitioning 
VAT   variable antigen type 
VSG   variable surface glycoprotein 
YNB   yeast nitrogen base 
YPD   yeast peptone dextrose media 








1.1 African animal trypanosomosis 
African animal trypanosomosis is a wasting disease that severely limits livestock production in 
the developing world. It is caused by protozoan parasites of the genus Trypanosoma, generally 
transmitted by tsetse flies. The disease is estimated to cost US$ 1.3-5 billion per annum in Africa 
alone (Kristjanson et al., 1999; Shaw, 2004). Moreover, a third of the African continent is 
infested with tsetse flies, preventing the use of a large area of land for livestock farming 
(Kristjanson et al., 1999). Distribution of the trypanosomes coincides with the presence of the 
tsetse fly vector in Africa while the disease also occurs in Asia and South America, transmitted 
by biting flies (Stevens and Brisse, 2004).  
 
Current methods used to control trypanosomosis are inadequate. The available trypanocidal 
drugs (isometamidium, diaminazene aceturate and homidium) have been on the market for over 
five decades. It is thus not surprising that drug-resistant parasites have been reported in Africa 
(Anene et al., 2001; Geerts et al., 2001). Although control of the tsetse fly vector using 
insecticidal spraying and bush clearing was effective, their negative impact on the environment is 
unacceptable. Hence, there is an urgent need to develop new methods to control African animal 
trypanosomosis. 
 
1.1.1 Pathogenesis of African animal trypanosomosis 
Nagana (caused by T, congolense, T. vivax and to a lesser extent T. b. brucei), surra (caused by T. 
evansi in equines, water buffaloes and camels) and dourine (caused by T. equiperdum in horses) 
represent the three disease states caused by pathogenic trypanosomes. The geographical location 
of a trypanosome isolate seems to contribute to varied pathogenicity between parasite stocks of 
the same species. Some T. vivax isolates from East Africa cause an acute haemorrhagic disease in 
cattle, while the West African isolates result in milder non-haemorrhagic disease (Taylor and 
Authié, 2004). Furthermore, infection with haemorrhagic strains of T. vivax seems to be more 
pathogenic to cattle than T. congolense and T. b. brucei as indicated by high parasitemia (108 




Generally, bovine trypanosomosis is characterised by three successive stages: acute, 
asymptomatic/stabilisation and chronic stages that are greatly influenced by the host, 
trypanosome species and strain of infecting trypanosome (Taylor and Authié, 2004). The acute 
phase of the disease is characterised by a severe drop in haematocrit value (packed cell volume, 
PCV), haemoglobin concentration and red blood cells numbers. Clinical signs of acute bovine 
trypanosomosis are anaemia, enlargement of the spleen and the lymph nodes, weakness, lethargy, 
loss of condition, abortion and reduced milk production. Anaemia is the major cause of death in 
animals infected with T. congolense and T. vivax (Taylor, 1998). The animals that survive the 
acute phase stabilise the infection after 6-8 weeks and begin a slow recovery process. These 
animals enter into a chronic phase of infection that is characterised by cachexia, intermittent 
parasitemia, stunting, wasting and infertility. Finally, the animals die of the chronic infection due 
to congestive heart failure, prolonged anaemia, myocardial damage and increased vascular 
permeability (Taylor and Authié, 2004).  
 
1.1.2 Trypanotolerance 
Certain breeds of cattle have long been recognised to possess a genetic ability to survive and 
remain productive in tsetse-infested areas without chemotherapeutic treatment. These animals are 
termed trypano-tolerant and include the Bos taurus N’Dama, Baoulé, Muturu and Dahomey 
breeds, found mainly in West Africa (Authié, 1994; d'Ieteren et al., 1998; Taylor, 1998; Murray 
et al., 2004). The B. indicus (Zebu) species of cattle is susceptible to infection with trypanosomes 
as indicated by their failure to survive in tsetse-infested areas without treatment. Trypano-
tolerant cattle are able to control anaemia and parasitemia (d'Ieteren et al., 1998). Many species 
of wild herbivores such as the Cape buffalo are resistant to an infection with trypanosomes as 
indicated by their ability to survive in tsetse infested areas (Black et al., 2001). These animals 
serve as reservoirs of parasites that infect domestic animals (and humans).  
 
1.2 Diagnosis of African animal trypanosomosis 
Survival of infected cattle relies on rapid and specific diagnosis of the disease in the field. The 
efficacy of trypanocidal drugs depends greatly on the stage of infection the animal is at during 




response to trypanocidal drugs, while cattle treated in the late chronic phase of infection take 
much longer to respond to the treatment or die of it (Taylor and Authié, 2004).  
 
Diagnosis of African trypanosomosis relies mainly on clinical and parasitological methods, 
although serological and molecular tools are becoming available. The clinical methods are most 
relevant in field conditions, where physical examination is often the sole means of diagnosis 
available (Eisler et al., 2004). The symptoms displayed by trypanosome infected cattle are not 
characteristic, thus, may often be mistaken for one of many other tropical diseases. 
 
Parasitological methods of diagnosis involve direct visualisation of the parasites in the blood of 
infected animals using microscopic techniques. Besides the low sensitivity of this technique, 
especially in detecting parasites in the chronic phase of infection, the high level of morphological 
similarity exhibited by different trypanosome species makes differential diagnosis difficult. 
Therefore, serological methods for detection of circulating parasite antigens or specific 
antibodies against parasite antigens, and molecular tools, have been developed. Serological 
methods include indirect immunofluorescent antibody (IFA) tests, direct and indirect enzyme-
linked immunosorbent assays (ELISAs), and complement fixation tests. Species-specific 
diagnosis was not achieved with the IFA test since cross-reactivity was detected between T. 
congolense, T. vivax and T. brucei (Eisler et al., 2004). However, direct and indirect ELISA 
allowed for species-specific diagnosis depending on the antigen used in the ELISA setup (Eisler 
et al., 1998). Molecular biology tools used to diagnose bovine trypanosomosis include the use of 
radioactively labelled DNA probes and polymerase chain reaction (PCR). Between the two 
methods, PCR is the best since it allows for species-specific diagnosis of the parasites and is 
more sensitive than radioactively labelled DNA probes (Desquesnes and Davila, 2002).  
 
1.3 Control of trypanosomosis 
1.3.1 Tsetse control 
Control of tsetse flies using conventional methods, including aerial and ground spraying with 
insecticides, insecticide-treated cattle, odour-baited traps and bush-clearing, is very effective 
(Allsopp and Hursey, 2004; Vale and Torr, 2004, 2005). In Nigeria, insecticides were used to 




Although insecticides such as DTT and benzene hexachloride are very effective against the 
vector, their application was regarded as unsound due to their negative impact on the 
environment (Allsopp and Hursey, 2004). Less conventional, the Pan-African Tsetse and 
Trypanosomosis Eradication Campaign (PATTEC) launched a large scale tsetse control project 
funded by the African Development Bank. The project was aimed at using the sterile insect 
technique as was done in the USA to eradicate the screwworm fly, and in Zanzibar for Glossina 
austeni to eradicate the tsetse fly populations (Torr et al., 2005). However, there are serious 
doubts about the feasibility of the project over the large area of land infested with tsetse flies 
(Rogers and Randolph, 2002). 
 
1.3.2 Chemotherapy 
The administration of trypanocidal drugs still remains the principal method for controlling 
African animal trypanosomosis. There are approximately 35 million doses of trypanocidal drugs 
administered each year by farmers (Holmes et al., 2004). Chemotherapeutic treatment of cattle 
relies on three trypanocidal drugs: Samorin® (isometamidium chloride), Novidium® (homidium 
chloride) and Berenil® (diaminazene aceturate). The exact mechanism of action of these drugs 
has not been fully elucidated; they are thought to target kinetoplast DNA (Holmes et al., 2004). 
Trypanocidal drugs such as pentamidine, diminazene and suramin have been shown to act by 
inhibiting oligopeptidase B, a trypanosomal serine protease and a pathogenic factor (Morty et al., 
1998). These trypanocidal drugs are supplied by European pharmaceutical companies at high 
cost. However, generic forms of the drugs have been available in the African market for a long 
time, but doubts surrounding their quality have often hindered their application by farmers 
(Holmes et al., 2004).  
 
Emergence of drug-resistant parasites has been reported in over thirteen countries in Africa 
(Geerts et al., 2001; Holmes et al., 2004). There is thus an urgent need to develop new 
trypanocidal drugs for the treatment of African animal trypanosomosis. However, pharmaceutical 
companies are not interested in pursuing the development of new trypanocidal drugs due to the 
unprofitability of the market. Studies have revealed that the total market value of trypanocidal 
drugs for farmers is approximately US$ 30 million per year, while the cost of developing and 








Emergence of drug-resistant parasites has been the impetus for research towards the development 
of an effective vaccine for the disease. Antigenic variation displayed by trypanosome species 
precludes vaccination with trypanosomes against bovine trypanosomosis (Donelson, 2003). 
Therefore, research has shifted towards targeting accessible invariant antigens of the parasites. 
Flagellar pocket antigens derived from T. b. rhodesiense protected cattle against infection with T. 
congolense and T. vivax (Mkunza et al., 1995). Immunisation studies conducted in mice using 
native tubulin isolated from T. brucei, provided complete protection against an infection with T. 
brucei and partial protection against T. congolense and T. b. rhodesiense (Lubega et al., 2002). 
Similar results were obtained using recombinant tubulin from T. evansi (Li et al., 2007).  
 
The concept of an anti-disease vaccine was first developed for malaria (Playfair et al., 1990). 
This concept is based on the assumption that pathogenic factors that are either secreted or 
released by dead parasites rather than the parasite itself cause the disease. Thus, antibodies 
inhibiting the activity of pathogenic factors are expected to provide protection against the disease 
(Playfair et al., 1990; Playfair et al., 1991; Authié, 1994; Schofield, 2007). A cysteine protease, 
named congopain, has been implicated in the pathology of trypanosomosis caused by infection 
with T. congolense. Immunisation experiments conducted with congopain in cattle provided 
partial protection against T. congolense infection (Authié et al., 2001). This suggested possible 
involvement of further pathogenic factors in bovine trypanosomosis. Identification of such 
factors and their inclusion in a multi-component vaccine should provide better protection against 
an infection with T. congolense.  
 
1.4 Trypanosomes 
Trypanosomes are protozoan parasites of medical and veterinary importance. Sir David Bruce 
demonstrated their involvement in an outbreak of nagana in the Zululand region of South Africa 
in 1894, that was responsible for the death of many cattle (Duggan, 1977). The tsetse transmitted 




trypanosomosis in sub-Saharan Africa (Taylor, 1998; Stevens and Brisse, 2004). However, T. 
vivax is endemic in Central and South America, where the parasite is mechanically transmitted 
by biting flies (Otte et al., 1994). The non-tsetse transmitted T. evansi is widespread in sub-
Saharan Africa, South America, Asia and has been reported in places as remote from the tropics 
as France and Australia (Payne et al., 1991; Franke et al., 1994). The infectivity of trypanosomes 
is not limited to cattle; they infect a wide range of domestic animals including horses, camels, 
sheep, goats, dogs and pigs (Stevens and Brisse, 2004). Trypanosoma b. gambiense and T. b. 
rhodesiense are the two sub-species of trypanosomes infective to humans, causing sleeping 
sickness or human African trypanosomosis (Stevens and Brisse, 2004). Trypanosoma cruzi 
occurs in South America and causes Chagas’ disease in humans (Schmidt and Roberts, 1989; 
Stevens and Brisse, 2004).  
 
1.4.1 Classification of trypanosomes 
The classification of trypanosomes of medical and veterinary importance is provided in Fig. 1.1. 
African trypanosomes belong to the order Kinetoplastida, characterised by the presence of a 
kinetoplast at the base of the flagellum that contains 20% of the total parasite DNA, and a single 
flagellum extending from the flagellar pocket, as an attached undulating membrane (El-Sayed et 
al., 2000; Stevens and Brisse, 2004). The family Trypanosomatidae is subdivided into two 
genera, Trypanosoma and Leishmania. Genus classification is based on morphological features 
and host range of the parasites (Momen, 2001).  
 
The Trypanosoma genus is divided into two sections that develop in different parts of the vector. 
In the section Stercoraria, the trypanosomes develop in the hindgut of the vector and are 
transmitted in faeces by the vector. In section Salivaria, the trypanosomes are inoculated with 
saliva into the host via the mouth parts of the vector. In addition, salivarian trypanosomes can 
change their surface coat, a phenomenon known as antigenic variation since they contain and 
express variable surface glycoprotein (VSG) genes (Donelson, 2003; Stevens and Brisse, 2004). 
At present, the Salivaria section contains four subgenera, viz. Duttonela, Nannomonas, 
Trypanozoon, and Pycnomonas. The Nannomonas subgenus contains three species: T. 
congolense, T. godfreyi and T. simiae. T. congolense is the most common pathogen of ruminants 
in Africa, while T. godfreyi and T. simiae are pathogenic to pigs (Stevens and Brisse, 2004). 




developmental cycle in the tsetse vector. T. congolense has been further divided into three groups 
based on the group of vector that carries the parasites. The three groups are savannah, 
riverine/forest and Kenya (Kilifi) coast. Unlike the other species belonging to the Nannomonas 
subgenus, T. congolense can be easily cultured in laboratory rodents (Stevens and Brisse, 2004).  
 
1.4.2 Biology of African trypanosomes 
1.4.2.1 Morphology and genomic organisation 
T. congolense (Fig. 1.2), is a unicellular, small and short trypanosome of between 8 and 24 µm in 
length. The parasite possesses a single flagellum that extends from the flagellar pocket to the 
posterior end of a parasite (Stevens and Brisse, 2004). T. congolense lacks a free flagellum, thus 
can be easily distinguished from T. brucei that possesses a free flagellum (Stevens and Brisse, 
2004). The parasite contains a Golgi apparatus, sac of secretion and a secretory reticulum 
(Stevens and Brisse, 2004). 
 
The kinetoplast and the nucleus contain the genomic DNA of the parasite. The highly unusual 
kinetoplast consists of a network of interlinked maxicircles and minicircles (El-Sayed and 
Donelson, 1997; Ersfeld et al., 1998; El-Sayed et al., 2000). The genome of T. brucei has been 
completely sequenced (www.sanger.ac.uk/Project/T.brucei). Although the genomes of T. 
congolense and T. vivax have not yet been completely sequenced, extrapolations from the 
genome of T. brucei are informative (Melville et al., 2004). The nuclear genome of T. brucei is 
approximately 35 Mb in size, roughly the same size as the genomes of Plasmodium falciparum, 
Leishmania major and T. cruzi (Melville et al., 2004). By comparison, the nuclear genome of 
Saccharomyces cerevisae is 12 Mb and contains 6 000 genes, while the Caenorhabditis elegans 
genome is 97 Mb with 19 000 genes (Mewes et al., 1997). Hence, the T. brucei genome is 
expected to harbour 12 000 genes with 50% of the genes coding for proteins involved in 
housekeeping (El-Sayed and Donelson, 1997).  
 
1.4.2.2 Antigenic Variation 
The membrane of bloodstream form trypanosomes is covered by a variant surface glycoprotein 




the most exposed, immunodominant antigen that is recognised by the host’s immune system. 
However, the parasite possesses a genetic capacity to alter the VSG coat by a process known as 
antigenic variation (Barry and McCulloch, 2001; Vanhamme et al., 2001). Each distinct VSG 
coat is termed variant antigen type (VAT). Although anti-VSG antibodies targeting a particular 
VAT are able to modulate parasitemia, trypanosomes expressing a different VAT evade the 
host’s immune response, giving rise to a new wave of parasitemia. Therefore, trypanosome 
infection is characterised by fluctuations (waves) of parasitemia indicating a different VAT on 
the surfaces of the parasites. Expression of VSG genes occurs by duplication of the usually non-
transcribed regions of a minichromosome into transcriptionally active subtelomeric regions 
(Barry et al., 2005). 
 
Immunisation of cattle with irradiated trypanosomes or purified VSG provides protection against 
the same VAT only (Morrison et al., 1982; Wells et al., 1982). Antigenic variation exhibited by 
trypanosomes hence prevents the development of a VSG-based vaccine for bovine 
trypanosomosis.  
 
1.4.3 Life cycle of African trypanosomes 
African trypanosomes are generally transmitted by the bite of a tsetse fly (Glossina spp). Both 
male and female tsetse flies transmit the parasites (Aksoy, 2003). At present, there are 23 species 
and eight subspecies of the Glossina genus which are divided into three groups: fusca (forest), 
palpalis (riverine) and morsitans (savannah) (Uilenberg, 1998). 
 
T. congolense, T. vivax and T. brucei spend part of their developmental cycle in the tsetse fly 
vector and part in the mammalian host (Fig. 1.3). The life cycle begins when a tsetse fly 
transmits non-dividing metacyclic forms of the parasites with saliva during a bloodmeal to its 
mammalian host. This causes swelling of the skin at the bite site, known as the chancre 
(Naessens, 2006). The parasites migrate via the lymphatic vessels to the local lymph nodes and 
from there into the bloodstream of the host, where they differentiate into rapidly dividing short 
bloodstream forms. The bloodstream form parasites are taken up by the tsetse fly vector as it 
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Figure 1.2. The general morphological features of Trypanosoma congolense in its bloodstream form stage 
(Vickerman, 1969) 
 
Upon ingestion by the tsetse fly, the parasites enter the midgut that contains proteases (Sbicego et 
al., 1999; Roditi and Lehane, 2008). Concurrent with the transformation of bloodstream form 
parasites to procyclic forms, is a change in energy metabolism, crucial for the survival of the 
parasites in the vector (Aksoy, 2003). The procyclic forms transform into the epimastigote forms 
by removing their variable surface coat in the proboscis of the vector. The epimastigote forms 
migrate to the salivary glands where they become the infective metacyclic forms. In contrast, the 
entire life cycle of T. vivax occurs in the proboscis of the vector (Matthews et al., 2004).  
 
1.5 Proteases 
Proteases are a group of enzymes that possess the ability to catalyse the hydrolysis of proteins 
into peptides and free amino acids (North et al., 1990). Hydrolysis of protein substrates occurs in 
the active site that is usually located in a groove on the surface of the enzyme. Amino acid 
residues lining the active site groove dictate the specificity of the enzyme for a particular 




substrate are designated P1, followed by P2, P3 etc., while P1’, P2’ etc. describe amino acid 
residues C-terminal of the scissile bond (Fig. 1.4). The corresponding sites on the protease 




Figure 1.3. Life cycle of T. congolense showing the different morphological stages present in both the vector 





   
Figure 1.4. Schematic diagram showing the specificity of the protease for the substrate (Sajid and McKerrow, 
2002).  
 
Proteases have been grouped into five major classes based on the mechanism of catalysis; viz. 
cysteine, aspartic, serine, metallo and threonine proteases (Rawlings and Barrett, 1999). There 
are a few proteases for which the catalytic mechanism has not been elucidated. Proteases play 
different roles within cells or organisms. Some proteases are very specific for their substrate, thus 
performing highly specialised roles while others, such as the lysosomal cysteine proteases, are 
active against a wide range of protein substrates.  
 
1.5.1 Cysteine proteases 
Cysteine proteases form a group of enzymes that is widely distributed amongst organisms. The 
cysteine proteases are classified into clans, which are further divided into families based on 
sequence similarity, presence of inserted peptide loops and substrate specificity. Clan CA 
contains two families, i.e. family C1 that contains the papain superfamily of cysteine proteases 
and family C2 that contains calpain-like cysteine proteases (Sajid and McKerrow, 2002). Family 
C1 enzymes are the most abundant in living organisms (Turk et al., 2000).  
 
Clan CA enzymes are characterised by a catalytic triad consisting of C25, H159 and N175 (papain 
numbering). This group of enzymes is completely inhibited by the irreversible inhibitor L-trans-




by the S2 pocket where a hydrophobic residue is preferred. Most enzymes belonging to this group 
are located in the lysosomal compartment such as mammalian cathepsins L and B or are secreted 
(Turk et al., 2000; Turk et al., 2001). Thus, lysosomal cysteine proteases are expected to be 
optimally active in the acidic pH range. However, some mammalian cathepsin L have also been 
shown to be highly active in the extracellular matrix where the pH is neutral (Dehrmann et al., 
1995). 
 
1.5.2 Parasite cysteine proteases 
Cysteine protease activity has been demonstrated in many protozoan parasites including Fasciola 
hepatica (Prowse et al., 2002), Entamoeba histolytica (Quintas-Granados et al., 2009), L. 
mexicana (Sanderson et al., 2000), T. cruzi (Martinez et al., 1991), T. congolense (Mbawa et al., 
1992), Toxoplasma gondii (Huang et al., 2009) and Trichobilharzia regenti (Dolečková et al., 
2009). These cysteine proteases are closely related to papain and mammalian cathepsins L and B 
as indicated by their enzymatic characteristics and amino acid sequence identity (Sajid and 
McKerrow, 2002). Lysosomal cysteine proteases of protozoan parasites play an important role in 
intracellular protein degradation, invasion of host cells and stimulation of the host immune 
system (Klemba and Goldberg, 2002; McKerrow et al., 2006). Cysteine proteases of protozoan 
parasites are the major virulence factors implicated in the disease process (Mottram et al., 1996; 
Alexander et al., 1998; McKerrow et al., 1999; Mottram et al., 2004). 
 
Expression of cysteine proteases by parasites is developmentally regulated. Mbawa et al. (1991a) 
showed that levels of expression of a major cysteine protease by T. congolense, T. brucei and T. 
vivax changes from one life cycle stage to another. Importantly, cysteine protease activity was 
observed to be highest in mammalian-infective stages of the parasites (metacyclics and 
bloodstream forms), thus, it was presumed that cysteine proteases may play a crucial role in host-
parasite interactions (Mbawa et al., 1991a; Mbawa et al., 1992). For these reasons, parasite 
cysteine proteases have become targets for the development of new inhibitors with potential 
chemotherapeutic use (McKerrow et al., 1999).  
 
Cysteine protease activity of T. brucei, T. congolense and T. cruzi is located in lysosomal 
organelles (Mbawa et al., 1991b; Cazzulo et al., 2001). Cysteine protease activity of T. 




1991b; Cazzulo et al., 2001). This extracellular location suggests a role for these proteases in the 
disease process. It is important to elucidate the biochemical characteristics of these enzymes in 
order to design and develop effective inhibitors or vaccines against the pathogenic effects of 
trypanosome infection.  
 
1.5.3 Cysteine proteases of T. congolense 
1.5.3.1 Congopain 
A cysteine protease of T. congolense was purified from bloodstream form parasite lysates using 
thiopropyl-Sepharose and was named trypanopain-Tc (Mbawa et al., 1992). Trypanopain-Tc was 
shown to cleave the synthetic substrate Z-Phe-Arg-AMC. In a similar independent study, a 33 
kDa antigen was isolated from T. congolense bloodstream form lysates using cystatin affinity 
chromatography and monoclonal antibody immunoaffinity chromatography (Authié et al., 1992). 
Analysis of enzymatic characteristics of the 33 kDa antigen revealed features similar to 
trypanopain-Tc. This led to the conclusion that trypanopain-Tc and the 33 kDa antigen are one 
and the same molecule, later named congopain (Authié, 1994).  
 
Congopain (Fig. 1.5) consists of a pre-region, a pro-region, a catalytic domain that contains the 
active site residues and an unusual C-terminal extension that is linked to the catalytic domain via 
a polyproline hinge region (polythreonine in cruzipain) (Fish et al., 1995; Chagas et al., 1997). 
The pre-region or signal peptide of congopain is hydrophobic and targets the proenzyme to the 
endoplasmic reticulum. The pro-region of the protease inhibits activity of the parent enzyme and 
also plays a crucial role in the proper folding of the enzyme (Vernet et al., 1995; Lalmanach et 
al., 1998). The inhibitory effect of the proenzyme was narrowed down to a pentapeptide 
“YHNGA” that was shown to specifically inhibit cruzipain and congopain but not mammalian 
cathepsins L and B and could form the basis of the development of new inhibitory drugs 






Figure 1.5. Schematic representation of the full-length congopain structure (Fish et al., 1995). The protease is 
composed of a signal peptide, a propeptide, a catalytic domain, polyproline hinge region, and a unique C-terminal 
domain. 
 
The zymogen form of congopain is converted into a mature, active enzyme through autocatalytic 
cleavage of the proregion at acidic pH (Boulangé et al., 2001; Serveau et al., 2003). Processing 
of the proregion is greatly influenced by ionic strength and the presence of polyamines (Serveau 
et al., 2003). Furthermore, processing of procongopain was shown to occur at pH 8.0 in the 
presence of dextran sulfate, an unusual feature among papain-like enzymes (Serveau et al., 
2003). The presence of procongopain in the plasma of infected cattle and the activity of the 
protease at neutral pH suggest extracellular processing of procongopain to the active form in the 
presence of blood vessel glycosaminoglycans (Serveau et al., 2003). This has serious 
implications for host-parasite relationships since congopain has been identified as a potential 
pathogenic factor in the disease process.  
 
Congopain, like mammalian cysteine proteases, is activated by reducing agents such as 
dithiothreitol (DTT), L-cysteine and 2-mercaptoethanol (Mbawa et al., 1992). The protease is 
inhibited by E-64, cystatin, T-kininogens and peptide diazomethane (Mbawa et al., 1992; Chagas 
et al., 1997; Lalmanach et al., 2002). Congopain has specificity for bulky, hydrophobic residues 
such as phenylalanine or the artificial analogue cyclohexylalanine at the P2 position (Lecaille et 
al., 2001). This specificity is conferred by the presence of leucine at position 205 at the bottom of 
the S2 pocket rather than glutamate in cruzipain (Lecaille et al., 2001). Thus, congopain has a 
higher specificity for Z-Phe-Arg-AMC than Z-Arg-Arg-AMC (Mbawa et al., 1992; Chagas et 
al., 1997). Native congopain has higher affinity for Z-Phe-Arg-AMC than the catalytic domain 
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Table 1.1. Kinetic characterisation of congopain and C2 (Boulangé et al., 2001). 
Enzyme Km Vmax kcat kcat/Km
(µM) pmol.s-1.µg-1 (s-1) (µM-1.s-1)
Congopain 4.8 229 21.8 4.5
C2 13.5 1.96 4.9 0.36
 
 
Analysis of the immune response of trypano-tolerant N’Dama cattle revealed that these animals 
possess an improved ability to mount a prominent IgG response against congopain when 
compared to trypano-susceptible Boran cattle (Authié et al., 1993b). This was further supported 
by data obtained from tests conducted using F1 crosses between N’Dama and Boran cattle 
(Taylor, 1998). The study revealed that a correlation exists between a degree of resistance to the 
disease and production of anti-congopain IgG by an infected animal (Taylor, 1998).  
 
Congopain has been shown to be circulating in the bloodstream of T. congolense-infected 
animals (Serveau et al., 2003). Since the protease was shown to be processed at neutral pH, it 
was suggested that cysteine proteases play a crucial role in the disease process. An immunisation 
challenge experiment was conducted in cattle using two recombinant isoforms of congopain (C1 
and C2) (Authié et al., 2001). The immunised cattle were challenged with T. congolense 
infection and the effects of immunisation on anaemia and immunosuppression were examined. 
Animals were partially protected from the disease even though the cattle developed acute 
anaemia during early stages of infection (Authié et al., 2001). Moreover, animals produced a 
prominent IgG response to native congopain and to VSG following challenge (Authié et al., 
2001). Therefore, inhibition of congopain activity by antibodies induced by immunisation might 
contribute to resistance to the disease.  
 
1.5.3.2 Dimerisation of congopain 
The catalytic domain of congopain (C2) has been expressed in Pichia pastoris (Boulangé et al., 
submitted). Analysis of the recombinantly expressed protein by PhastGel® SDS-PAGE revealed 
dimerisation of congopain at physiological pH, an unusual feature amongst cathepsin L-like 
cysteine proteases. Dimerisation of congopain is a pH dependant phenomenon (Boulangé et al., 




of the protease as revealed by western blotting (Boulangé et al., submitted). It was hypothesised 
that protective epitopes are associated with the dimeric conformation of the protease. 
 
A dimerisation model was proposed based on the 3-D structure of cruzipain, that is always a 
monomer (McGrath et al., 1995) and cathepsin W that is a dimer (Brinkworth et al., 2000). The 
model identified a stretch of charged and uncharged amino acid residues that form salt bridges 
depending on pH to be involved in the dimerisation mechanism (Prof J. Hoebeke, IBMC, 
Strasbourg, France, personal communication). In congopain, K39 and E44 were identified to be 
crucial for the dimerisation of the protease, while R39 and D43 are essential for dimerisation of 
cathepsin W (Fig. 1.6). However, cruzipain, the monomeric form of the model, contains F39 and 
P44 (Fig. 1.6).  
 
Congopain    ( 38-45)   dimer pH>5 / monomer pH<5
Cruzipain    ( 38-45)   
Cathepsin W  ( 38-45)   










Figure 1.6. Schematic representation of the region thought to be responsible for the dimerisation of 
congopain. The congopain dimerisation model was proposed by Prof. J. Hoebeke (IBMC, Strasbourg, France, 
personal communication). 
 
At acidic pH, K39 and H43 are positively charged, while E44 is negatively charged. Thus, a salt 
bridge is formed between H43 and E44 resulting in formation of an α-helix that is poorly 
immunogenic (Prof. J. Hoebeke, IBMC, Strasbourg, France, personal communication). Under 
these conditions, the protease exhibits a monomeric conformation. However, at 
neutral/physiological pH, H43 is deprotonated while K39 is positively charged and E44 is 
negatively charged. Therefore, these residues form a salt bridge resulting in a β-sheet formation 
(Prof. J. Hoebeke, IBMC, Strasbourg, France, personal communication). In this state, the 
protease displays a dimeric conformation. Table 1.2 describes in detail the side chain charges that 






Table 1.2. Amino acid side chain charges determining the proposed monomer or dimer 
conformation in congopain (Prof. J. Hoebeke, IBMC, Strasbourg, France, personal 
communication). 
 
Protease         Residue     pKa          Charge     Monomer/   Charge         Monomer/
side chain   at pH 5     dimer            at pH 7         dimer
Congopain         K             10               +              +
H              6.0            +      monomer      No charge   dimer
E              3.8             - -
Cruzipain            F               - None          monomer      None           monomer
P               - None                               None
Cathepsin W       R              12.5           +               +
W              - None           dimer           None           dimer
D              3.9            - -  
 
1.5.3.3 Crystallisation of congopain. 
The crystal structure of congopain has not yet been elucidated. However, the catalytic domain of 
cruzipain, the congopain homologue in T. cruzi has been crystallised and its structure determined 
(McGrath et al., 1995). Congopain shares 68% sequence identity with cruzipain in its catalytic 
domain (Lecaille et al., 2001; Serveau et al., 2003). Thus, a 3-D structural model of congopain 
(Fig. 1.7) was constructed based on the crystal structure of cruzipain (Lecaille et al., 2001). 
Similarly to the structure of papain-like cysteine proteases, the model revealed that congopain 
consists of two domains: an α-helical L domain and an R domain comprised mainly of β-sheets 
(Lecaille et al., 2001). The catalytic triad consisting of C25, H159 and N175 (papain numbering) is 
buried in a cleft between the L and the R domains (Lecaille et al., 2001).  
 
Crystallisation of full-length cruzipain that includes its C-terminal domain has not been achieved. 
This is mainly due to the difficulty associated with recombinantly expressing a full-length 
enzyme to the quantities required for crystallisation (Alvarez et al., 2002). Heterologous 
expression of functionally active full-length congopain in P. pastoris revealed intensive self-




high level expression of truncated congopain devoid of the C-terminal domain was achieved in 
P. pastoris (Boulangé et al., submitted).  
 
  
Figure 1.7. Structure of the congopain catalytic domain based on sequence identity with cruzipain (Lecaille et 
al., 2001). The X-Ray crystallographic structure of cruzipain is represented in black and that of congopain is 
represented in grey. The catalytic domain (C25, H159 and N175, papain numbering) is located in the cleft between the L 
and the R domain. 
 
Immunisation of animals with recombinant congopain provided incomplete protection against a 
T. congolense infection (Authié et al., 2001). The inability of congopain to stimulate a protective 
immune response seems to be associated with its limited antigenicity. Protective epitopes 
recognised by sera from trypano-tolerant cattle are associated with the dimeric conformation of 
the protease (Boulangé et al., submitted). Therefore, it was important to study the effects of 
adjuvants in maintaining the appropriate conformation of the protease during immunisation and 
thereby stimulating high levels of antibodies that inhibit congopain activity.  
 
1.6 Adjuvants 
Subunit vaccines are increasingly used instead of live or attenuated vaccines (Wilson-Welder et 
al., 2008). Unlike live or attenuated vaccines that are potent stimulators of the immune system, 
subunit vaccines are poorly immunogenic and require frequent boosting (Singh and O'Hagan, 




enhancing molecules (adjuvants) gives rise to an inadequate immune response (Storni et al., 
2005).  
 
The major functions performed by adjuvants in immune stimulation include firstly a depot effect 
for the antigen, allowing for sustained release of an immunogen to the immune system, resulting 
in prolonged antigen presentation. Slow release of an antigen from the injection site allows for 
transport to the draining lymph nodes, where the antigen interacts with immune cells, resulting in 
antigen presentation to the T cells and B cells by MHC molecules (Storni et al., 2005). Oil-based 
adjuvants such as Freund’s incomplete adjuvant and aluminium salts are efficient at maintaining 
an antigen at the injection site. However, the toxicity of Freund’s adjuvant has prevented its 
application in human vaccine formulations (Singh and O'Hagan, 2003). 
 
Secondly, an adjuvant must specifically direct the antigen to the cells of the immune system. 
This activates both the innate and the adaptive immune response and stimulates the production of 
co-stimulatory molecules by antigen presenting cells (Storni et al., 2005; Wilson-Welder et al., 
2008). Cells of the innate immune response display pathogen-recognition receptors that interact 
with the pathogen-associated microbial patterns triggering an immune response (Fearon and 
Locksley, 1996). This feature is characteristic of adjuvants derived from microbial components 
such as pertussis toxin, lipopolysaccharide, CpG-rich motifs and lipid A (Schijns, 2000), as well 
as HSP70.  
 
Heat shock protein (HSP) expression is up-regulated in stressed cells indicating their role as 
chaperonins (Schijns, 2000; Robert, 2003). Heat shock proteins generated during necrotic but not 
apoptotic death of a cell bind peptides and present them to antigen presenting cells (Basu and 
Srivastava, 2000). This demonstrated the capacity of HSPs to act as natural adjuvants of the 
immune system (Suto and Srivastava, 1995). Thus, HSPs from different organisms have been 
extensively studied to elucidate their role in immune stimulation against infectious agents, 






1.6.1 Heat shock proteins 
Heat shock proteins are amongst the most conserved proteins in evolution (Robert, 2003; Gullo 
and Teoh, 2004). The capacity of the HSPs to protect the cell against various physical stressors 
(e.g. elevated temperatures, heavy metals, glucose deprivation, ischemia, cancer and microbial 
infections) is mediated by their ability to bind denatured proteins (Hartl, 1996; Bukau et al., 
2006).  
 
There is another group of heat shock proteins that is usually neglected by researchers, the 
constitutively expressed heat shock proteins that are expressed in unstressed normal cells 
(Pelham, 1986). These proteins play a pivotal role in “housekeeping”, particularly in 
transmembrane transport of proteins, degradation of unstable and misfolded proteins, prevention 
and dissolution of protein complexes, uncoating of clathrin coated vesicles and folding and 
refolding of proteins (Li and Srivastava, 2004; Saibil, 2008; Jonak et al., 2009). 
 
Heat shock proteins are classified into three major groups based on molecular mass, i.e. HSP90, 
HSP70 and HSP50-60, the later also called BiP (Gullo and Teoh, 2004). These groups of proteins 
can be further subdivided by localisation of the proteins within a cell (Table 1.3). The HSP70 
group contains three members: viz. HSP70, HSC70 and glucose regulated protein 78 (GRP78), 
the later also called BiP (immunoglobulin heavy-chain binding protein). The HSP70 and HSC70 
proteins are located within the cytosol while GRP78/BiP is located within the ER lumen (Gullo 
and Teoh, 2004). 
 
HSP70 family proteins are potent stimulators of the immune system against infectious agents and 
cancers (Harmala et al., 2002). Immunisation of mice with ovalbumin genetically fused to 
Mycobacterium tuberculosis HSP70 demonstrated the adjuvant potential of mycobacterial 
HSP70. The immunised mice produced an ovalbumin specific CD8+ T cells response within 
three days post immunisation (Harmala et al., 2002). Rico et al. (1998) demonstrated the 
adjuvant potential of L. infantum HSP70 fused to Escherichia coli maltose binding protein. L. 
infantum HSP70 induced a strong humoral and cellular immune response against bacterial 
maltose binding protein. These independent studies unequivocally demonstrated the adjuvanticity 





1.6.2 T. congolense immunoglobulin heavy-chain binding protein (BiP).  
A 69 kDa antigen was identified in T. congolense lysates through probing a western blot with 
sera from infected trypano-tolerant N’Dama cattle and trypano-susceptible Boran cattle (Authié 
et al., 1992). The antigen was recognised by sera of both infected cattle species. However, the 
infected tolerant and susceptible cattle produced different anti-69 kDa antibody isotypes. 
Differences in the isotypes characterising the immune responses of animals differing in 
susceptibility to trypanosomosis triggered interest into researching the diagnostic potential of the 
antigen and determining its nature through molecular cloning. The cDNA of the 69 kDa antigen 
had been cloned by immunoscreening and sequenced. Sequencing revealed that the 69 kDa 
antigen is a member of the HSP70 family with most identity to mammalian heavy-chain binding 
protein (BiP). A similar protein has been shown to be present in many protozoan parasites 
including T. brucei (Bangs et al., 1993), T. vivax and T. cruzi  (Boulangé and Authié, 1994) as 
well as Toxoplasma gondii (Kang et al., 2004). Trypanosomal BiP is expressed in all parasite life 
cycle stages (Boulangé and Authié, 1994).  
 
Table 1.3. Classification of heat shock proteins into three major groups (Gullo and Teoh, 
2004).  
Family member          Location within cell                     Function    
Hsp110                          Cytosolic                       Binds full length proteins   
GPR94                           ER lumen                       Substrate folding and stabilisation
GRP78                           ER lumen                       Molecular ratchet
Hsc70                             Cytosolic, nuclear          Protein folding
Hsp70                             Cytosolic, nuclear         Immunogenic for adaptive and
innate responses
Hsp60                             ER lumen                      Adjuvant property 
Hsp55                             ER                            Chaperone               
 
A 2.35 kb cDNA contains the complete BiP open reading frame encoding 653 amino acid 
residues (Boulangé and Authié, 1994). The ORF of T. congolense BiP had been successfully 




(Fig. 1.8) is composed of a localisation signal sequence, a highly conserved ATPase domain (44 
kDa), a hinge region with a protease sensitive site, a peptide binding domain (18 kDa) and a G/P 
rich C-terminal domain containing the trypanosome specific MDDL retention signal (Wang et 
al., 2002; Daugaard et al., 2007). The ATPase domain has two lobes with a deep cleft that binds 
ATP (Wang et al., 2002). The 18 kDa peptide binding domain consists of two subdomains 
composed of an antiparallel β-sheet sandwich that interacts with the substrate and an α-helical 















Figure 1.8. Heat shock protein 70 structure (Daugaard et al., 2007). The protein is composed of a localisation 
signal sequence, ATPase domain, peptide binding domain, variable region and the MDDL retention signal. 
 
T. congolense BiP has a high degree of identity with other members of the HSP70 family except 
in the C-terminal domain (Boulangé and Authié, 1994). The C-terminal region contains epitopes 
unique to T. congolense BiP and could therefore potentially be used in species-specific diagnosis. 
The diagnostic potential of T. congolense BiP has been explored (Boulangé et al., 2002). 
Different regions of BiP were cloned and heterologously expressed in a bacterial expression 
system. Dot-blot assays were conducted on recombinant proteins to identify protein regions 
recognised by monoclonal antibodies, rabbit anti-BiP antibodies and sera from infected and 
uninfected N’Dama cattle (Boulangé et al., 2002). Antibodies predominantly recognised epitopes 
located in the C-terminal region of the proteins (Boulangé et al., 2002). A C-terminal antigen 
was used in an indirect ELISA to detect anti-BiP antibodies from sera of infected and uninfected 
cattle. These experiments showed that the C-terminal antigen-based ELISA has limited 
sensitivity for detecting primary infections but accurately detected secondary infections 





1.6.2.1 Adjuvant property of heat shock protein 70 
The adjuvant potential of HSP70 of M. tuberculosis, L. infantum and T. cruzi have been widely 
documented (Suzue and Young, 1996; Rico et al., 1998; Planelles et al., 2002; Ge et al., 2006). 
Suzue and Young (1996) demonstrated the adjuvanticity of M. tuberculosis HSP70 fused with 
recombinant HIV p24 antigen. M. tuberculosis HSP70 elicited a strong humoral and cellular 
immune response against HIV p24 antigen. The capacity of HSP70 to stimulate the production of 
C-C chemokines by immune cells has been shown to be crucial for their adjuvanticity against a 
whole pathogen (Lehner et al., 2000). C-C chemokines play a role in attracting monocytes, B 
cells and T cells to the site of infection (Dieu et al., 1998). Moreover, chemokines signal for 
maturation of dendritic cells into professional APCs that migrate into the draining lymph nodes. 
In the lymph nodes, professional APCs interact with T cells and B cells resulting in a stronger 
cellular and humoral immune response (Lehner et al., 2000). Ge et al. (2006) conducted a study 
where mice were immunised with Japanese encephalitis virus (JEV) E-protein alone, 
mycobacterial HSP70 alone and E-protein fused to mycobacterial HSP70. Analysis of an 
immune response of mice revealed that mycobacterial HSP70 fused to E-protein elicited a 
stronger humoral and cellular immune response than E-protein or mycobacterial HSP70 alone. 
These results were corroborated by a study performed using foot and mouth disease virus 
(FMDV) antigens administered alone or fused with mycobacterial HSP70 (Su et al., 2007). Thus, 
covalent linkage of an antigen to the HSP70 molecule is a prerequisite for efficient stimulation of 
an immune response against an antigen.  
 
Studies were done to identify the domain of HSP70 responsible for the adjuvant function. Ge et 
al. (2006) compared an immune response of mice immunised with JEV E-protein fused to full-
length mycobacterial HSP70 and E-protein fused to the peptide binding domain of mycobacterial 
HSP70. The fusion protein consisting of E-protein and the peptide binding domain was more 
efficient at stimulating the immune response than E-protein fused to mycobacterial HSP70 (Ge et 
al., 2006). Furthermore, the E-protein-peptide binding domain fusion protein stimulated 
monocytes to produce IL-12, tumour necrosis factor-α (TNF-α) and enhanced the production of 
C-C chemokines (Ge et al., 2006). The ATPase domain of M. tuberculosis HSP70 plays a 
suppressive role in rats by inducing the production of IL-10 and TGF-α (Wendling et al., 2000; 
Wang et al., 2002). Therefore, it can be concluded that the peptide binding domain of HSP70 is 




The efficiency of HSP70 to stimulate an appropriate immune response seems to be associated 
with their capacity to be rapidly internalised by APCs especially macrophages and DCs 
following binding of HSP-peptide complexes to their receptors (Castellino et al., 2000).  
 
1.6.2.2 Receptor mediated endocytosis of HSP70-peptide complex 
Mycobacterium tuberculosis HSP70 has been shown to specifically bind to CD40 on the surface 
of APC and stimulates the production of chemokines (Wang et al., 2002). C40 plays a crucial 
role in T-cell dependant B-cell activation, differentiation and immunoglobulin-class switching 
(van Kooten and Banchereau, 1997). Lazarevic et al. (2003) generated CD40-/- mice and 
demonstrated that stimulation of these mice with mycobacterial HSP70 failed to activate APC or 
activate CD8+ and CD4+ T-cells. It can be concluded that CD40 is the major receptor for 
microbial HSP-peptide complexes on the surfaces of APCs (Lazarevic et al., 2003).  
 
Mammalian HSP70 has been shown to induce maturation of DCs through interaction with toll-
like receptor-4 (TLR-4), CD91 and LOX-1 (Asea et al., 2000; Basu and Srivastava, 2000). There 
is no evidence showing interaction of mycobacterial HSP70 with TLR-4 and CD91 receptors 
(Harmala et al., 2002).  
 
1.6.2.3 Mechanism of antigen presentation by HSP70 
The mechanism through which HSP70 induces an immune response has not been unequivocally 
elucidated. However, most researchers have proposed that HSP70 presents antigens to the APCs 
via a process known as cross-presentation or cross-priming (Suto and Srivastava, 1995; 
Castellino et al., 2000). Presentation via the MHC class I pathway involves degradation of the 
proteins by the proteasome in the cytosol, followed by the transport of peptides by TAP to the 
ER where they bind to the MHC class I molecule (Germain, 1994; Pamer and Cresswell, 1998). 
Castellino et al. (2000) conducted a study to determine the pathway by which the peptides 
complexed to the HSP70 molecule are presented to the MHC class I molecule. The study showed 
that presentation of peptides linked to the HSP70 molecule by the MHC class I molecule is 





Initially, it was thought that B cells were unable to perform cross-presentation of HSP-peptide 
complexes (Suto and Srivastava, 1995). However, more recent work by Tobian et al. (2005) 
demonstrated the capacity of B cells to cross-present ovalbumin complexed to mycobacterial 
HSP70 to MHC class I molecules. This enhanced priming of CD8+ T cells and improved 
antibody production by the B cells (Tobian et al., 2005). The capacity of HSP70 to induce a 
prominent antibody response against infectious agents makes it an attractive adjuvant for 
inducing an immune response against trypanosomes antigens.  
 
1.7 Objectives of the present study 
Congopain is a major cathepsin L-like cysteine protease of T. congolense. The protease was 
shown to be recognised by sera from infected cattle differing in their susceptibility to 
trypanosomosis. The trypano-tolerant N’Dama cattle were shown to mount a prominent IgG 
response to congopain during an infection with T. congolense compared to trypano-susceptible 
Boran cattle (Authié et al., 1993a). In addition, studies conducted using F1 crosses between 
N’Dama and Boran cattle revealed that a correlation exists between anti-congopain antibodies 
produced and the degree of susceptibility to trypanosomosis (Authié et al., 1993b). Hence, a 
hypothesis was proposed that efficient inhibition of cysteine proteases in vivo is an effector of 
trypanotolerance. In addition, it was shown that congopain exists as a dimer, and that protective 
epitopes are dimer-associated (Boulangé et al., submitted). 
 
Immunisation trials were conducted in cattle using the baculovirus expressed catalytic domain of 
congopain (C2) in a proprietary, saponin-based adjuvant called RWL (Authié et al., 2001; 
Boulangé et al., 2001). The animals were challenged with T. congolense and the immune 
response was assessed and compared to that of control animals. The immunised animals 
maintained or gained weight during infection and showed less severe anaemia than the control 
animals during the chronic phase of the disease (Authié et al., 2001). The haematological and 
immunological features of immunised animals were similar to those shown by trypano-tolerant 
cattle. However, attempts to reproduce these results using yeast-expressed recombinant C2 with 
ISA206 oil-in-water adjuvant from Seppic, were unsuccessful (E. Authié and A. Boulangé, 
personal communication). The failure of the study was attributed to poor antigenicity of C2, the 
expression system used to produce the antigen and the type of adjuvant used (E. Authié and A. 




improve the antigenicity of congopain using three approaches. The first approach involved 
validation of the proposed dimerisation model of congopain using PCR-based site directed 
mutagenesis. Understanding the dimerisation mechanism of congopain is crucial for the 
development of an effective anti-disease vaccine. The second objective was to determine the 3-D 
structure of the catalytic domain of congopain using X-ray crystallography in order to identify 
protective epitopes exposed on the surface of the protease. The last approach involved improving 
the delivery of C2 to the cells of the immune system while maintaining the antigen in an 
appropriate conformation to induce the production of activity inhibiting antibodies, by 
genetically fusing it to recombinant T. congolense BiP. 
 
Recombinant C2 expressed in P. pastoris is a dimer at physiological pH. Moreover, sera from 
trypano-tolerant cattle detected epitopes associated with the dimeric conformation of the 
protease. Therefore, it is thought that protective epitopes are associated with the dimeric 
conformation. In order to develop an effective anti-disease vaccine based on congopain, it was 
crucial to understand the dimerisation mechanism of the protease. A dimerisation model was 
proposed based on the crystal structure of cruzipain, a monomer and the theoretical dimeric 
model for cathepsin W (Brinkworth et al., 2000; Prof. J. Hoebeke, IBMC, Strasbourg, France, 
personal communication). A stretch of charged and uncharged amino acid residues that form salt 
bridges depending on pH was identified to be involved in the dimerisation process. Amino acid 
residues located within the dimerisation motif of congopain were altered to mimick either 
cathepsin W [C2 (H43W)] or cruzipain [C2 (K39F, E44P)]. The generated C2 mutants were 
heterologously expressed in P. pastoris and their capacity to dimerise was assessed by PhastGel® 
SDS-PAGE. Furthermore, the effect of mutations on enzymatic characteristics of the mutants 
was investigated. The results obtained in this part of the study are presented in Chapter 2.  
 
In the second approach, the aim was to determine the crystal structure of the catalytic domain of 
congopain using X-ray crystallography in order to elucidate major epitopes located on the 
surface of the protease and assist in the understanding of the dimerisation mechanism of 
congopain. The information acquired from the crystallisation of C2 was going to be utilised to 
design and develop mimotopes with potential use in vaccination studies. High level expression of 
C2, mutant proenzyme [proC2 (C25A)] and C2 mutants [C2 (H43W) and C2 (K39F, E44P)] was 




proteins is currently underway. In the absence of crystallographic data, we embarked on in silico 
homology modelling of the 3-D structure of congopain. The results obtained in this part of the 
study are presented in Chapter 3. 
 
The aim of the final part of the study was to assess the capability of T. congolense BiP to 
stimulate the production of congopain activity inhibiting antibodies while maintaining the 
antigen in an appropriate conformation. To this end, constructs were designed that had the 
catalytic domain of congopain fused to BiP. The constructs were designed in a way to allow for 
their cloning into pPic9 and pMal expression vectors for their expression in both P. pastoris and 
E. coli. The proregion of congopain was included in most constructs because of its importance in 
the proper folding of the protease (Lalmanach et al., 1998; Sanderson et al., 2000). On the other 
hand, the 10 kDa C-terminal domain of BiP was omitted in most constructs because of its high 
variability and antigenicity (Boulangé and Authié, 1994). The BiP-C2 chimeras were 
successfully expressed in both eukaryotic and bacterial expression systems. Due to problems 
associated with poor expression levels of the chimeras in yeast and difficulty with the 
purification of bacterial expressed chimeras, the chimeras were not tested in laboratory rodents. 
The results obtained in this part of the study are presented in Chapter 4. All the results are 
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ABSTRACT 
Congopain is the major cathepsin L-like cysteine protease of Trypanosoma congolense. 
Congopain has been implicated in the disease process, thus has vaccine potential and is a 
possible target for chemotherapy. The catalytic domain of congopain (C2) has been 
recombinantly expressed in P. pastoris and shown to dimerise at physiological pH, an unusual 
feature amongst cathepsin L-like cysteine proteases. Of direct relevance to vaccine design, 
antibodies from trypano-tolerant cattle better recognised the dimer conformation, advocating for 
protective epitopes to be dimer-associated. A dimerisation model was proposed based on the 3D-
structure of cruzipain (always a monomer) and cathepsin W (always a dimer). The model relies 
on a stretch of charged and uncharged amino acid residues that form salt bridges depending on 
the pH. To validate the model, K39 and E44 were substituted with F39 and P44, to mimick cruzipain 
while H43 was substituted with W43 to mimick cathepsin W using PCR-based site-directed 
mutagenesis in the presence of a thermostable DNA ligase. The mutated congopain variants were 
functionally expressed in P. pastoris and purified. Analysis of the purified mutants [C2 (H43W) 
and C2 (K39F; E44P)] by PhastGel® SDS-PAGE revealed unexpected electrophoretic mobility 
compared to wild-type C2. The non-boiled and non-reduced C2 (H43W) migrated at 60 kDa 
while C2 (K39F; E44P) migrated at 50 kDa and wild-type C2 displayed a mobility shift at 42 
kDa. In denaturing conditions or acidic pH, the C2 mutants and wild-type C2 migrated as 
monomers at 27 kDa. C2 mutants and wild-type C2 displayed similar pH profiles, but different 
kinetic constants for the hydrolysis of Z-Phe-Arg-AMC. It can be concluded that these amino 
acid residues indeed play a role in the dimerisation mechanism of congopain; however, these are 
not the only participating residues. 
 





African animal trypanosomosis or nagana is a major constraint to livestock production in sub-
Saharan Africa. The disease is estimated to cost $ 1.3 to 5 billion per year in Africa alone 
(Kristjanson et al., 1999). The disease is caused by tsetse transmitted protozoan parasites 
including Trypanosoma congolense, T. vivax and to a lesser extent T. b. brucei (Stevens and 
Brisse, 2004). Generally, the disease manifests itself by weight loss, severe anaemia, 
immunosuppression, and is often fatal if untreated.  
 
Currently, control of trypanosomosis relies on three principal strategies: vector 
eradication/control, trypanocidal drugs (chemotherapy) and trypano-tolerant cattle (McDermott 
and Coleman, 2001). Complete eradication of the vector is improbable; hence, control of the 
disease at herd or individual level relies on trypanocidal drugs (Holmes et al., 2004). The three 
widely used trypanocidal compounds are isometamidium (Samorin®), diminazene aceturate 
(Berenil®) and homidium bromide (Ethidium®). Prolonged exposure of the parasites to these 
drugs has culminated in the emergence of drug resistance (Geerts et al., 2001). Hence, there is an 
urgent need to develop new, effective and safe trypanocidal drugs. Although potential new drugs 
have been identified (McKerrow et al., 1995; McKerrow et al., 2006), they are far from 
commercialisation. 
 
Vaccination offers an attractive alternative strategy for the treatment of trypanosomosis. 
However, it is significantly limited by the exposed, variable surface glycoprotein (VSG) coat of 
the parasite. VSG undergoes rapid antigenic variation during an infection cycle (Donelson, 
2003), hence, cannot be regarded as a vaccine target. This obstacle facilitated a paradigm shift 
towards targeting accessible parasite invariant antigens. Immunisation trials with flagellar pocket 
antigen (Mkunza et al., 1995) and tubulin (Lubega et al., 2002) showed that these antigens confer 
partial protection against the parasite. However, the results are still subject to controversy within 
the scientific community. 
 
Trypano-tolerant cattle, such as the West African N’Dama, Muturu and Dahomey breeds, possess 
an ability to resist the disease caused by an infection with trypanosomes (Authié, 1994; Murray 
et al., 2004). These animals are able to limit parasitemia and control the pathogenic effects of 




susceptible cattle revealed that trypano-tolerant cattle specifically recognised a 33 kDa 
immunodominant antigen (Authié et al., 1992). In an independent study, a 33 kDa antigen was 
purified from T. congolense bloodstream form lysates using thiopropyl-Sepharose (Mbawa et al., 
1992). After determination of the enzymatic characteristics of the two antigens, it was concluded 
that the two proteases are actually one and the same protease, later named congopain (Authié, 
1994). Congopain belongs to the papain superfamily of cysteine proteases and exhibits the 
highest identity to mammalian cathepsin L (Authié et al., 1992). 
 
Congopain is present in the bloodstream of infected animals where it is thought to contribute to 
trypanosome-induced disease pathology (Authié, 1994). To test this hypothesis, 
immunisation/challenge experiments were conducted in cattle, using baculovirus-expressed C2, 
the catalytic domain of congopain (Authié et al., 2001; Boulangé et al., 2001). It was shown that 
antibodies directed against congopain control trypanosome-induced pathology. Animals 
immunised with C2 developed less severe anaemia and gained weight after a few months of 
being challenged with T. congolense. Although the effects were limited; this initial experiment 
showed that a vaccine strategy based on targeting the disease rather than the parasite, that is 
called an “anti-disease vaccine” approach, seems to be a viable and promising avenue for 
preventing trypanosomosis in cattle (Schofield, 2007). 
 
Congopain is composed of a signal peptide for secretion, a propeptide that governs proper 
folding, a central domain that bears the catalytic site, and an unusual C-terminal extension, 
present only in the cathepsin L-like cysteine proteases of Trypanosomatidae, the function of 
which remains to be elucidated. The catalytic domain of congopain (C2) was expressed in Pichia 
pastoris (Boulangé et al., submitted), an expression system known to produce higher yields than 
the baculovirus expression system. Western blot analysis of congopain revealed that the protease 
exists in two conformations, depending on pH. The protease is monomeric at acidic pH and 
dimeric at neutral pH (Boulangé et al., submitted). Antibodies from trypano-tolerant cattle better 
recognised the dimeric form of the protease (Boulangé et al., submitted). It seems that protection 
against the disease is associated with dimer-specific epitopes, thus it is crucial to understand the 





Based on the 3D structures of cruzipain (Eakin et al., 1993; McGrath et al., 1995), the congopain 
homologue from T. cruzi that is known to exist as a monomer, and of cathepsin W (Brinkworth 
et al., 2000), that exists as a dimer, a dimerisation model was proposed (Prof. J. Hoebeke, IBMC, 
Strasbourg, France, personal communication). The model is based on a stretch of charged and 
uncharged amino acid residues that can form salt bridges depending on the pH. In congopain, K39 
and E44 were suggested to be the amino acid residues essential for dimerisation (Fig. 2.1). 
 
At acidic pH, the side chains of K39 and H43 are positively charged, whereas, E44 is negatively 
charged. Thus, the salt bridge could be formed between H43 and E44 resulting in the formation of 
an α-helix. Therefore, the protease exhibits the monomer conformation that is poorly 
immunogenic. At physiological pH, H43 is deprotonated allowing for salt bridge formation 
between K39 and E44 resulting in β-turn formation that constitutes the dimeric conformation of 
the protease. In cruzipain, K39 and E44 are substituted with F39 and P44, respectively. This 
prevents salt bridge formation, thus, the protease exists as a monomer regardless of pH. In 
cathepsin W, H43 is substituted with W43 preventing competition between R39 and D44 for the 
formation of the salt bridge at acidic pH. Thus, the protease exists as a dimer regardless of pH. 
The interaction of R39 and D44 is equivalent to the interaction between K39 and E44 in congopain. 
Thus, substitution of H43 by W43 in congopain is expected to produce the mutant mimicking 
cathepsin W. Therefore, the mutant congopain was expected to always exist as a dimer regardless 
of pH. The mutant congopain containing the substitution of K39 and E44 with F39 and P44, 
respectively was expected to behave like cruzipain and be monomeric regardless of pH.  
 
Congopain    ( 38-45)   dimer pH>5 / monomer pH<5
Cruzipain    ( 38-45)   
Cathepsin W  ( 38-45)   










Figure 2.1. Schematic representation of the region thought to be responsible for the dimerisation of 
congopain. The congopain dimerisation model was proposed by Prof. J. Hoebeke (IBMC, Strasbourg, France, 
personal communication). The model is based on the capacity of certain amino acid residues to form salt bridges 
depending on pH. In congopain, K39, H43 and E44 were suggested to be crucial for dimerisation. 
 
The present study attempts to validate the proposed dimerisation model of congopain by 




cruzipain. To resemble cathepsin W, H43 in congopain was replaced with W43. Mutagenesis was 
performed through incorporation of a 5’ phosphorylated mutagenesis primer by the flanking 
central domain primers in the presence of a thermostable DNA ligase during the standard PCR 
reaction (Michael, 1994). The mutated open reading frame (ORF) was expressed in P. pastoris 
and the capacity of the mutant proteins to dimerise assessed by PhastGel® SDS-PAGE. In 
addition, the enzymatic characteristics of the purified mutants were investigated. 
 
2.2. MATERIALS AND METHODS 
2.2.1. Materials 
Molecular Biology: EcoRI, NotI, SacI, shrimp alkaline phosphatase (SAP), T4 DNA ligase, 
dNTP mix, X-gal, MassRuler™ DNA Ladder Mix, O’GeneRuler ™ DNA Ladder Mix 1kb, 
GeneJet™ Plasmid Miniprep kit and TransformAid™ Bacterial transformation kit were 
purchased from Fermentas (Vilnius, Lithuania). Taq DNA polymerase, 10× PCR buffer B and 25 
mM magnesium chloride were purchased from Solis Biodyne (Tartu, Estonia). The pGEM-T® 
vector cloning kit was purchased from Promega (Madison, WI, USA) and the DNA Clean and 
concentrator kit was purchased from ZymoResearch (Orange, CA, USA). The E. Z. N. A® Gel 
Extraction kit was purchased from peQLab (Erlangen, Germany). Competent Escherichia coli 
cells (NEB 5-α and JM 109) were purchased from New England Biolab (Ipswitch, MA, USA). 
The P. pastoris yeast strain (GS 115) and the vector pPic9 were purchased from Invitrogen 
(Carlsband, CA, USA). The BioRad GenePulser™ electroporator was from BioRad (Hercules, 
CA, USA).  
 
PhastGel® electrophoresis: PhastGel® homogenous 12.5% gels, PhastGel™ SDS-Buffer Strips, 
PhastGel™ Blue R tablets were purchased from Amersham Biosciences (Uppsala, Sweden). The 
PhastSystem Separation and Control unit was purchased from Amersham Biosciences (Uppsala, 
Sweden) 
 
Enzyme Kinetics: The fluorogenic substrate benzoyloxycarbonyl-phenylalanine-arginine-7-
amino-4-methylcoumarin (Z-Phe-Arg-AMC) and irreversible inhibitor trans-epoxysuccinyl-L-
leucyl-amido (4-guanidino) butane (E-64) were purchased from Sigma. The FLUOStar Optima 





2.2.2.1 Isolation of plasmid DNA 
A glycerol stock of E. coli containing pPic9-proC2 (Fig. 2.2) was streaked on 2× YT plates 
[1.6% (w/v) tryptone, 1% (w/v) yeast extract and 0.5% (w/v) NaCl] containing ampicillin (50 
µg/ml). The plates were incubated overnight at 37ºC. Liquid 2× YT (10 ml, 50 µg/ml ampicillin) 
was inoculated with a single colony and the culture was grown at 37ºC overnight. Plasmid DNA 
was isolated using the GeneJet® Miniprep kit (Fermentas) according to manufacturer’s 
instructions. Isolated plasmid DNA was subjected to electrophoresis on a 1% (w/v) agarose gel in 




Figure 2.2. pPic9 expression vector map (Invitrogen). The vector contains the following features for efficient 
expression: ColE1 origin of replication (pBR322), 5’ AOX fragment (5’AOX), multiple cloning sites, α-factor 
secretion signal (S), c-myc epitope (TT), ampicillin resistance gene, and the his4 gene for the selection by 
complementation in the his4 yeast strain. 
 
2.2.2.2. PCR-based-site-directed mutagenesis 
Site-directed mutagenesis was performed following the protocol described by Michael (1994). 
The isolated plasmid DNA (pPic9-proC2) was used as the template for site-directed mutagenesis. 
Mutations were introduced by a mutagenesis primer (H43W or K39F; E44P) incorporated during 
a standard PCR reaction using two flanking primers (Table 2.1). The mutagenesis primers were 
5’-phosphorylated (Proligo, France) to allow for efficient ligation of the two newly synthesised 




The flanking primers (CD primers) were used in combination with the mutagenesis primer 
(H43W or K39F; E44P) at a ratio of 1:10 (Fig. 2.3B). 
 
Table 2.1. Sequences of primers used for the mutagenesis of C2 open reading frame (ORF). 
The central domain (CD) primers were used as flanking primers to amplify the catalytic domain 
of congopain (C2). The mutagenesis primer (H43W or K39F; E44P) was used to introduce the 
desired mutations.  
Primer     Sequence    Restriction 
               site 
CDFw      5’CCGAATTCTGCTTTCCCGTGGGCCGTTGC3’          EcoRI 
CDRv      5’TGCGGCCGCCGTGCCGCACGAGCCGGGCGG3’    NotI 
H43W      5’CAGTGGTTCGTTGCAGGCATCCGCTGACG3’         None 










H43W or K39F; E44P
5’ 3’
5’ 3’







ligase H43W or K39F; E44P
 
Figure 2.3. Schematic diagram showing the mutagenesis reaction and the mutagenic products expected from 
the mutagenesis reaction. Panel A, schematic diagram showing the mutagenesis reaction. Panel B, products 
expected from the mutagenesis reaction. The flanking central domain primers (CDFw and CDRv) were used to 
incorporate the mutagenesis primer (H43W or K39F; E44P) during a standard PCR reaction. Two expected 
products, the full-length product containing the mutation of interest, and a truncated product resulting from the 




The PCR reaction was carried out in a 100 µl reaction volume, containing 0.5 ng plasmid DNA 
(pPic9-proC2), 1 µM flanking primers (CD), 10 µM mutagenesis primer (H43W or K39F; 
E44P), 200 µM dNTP mix, 2.5 mM Mg2+, 1 mM DTT, 1 mM NAD+, 2.5 U Taq DNA ligase 
(NEB), and 2.5 U FirePol® DNA polymerase (Solis Biodyne) using the 1× Taq polymerase 
buffer B [80 mM Tris-Cl buffer, pH 9.4, 20 mM (NH4)2SO4, 0.02% (v/v) Tween 20]. The initial 
denaturation step (95ºC for 5 min) was followed by 25 cycles composed of denaturation at 95ºC 
for 1 min, primer annealing at 45ºC for 1 min, and elongation at 65ºC for 3 min. Finally, 
elongation at 65ºC for 6 min was performed to allow for ligation of the fragment primed with 
mutagenesis primer into the full length product. 
 
2.2.2.3. Cloning of the full-length mutated product 
Cloning into pGEM-T vector 
The full-length PCR product (930 bp) was purified from the smaller fragment and other 
contaminants using the peQLab Gel extraction kit. Pure mutated full-length product was ligated 
into the pGEM-T vector (Fig. 2.4) in a ratio of 3:1 using T4 DNA ligase in a 10 µl reaction 
volume. The ligation mix (2 µl) was used to transform NEB 5-α competent E. coli cells (NEB) 
according to the manufacturer’s instructions. The transformed cells (100 µl) were plated onto 2× 
YT containing ampicillin (50 µg/ml), X-gal (20 µg/ml) and IPTG (10 µg/ml) to allow for blue 




Figure 2.4. pGEM-T® vector map (Promega). The vector contains a multiple cloning site, ampicillin resistance 





White colonies were selected from a plate, and colony PCR was performed using the T7 and the 
SP6 primers (Table 2.2). The template was denatured for 1 min at 95ºC, followed by 25 cycles 
consisting of denaturation at 95ºC for 30 s, primers annealing at 45ºC for 30 s, elongation at 72ºC 
for 1 min, and finally elongation at 72ºC for 7 min. Recombinants were grown in selective media 
overnight at 37ºC. Plasmid DNA was isolated using the GeneJet® Miniprep kit (Fermentas). 
 
Cloning into pPic9 expression vector 
Recombinant pGEM-T-proC2 (H43W), pGEM-T-proC2 (K39F; E44P) and pPic9 were restricted 
with EcoRI and NotI in 1× Orange buffer™ (0.05 M Tris-Cl buffer, pH 7.5, 0.01 M MgCl2, 0.1 
M NaCl, 0.1 mg/ml BSA). The dropped out insert was purified using the E. Z. N. A® Gel 
Extraction kit (peQLab). The vector was dephosphorylated with 1 U of SAP and concentrated 
using the ZymoResearch™ DNA Clean and Concentrator kit. The insert was ligated into linear 
pPic9 vector as described in Section 2.2.2.3. Competent E. coli cells (NEB 5-α) were 
transformed and recombinant colonies screened by colony PCR using AOX primers (Table 2.2). 
Positive colonies were grown overnight in selective media and plasmid DNA isolated. 
 
Table 2.2. Sequences of primers used for screening of recombinants in pGEM-T vector and 
pPic9. The T7 and SP6 primers were used to screen for pGEM-T vector recombinants. The AOX 
primers were used to screen for pPic9 recombinants. 
Primer   Sequence       Tm (ºC) 
T7   5’TAATACTGACTCATATAGGG3’   46 
SP6   5’CATATGATTTAGGTGACACTATA3’   48 
AOX Fw  5’ACTGGTTCCAATTGACAAGC3’   50 
AOX Rv  5’GCAAATGGCATTCTGACATCC3’   52 
 
2.2.2.4. Transformation of Pichia pastoris (GS 115 strain) 
Pichia pastoris strain GS 115 cells were treated as described by Wu and Letchworth (2004) to 
improve the efficacy of transformation. Briefly, P. pastoris cells were grown in 500 ml YPD [1% 
(w/v) yeast extract, 2% (w/v) peptone, and 2% (w/v) dextrose] until they reached an OD600 
between 1 and 2. The cells were pelleted (2000×g, 20 min, 4ºC) and resuspended in 400 ml of 
100 mM lithium acetate, 10 mM DTT, 0.6 M sorbitol, and 10 mM Tris-Cl buffer, pH 7.5, and 




1 M sorbitol, and finally resuspended in 1.5 ml of 1 M sorbitol. The final concentration of the 
cells was 1010 cells/ml. Recombinant pPic9-proC2 (H43W) and pPic9-proC2 (K39F; E44P) were 
linearised with SacI, to improve the efficiency of integration of the insert into the P. pastoris 
genome by homologous recombination. Linear plasmid DNA (200 ng) was used to transform 
competent GS 115 yeast cells (200 μl) by electroporation (1.5 kV, 25 µF, 186 Ω) using a BioRad 
Gene Pulser™ (BioRad) in pre-chilled 2 mm electroporation cuvettes.  The cells were 
immediately resuspended in chilled 1 M sorbitol (1 ml). The cells were concentrated by 
centrifugation (2000×g, 10 s, RT) and plated on MD plates [1.34% (w/v) yeast nitrogen base 
without amino acids, 0.0004% (w/v) biotin, 2% (w/v) glucose, 15 g/l bacteriological agar] 
containing ampicillin (50 µg/ml). The plates were incubated at 30ºC until the colonies were 
visible. Colony PCR using the AOX primers (Table 2.2) was performed on the P. pastoris 
genome to confirm integration of foreign DNA (Ayra-Pardo et al., 1998). Fresh single colonies 
(not more than a week old) were screened using a protocol adapted from Ayra-Pardo et al. 
(1998). The protocol was adapted by changing the quantity of primers used in the reaction. The 
AOX primers were used at a 10× higher concentration as compared to the original protocol. 
Positive colonies were grown in selective media (Section 2.2.2.5) for protein expression. 
 
2.2.2.5 Expression of C2 mutants in Pichia pastoris 
Liquid YPD (100 ml) containing ampicillin (50 µg/ml) was inoculated with a single recombinant 
colony and grown at 30ºC in an orbital shaking incubator for two to three days. Ampicillin was 
added to the media to prevent contamination of the culture. These cells were transferred into 1 L 
BMGY [1% (w/v) yeast extract, 2% (w/v) peptone, 100 mM potassium phosphate buffer, pH 6.5, 
and 1.34% (w/v) YNB]. The culture was grown at 30ºC for a further two days to increase 
biomass. The cells were pelleted (6000×g, 10 min, RT) and resuspended in 500 ml buffered 
minimal medium [BMM, 100 mM potassium phosphate buffer, pH 6.5, 1.34% (w/v) YNB, 
0.0004% (w/v) biotin, and 5% (v/v) methanol]. The culture was grown in a baffled flask at 30ºC 
in a shaking incubator. Methanol (0.5%) was added daily during the four to six days expression 
period. The daily addition of methanol to the culture media induces continuous expression of the 
protein of interest by P. pastoris that secretes the protein of interest into the media. Cells were 






2.2.2.6 Purification of the C2 mutants 
Three phase partitioning (TPP) 
The expression supernatants were thawed and filtered through Whatman No 1 filter paper. The 
recombinantly expressed C2 mutants were purified by three phase partitioning (TPP) (Pike and 
Dennison, 1989). The protease was autocatalytically processed into the mature form by lowering 
the pH to 4.2 with phosphoric acid. Tertiary butanol (1/3 final volume, 250 ml) was added to 500 
ml supernatant. The mutants were precipitated with the kosmotrope ammonium sulfate (40% of 
total volume, 300 g). The salt was dissolved by gentle stirring on a magnetic stirrer until 
completely dissolved. The precipitated protein mixture was centrifuged (6000×g, 10 min, 4ºC) 
using a pre-chilled swing-out rotor. The protein layer was collected at the interface between the 
tertiary butanol and aqueous phases and the precipitate was dissolved in dialysing buffer (PBS, 
pH 7.2). The precipitated protein was dialysed (PBS, pH 7.2) using 10 kDa cut-off dialysis 
membrane (Pierce, Rockford, IL, USA) overnight at 4ºC to remove traces of tertiary butanol and 
salts. Solid polyethylene glycol Mr 20 000 was used to concentrate the dialysed proteins in the 
dialysis bag to approximately 5 ml. 
 
Molecular Exclusion Chromatography (MEC) 
A 25 × 840 mm column was packed with Sephacryl S-300 HR resin (Sigma) and equilibrated 
with one column volume of 50 mM sodium acetate buffer, pH 4.2 (25 cm.h-1, 4ºC). The column 
was calibrated with a calibration mixture (5 ml) comprising of blue dextran (2000 kDa), 
phosphorylase b (97 kDa), bovine serum albumin (66 kDa), ovalbumin (45 kDa), carbonic 
anhydrase (34.3 kDa), and soybean trypsin inhibitor (25 kDa). The availability constant (Kav) 
was determined for each protein, where the elution volume (Ve) of blue dextran denotes the void 
volume (Vo). 
 Kav = Ve-Vo 
                       Vt-Vo 
 
Where, Kav is the availability constant, 
 Ve is the elution volume, 
 Vo is the void volume, 





The Fischer’s plot, Kav vs logMr (Fig. 2.5) was used as a standard curve to estimate Mr of eluted 
protein (Dennison, 1999). The TPP concentrated protein sample (2.5% of column volume, 8 ml) 
was applied to the column and eluted with 50 mM sodium acetate buffer, pH 4.2. Elution of the 














Figure 2.5. Fischer’s plot for the estimation of protein Mr from MEC data. The calibration mixture was applied 
to a Sephacryl S-300 column (25 × 840 mm) and eluted with 50 mM sodium acetate buffer, pH 4.2 (25 cm.h-1, 4ºC). 
The availability constant (Kav) was determined for each protein standard. 
 
2.2.2.7 Protein assay of the dimer C2 mutants 
The BCA™ Protein Assay (Pierce, Rockford, IL, USA) was used to determine protein 
concentration. Working reagent solution was made by combining reagent B with reagent A in a 
1:20 ratio. Bovine serum albumin (BSA) standards were mixed with working reagent solution 
(200 μl) in a Nunc® 96 microtiter plate and incubated at 37ºC for 30 min. Proteins interacted with 
bicinchoninic acid in the working reagent to produce a purple coloured product that was 
measured at 562 nm. A standard curve was constructed to determine unknown protein 




























Figure 2.6. Calibration plot for determination of protein concentration. Proteins of unknown concentration were 
mixed with working reagent solution and A562nm measured. The absorbance was used to extrapolate protein 
concentration from the standard curve. The equation of the trend line is y = 0.00032x + 0.252, with a correlation 
coefficient of 0.994.  
 
2.2.2.8 Analysis of the dimer C2 mutants 
Laemmli SDS-PAGE 
Discontinuous SDS-PAGE was carried out using the method described by Laemmli (1970). The 
proteins were resolved through two gel types, a stacking gel (pH 6.8) and a smaller pore size 
resolving gel (pH 8.8) in Tris-Cl buffer. The samples were treated with either the non-reducing 
treatment buffer [125 mM Tris-Cl buffer, pH 6.8, 4% (w/v) SDS, and 20% (v/v) glycerol] or 
reducing treatment buffer (10% (v/v) 2-mercaptoethanol added to non-reducing buffer) in a 1:1 
ratio (Laemmli, 1970). Reduction and presence of SDS are essential for the determination of Mr 
of proteins. SDS tightly binds to proteins giving them a net negative charge. Therefore, when an 
electric field is applied, proteins will be separated solely based on their size. The reducing agent, 
2-mercaptoethanol, reduces all the disulfide bridges in the proteins giving rise to a more unfolded 
protein structure. The proteins were run at 20 mA/gel for 2 h in tank buffer [250 mM Tris-Cl 
buffer, 192 mM glycine, 0.1% (w/v) SDS, pH 8.3]. There is an inversely proportional 
relationship between relative mobility of a protein in an electric field and Mr. This relationship 
can be exploited to determine Mr of unknown proteins. A standard curve was constructed using 

















Figure 2.7. Standard curve for estimation of protein Mr by SDS-PAGE. The BioRad low range marker is 
composed of phosphorylase b (97 kDa), bovine serum albumin (66 kDa), ovalbumin (45 kDa), soybean trypsin 
inhibitor (31 kDa), and lysozyme (14 kDa). The equation of the trend line is y = -0.0147x + 1.9845, with correlation 
coefficient of 0.997. 
 
Protein visualisation can be achieved by staining the gel with Coomassie blue R-250 [0.125% 
(w/v) Coomassie blue R-250, 50% (v/v) methanol, and 10% (v/v) acetic acid]. The detection 
limit of Coomassie blue is approximately 50-100 ng of protein. When more sensitive detection is 
required, silver staining is employed (Blum et al., 1987). This method has a detection limit of 1-
10 ng of protein.  
 
PhastGel® SDS-PAGE 
Dimerisation of the C2 mutants was evaluated by PhastGel® SDS-PAGE. The proteins were 
resolved on a 12.5% PhastGel® homogeneous gel buffered with PhastGel™ SDS-buffer strips. 
Electrophoresis was carried out using the pre-set program (10 mA, 100 V, 30 min) on a 
PhastSystem Separation and Control unit (Amersham Biosciences). The gel was stained with 
PhastGel™ Blue R tablet solution [10% (v/v) acetic acid, 50% (v/v) methanol] for 1 hour. 
 
2.2.2.9 Western blot analysis of dimer C2 mutants 
Proteins were transferred from the Laemmli SDS-PAGE gels to a nitrocellulose membrane using 
a semi-dry blotter (Towbin et al., 1979). Afterwards, the nitrocellulose was transiently stained 
with Ponceau S [0.1% (w/v) Ponceau S in 1% (v/v) glacial acetic acid]. Protein marker bands 
were marked with a pencil after destaining the membrane with distilled water. The membrane 




NaCl, pH 7.4)] for 1 hour. The membrane was washed with TBS (3 × 5 min) and incubated in 
primary antibody (chicken anti-C2 N-terminal peptide antibody) diluted in 0.5% BSA in TBS for 
2 h. The membrane was further washed with TBS (3 × 5 min) and probed with horse radish 
peroxidase (HRPO) conjugated rabbit anti-chicken antibodies for 1 hour. Finally, the membrane 
was washed with TBS and incubated with substrate solution [0.006% (w/v) 4-chloro-1-naphthol, 
0.1% (v/v) methanol, and 0.0015% (v/v) H2O2] until bands became visible.  
 
2.2.2.10 Gelatin SDS-PAGE analysis of dimer C2 mutants 
The standard Laemmli SDS-PAGE gel was modified as described by Heussen and Dowdle 
(1980) to allow for detection of protease activity. Gelatin [1% (m/v)] was added to the running 
gel buffer and dissolved by heating the mixture (Heussen and Dowdle, 1980). The mixture was 
added to the rest of the solutions required to cast a SDS-PAGE (12%) gel. SDS-PAGE was 
carried out as usual. After electrophoresis, the running gel was soaked in two changes of 2.5% 
(v/v) Triton X-100 for one hour at room temperature. The gel was incubated in congopain assay 
buffer [100 mM Bis-Tris buffer, pH 6.0, 4 mM EDTA, 0.02% (w/v) NaN3, 6 mM DTT] for 3 h at 
37ºC. The gel was stained with amido black solution [0.1% (w/v) amido black, 30% (v/v) 
methanol, 10% (v/v) acetic acid, 60% (v/v) water] for one hour. The gel was destained with 
several changes of destaining solution [30% (v/v) methanol, 10% (v/v) acetic acid, 60% (v/v) 
water] until clear bands indicating proteolytic activity were visible. 
 
2.2.2.11 Enzymatic characterisation of dimer C2 mutants 
Active site titration 
The active concentration of cysteine proteases was determined by active site titration with the 
irreversible inhibitor E-64 (Barrett and Kirschke, 1981; Barrett et al., 1982). The enzyme [1 µM 
diluted in 0.1% (w/v) Brij-35] was combined with E-64 [0.1 to 1 µM diluted in 0.1% (w/v) Brij-
35] in congopain assay buffer [100 mM Bis-Tris buffer, 4 mM EDTA, 0.02% (w/v) NaN3, 6 mM 
DTT, pH 6.0] and incubated at 37ºC for 30 min. Activity against Z-Phe-Arg-AMC (20 µM) was 
measured (excitation 360 nm; emission 460 nm) using a FLUOSstar Optima spectrophotometer 
(BMG Labtech, Offenburg, Germany). A standard curve for AMC product (Fig. 2.8) was 
























Figure 2.8. Standard curve for AMC product released. AMC stock (1 mM) solution was diluted (0-15 nM) in 
congopain assay buffer. Fluorescence of the AMC product (100 μl, triplicates) was read (Ex360nm; Em460nm). The 
equation of the trend line is y = 3.35 + 0.000547x, with a correlation coefficient of 0.998. 
 
pH profiling 
Constant ionic strength AMT buffers (100 mM Na-acetate, 200 mM Tris-Cl, 100 mM MES, 6 
mM DTT, 4 mM EDTA) were used to determine pH optimum of the cysteine protease (Ellis and 
Morrison, 1982). The buffers were titrated from pH 4.0 to pH 9.0 in 1.0 pH increments by 
addition of HCl or NaOH. The enzyme (1.5 ng diluted in 0.1% (w/v) Brij-35) was combined with 
each buffer at different pH-values and incubated at 37ºC for 1 min. The substrate Z-Phe-Arg-
AMC (20 μM) was added and the fluorescence measured (Ex360nm; Em460nm). 
 
Activity Assays 
Activity assays were conducted to determine the kinetic constants (Km and kcat) of the proteases. 
Enzyme (1.5 ng diluted in 0.1% (w/v) Brij-35) was incubated in congopain assay buffer 
containing 6 mM DTT for 15 min at 37ºC. The substrate Z-Phe-Arg-AMC (0-30 µM) was added 
and fluorescence measured (Ex360nm, Em460nm) using a FLUOStar Optima spectrophotometer 
(BMG Labtech, Offenburg, Germany). The Hyper32© software package (1991-2003, J. S. 
Easterby, University of Liverpool, UK) was used to plot the Michaelis-Menten curve. 
 
2.3 RESULTS 
2.3.1 Mutagenesis, cloning and expression of C2 mutants 
The open reading frame (ORF) encompassing the truncated wild-type catalytic domain of 




P. pastoris (Boulangé et al., submitted). Analysis of the expressed truncated C2 revealed 
dimerisation of the protease at physiological pH, an unexpected feature amongst cathepsin L-like 
cysteine protease. Moreover, sera from trypano-tolerant cattle recognised the dimer conformation 
of the protease. Thus, it is important to understand the dimerisation mechanism of congopain in 
order to gain access to the protective epitopes. 
 
Recombinant plasmid DNA (pPic9-proC2) was isolated using the GeneJet® plasmid miniprep kit 
(Fig. 2.9, lane 2). The recombinant plasmid DNA was observed as a single band of about 10 kb 
as expected. The plasmid was linearised with EcoRI (Fig. 2.9, lane 3) and NotI (Fig. 2.9, lane 4). 
The linear plasmid DNA migrates slower compared to the covalently closed circular plasmid 
DNA. Double digestion of plasmid DNA (pPic9-proC2) with EcoRI/NotI dropped out a 0.93 kb 
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Figure 2.9. Isolation of recombinant plasmid DNA (pPic9-proC2). Plasmid DNA was analysed by 
electrophoresis on a 1% agarose gel in 1× TAE buffer. Lane 1, MassRuler™ DNA Ladder Mix; lane 2, uncut pPic9-
proC2; lane 3, EcoRI cut pPic9-proC2; lane 4, NotI cut pPic9-proC2 and lane 5, EcoRI/NotI cut pPic9-proC2. The 
arrow indicates the cloned proC2 ORF.  
 
The isolated plasmid DNA (pPic9-proC2) was used as the template for mutagenesis. Mutagenesis 
was performed through incorporation of the 5’ phosphorylated mutagenesis primer (H43W or 
K39F; E44P) by the flanking central domain (CD) primers during a standard PCR reaction in the 
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Figure 2.10. Mutation of the proC2 ORF by PCR-based site-directed mutagenesis. Panel A, PCR-based site-
directed mutagenesis of proC2 ORF using mutagenesis primers (H43W or K39F; E44P) in the presence of a 
thermostable DNA ligase. The mutagenesis primer (H43W and K39F; E44P) was incorporated into the full-length 
product by the flanking (CD) primers in the presence of Taq DNA ligase (A). The reaction mixture was analysed by 
electrophoresis on a 1% (w/v) agarose gel in 1× TAE buffer. Lane 1, MassRuler™ DNA Ladder Mix; lane 2, H43W 
mutagenesis reaction; lane 3, H43W control reaction (without Taq DNA ligase); lane 4, K39F; E44P mutagenesis 
reaction and lane 5, K39F; E44P control reaction (without Taq DNA ligase). Panel B, purification of the mutated 
PCR products. The purified PCR product was analysed by electrophoresis on a 1% (w/v) agarose gel in 1 × TAE 
buffer. Lane 1, MassRuler™ DNA Ladder Mix; lane 2, purified H43W PCR product and lane 3, purified K39F; 
E44P PCR product. 
 
After mutagenesis PCR amplification, three prominent bands were observed on the gel in the 
lanes containing mutagenesis products (Fig. 2.10A, lanes 2 and 4), compared to the two weak 
intensity bands in the control mutagenesis lanes (Fig. 2.10A, lanes 3 and 5). Two bands were 
expected in the mutagenesis reaction lanes (Michael, 1994). The bands should be corresponding 
to the full-length mutagenesis product (0.93 kb) and the truncated product from the mutagenesis 
primer to the downstream primer (0.6 kb). The third product (2.0 kb) was rather unexpected (Fig. 
2.10A, lanes 2 and 4). This is thought to be a combination of the full-length product and the 
truncated product ligated by the thermostable DNA ligase present in the reaction mix. This 
hypothesis is confirmed by the absence of this particular band in the control reaction lanes that 
lack the thermostable DNA ligase (Fig. 2.10A, lanes 3 and 5).  
 
The mutagenesis technique employed in this study involved addition of the mutagenesis primer 
in ten-fold excess to lower the risk of obtaining a non-mutated full-length product. The reaction 
mix was supplemented with NAD+ and DTT, co-factors of the Taq DNA polymerase (Michael, 
1994; Michael et al., 1997). This mutagenesis technique is simple, rapid, reproducible and cost 




other PCR-based mutagenesis techniques like the “megaprimer” (Sarkar and Sommer, 1990) and 
“overlap extension” (Urban et al., 1997) that involve two or more rounds of PCR. Thus, these 
techniques have a high incidence of errors. Traditional techniques, based on the original protocol 
described by Kunkel and co-workers are more tedious, costly and of uncertain results (Kunkel, 
1985; Kunkel et al., 1987). An attempt made with the GeneEditor™ in vitro site directed 
mutagenesis kit was unsuccessful. 
 
The 0.93 kb band corresponding to the expected mutagenesis PCR product was excised from the 
gel and purified using the peQLab gel extraction kit. The purified product was observed as a 
band at 0.93 kb (Fig. 2.10B, lanes 2 and 3). No contaminating bands were observed on the gel. 
The intensity of both the purified bands [proC2 (H43W) and proC2 (K39F; E44P)] was the same. 
This means that the quantity of DNA contained in each band is the same. 
 
The mutated PCR product [proC2 (H43W) and proC2 (K39F; E44P)] was subcloned into the 
pGEM-T vector. White colonies were screened with T7 and SP6 universal primers to amplify the 
cloned mutated PCR product (Fig. 2.11). Plasmid DNA from recombinant colonies produced a 
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Figure 2.11. Screening of recombinant colonies by colony PCR using T7 and SP6 universal primers. The 
reaction mixture was analysed by electrophoresis on a 1% agarose gel in 1× TAE buffer. Lane 1, MassRuler™ DNA 
Ladder Mix, lanes 2-8, H43W clones 1-7 and lanes 9-14, K39F; E44P clones 1-6. 
 
Two recombinant colonies per mutagenesis experiment were grown in selective media overnight. 
Recombinant plasmid DNA [pGEM T-proC2 (H43W) and pGEM-T-proC2 (K39F; E44P)] was 
isolated and sequenced to check for the presence of the desired mutations. All clones contained 
the desired mutations in the correct positions without any extra random mutations (Appendix). 




of the amplicon limits the risk of introducing unwanted mutations by Taq DNA polymerase. Taq 
DNA polymerase is a low fidelity, less versatile enzyme with an error rate per nucleotide per 
cycle of approximately 1-2/12000 (Solis Biodyne). The use of high fidelity thermostable 
polymerases like Vent® or Pfu® DNA polymerase could subjugate the risk. 
 
Recombinant pGEM-T vector was double-digested with EcoRI/NotI (Fig. 2.12A, lanes 3, 5, 7 
and 9). The digestion produced two prominent bands at 3.2 and 0.93 kb corresponding to pGEM-
T vector and the mutated insert respectively. The 0.93 kb band was excised and purified (Fig. 















Figure 2.12. Screening of recombinant pGEM-T vector DNA by restriction digestion. Panel A, restriction of 
recombinant pGEM-T vector DNA with EcoRI and NotI. The digestion mix was analysed by electrophoresis on a 
1% (w/v) agarose gel in 1× TAE buffer. Lane 1, MassRuler™ DNA Ladder Mix; lane 2, uncut pGEM T-proC2 
(H43W) clone 1; lane 3, EcoRI/NotI cut pGEM T-proC2 (H43W) clone1; lane 4, uncut pGEM T-proC2 (H43W) 
clone 2; lane 5, EcoRI/NotI cut pGEM T-proC2 (H43W) clone 2; lane 6, uncut pGEM-T-proC2 (K39F; E44P) clone 
1; lane 7, EcoRI/NotI cut pGEM-T-proC2 (K39F; E44P) clone 1; lane 8, uncut pGEM-T-proC2 (K39F; E44P) clone 
2 and lane 9, EcoRI/NotI cut pGEM-T-proC2 (K39F; E44P) clone 2. Panel B, purified mutated insert. Lane 1, 
MassRuler™ DNA Ladder Mix; lanes 2-3, proC2 (H43W) and lanes 4-5, proC2 (K39F; E44P). 
 
The next step was to ligate the mutated insert [proC2 (H43W) and proC2 (K39F; E44P)] into an 
expression vector (pPic9). Prior to ligation of the mutated insert into pPic9, the vector was 
digested with EcoRI/NotI and dephosphorylated with shrimp alkaline phosphatase (SAP) to 
prevent recircularisation of the vector during ligation. The ligation mix was transformed into 
competent E.coli cells. Alcohol dehydrogenase (AOX) primer pairs were used to screen for 
recombinants. The recombinant colonies produced a slightly larger band (1.5 kb) due to 





Recombinant colonies [pPic9-proC2 (H43W) and pPic9-proC2 (K39F; E44P)] were grown in 
selective media overnight and recombinant plasmid DNA isolated. Recombinant plasmid DNA 
was linearised with SacI and used to transform P. pastoris GS 115 cells by electroporation. SacI 
digestion of plasmid DNA drastically improved the transformation efficiency (Wu and 
Letchworth, 2004). 
 
Transformed P. pastoris cells were grown in minimal media until colonies were visible. Colony 
PCR screening with AOX primers was performed on transformants using the adapted Ayra-
Pardo et al. (1998) protocol to check integration of plasmid DNA into the P. pastoris genome. 
The clones containing the integrated plasmid DNA produced a 1.5 kb product (Fig. 2.13, lanes 2-
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Figure 2.13. Screening of P. pastoris clones with AOX primers to confirm integration of mutated DNA in the 
P. pastoris genome. The reaction mix was analysed by electrophoresis on a 1% (w/v) agarose gel in 1× TAE. Lane 
1, MassRuler™ DNA Ladder Mix; lanes 2-4, H43W clones 1-3 and lanes 5-7, K39F; E44P clones 1-3. 
 
The PCR products were sequenced in both directions with AOX primers. Comparison of the 
PCR product sequences with the wild-type C2 sequence confirmed the presence of the introduced 
mutation in the correct positions. Therefore, the next step was to express the C2 mutants in P. 
pastoris. 
 
Two transformants per construct were grown in minimal media and tested for protein expression. 
Alongside the expression of the mutants, wild-type C2 was also expressed. All clones expressed 
recombinant mutant protein at the same level within a given construct (Fig. 2.14, lanes 3-6). The 
mutants [C2 (H43W) and C2 (K39F; E44P)] and wild-type C2 migrated as prominent bands at 




Therefore, it can be deduced that the level of expression of both proteins is the same. Higher 
molecular weight, weak intensity bands were observed in all the lanes (Fig. 2.14, lanes 2-6).  
 
   







Figure 2.14. Silver stained reducing SDS-PAGE (12%) gel showing the expression of the C2 mutants by P. 
pastoris. Expression supernatants were collected by pelleting the cells at 6000×g for 10 min. Lane 1, BioRad low 
molecular weight marker; lane 2, C2 supernatant; lane 3, C2 (H43W) supernatant from clone 1; lane 4, C2 (H43W) 
supernatant from clone 2; lane 5, C2 (K39F; E44P) supernatant from clone 1 and lane 6, C2 (K39F; E44P) 
supernatant from clone2. 
 
2.3.2 Purification of C2 (H43W) and C2 (K39F; E44P) 
Initially, the expression supernatants for the mutants were subjected to three phase partitioning 
(TPP) as a purification/concentration step. The percentage of ammonium sulfate required to 
precipitate wild-type C2 was optimised to be 40% (data not shown). This was done by subjecting 
the expression supernatant to 10% increments of ammonium sulfate until saturation. Hence, 40% 
ammonium sulfate was applied to precipitate mutants in the presence of tertiary butanol. The 















Figure 2.15. Reducing SDS-PAGE evaluation of the C2 mutants after three phase partitioning (TPP) 
purification. (A) Purification of C2 (H43W) mutant and (B) purification of C2 (K39F; E44P) mutant. The mutants 
were analysed by 12% reducing SDS-PAGE and the gel was stained with Coomassie blue. Panel A, lane 1, BioRad 
LMWM; lanes 2-4, different C2 (H43W) TPP fractions after dialysis and concentration. Panel B, Lane 1, BioRad 




The next step was to remove the higher molecular weight contaminants that were still present 
after TPP. Sephacryl S-300 molecular exclusion chromatography was used to achieve this. The 
different TPP preparations of C2 (K39F; E44P) were pooled, concentrated and applied to the 
Sephacryl S-300 column. Three elution peaks were observed for this mutant preparation (Fig. 
2.16A). This observed elution pattern is similar to that of C2 (H43W) (Fig. 2.16C). The first peak 
corresponds to higher molecular weight contaminants. The second elution peak corresponds to 
the contaminants that are approximately 97 kDa in size. The C2 (K39F; E44P) mutant eluted in 
the last peak at 45 kDa whereas C2 (H43W) eluted at 66 kDa. The introduced mutations might be 
playing a role in this observed apparent different elution pattern of mutants on the column. 
Analysis of the peak fractions for both mutants by SDS-PAGE revealed that purification was 
effected by MEC. Only one band at 27 kDa was observed on both gels (Fig. 2.16B and D). The 
peak fractions were pooled and concentrated by ultrafiltration using an Amicon PM 10 filter. 
 



























































































































































































Figure 2.16. Purification of the C2 mutants by molecular exclusion chromatography and analysis by reducing 
SDS-PAGE. Panels A and C, elution profiles of C2 (K39F; E44P) and C2 (H43W) on a Sephacryl S-300 HR 
column. Sephacryl S-300 HR (25 × 840 mm, 25 cm.h-1) was equilibrated with 50 mM sodium acetate buffer, pH 4.2. 
Panels B and D, reducing SDS-PAGE analysis of C2 (K39F; E44P) and C2 (H43W) peak fractions. The fractions 
were boiled and reduced prior to loading. Panel B, lane 1, BioRad LMWM; lanes 2-10, C2 (K39F; E44P) peak 





Wild-type C2 was also purified on the Sephacryl S-300 column. The wild-type C2 eluted in three 
major peaks as was observed for the C2 dimer mutants (Fig. 2.17A). The protein eluted as a 
dimer at 45 kDa. This elution profile is similar to that of C2 (K39F; E44P) mutant. Analysis of 
C2 peak fractions revealed that purification was achieved. The higher molecular weight 
contaminating bands were no longer present after MEC (Fig. 2.17B). The peak fractions were 



































































Figure 2.17. Purification of wild-type C2 by MEC. Panel A, elution profile of wild-type C2 after purification on 
the Sephacryl S-300 HR column (25 × 840 mm, 25 cm.h-1). Panel B, reducing SDS-PAGE (12%) analysis of C2 
peak fractions. The fractions were boiled and reduced prior to loading. Lane 1, BioRad LMWM and lanes 2-8, C2 
fractions.  
 
The concentrated C2 mutants were observed as a prominent band at 27 kDa (Fig. 2.18, lanes 2 
and 4). The C2 (K39F; E44P) mutant band intensity was stronger than that of the C2 (H43W) 
mutant. This means that removal of the higher molecular weight contaminants was achieved by 
MEC. Since the contaminants were successfully removed, a dye-binding technique (BCA™ kit) 
was used to estimate protein concentration. The concentration of C2 (H43W) was estimated to be 
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Figure 2.18. Coomassie stained reducing SDS-PAGE gel of the concentrated mutants after MEC. The mutants 
were boiled and reduced prior to loading. Lane 1, BioRad LMWM; lane 2, concentrated C2 (H43W); lane 3, C2 
(H43W) filtrate; lane 4, concentrated C2 (K39F; E44P) and lane 5, C2 (K39F; E44P) filtrate. 
 
Western blotting of the mutants after treatment under non-boiled and non-reduced conditions 
revealed that the C2 mutants migrate as a smear on a standard Laemmli SDS-PAGE gel (Fig. 
2.19, lanes 2 and 5). Therefore, the C2 dimer cannot be resolved on a standard Laemmli gel. 
There is no plausible explanation for this phenomenon. However, it can be proposed that the SDS 
present in Laemmli buffers disrupt dimerisation. This is because dimerisation has been proposed 
to occur through non-covalent interaction of charged amino acid residues. Boiling and/or 
reduction disrupt dimerisation of the mutants. Hence, the mutants resolved as a conspicuous band 
at 27 kDa (Fig. 2.19, lanes 3 and 4 and lanes 6 and 7). 
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Figure 2.19. Western blotting of the C2 mutants treated under different conditions. Following 12% reducing 
SDS-PAGE of the C2 mutants, the gel was electroblotted to a nitrocellulose membrane using a semi-dry-blotter run 
at 7 V overnight. The blot was probed with chicken anti-C2 N-terminal peptide antibodies. Lane 1, BioRad LMWM; 
lanes 2 and 5, non-boiled and non-reduced C2 mutants; lanes 3 and 6, boiled and non-reduced C2 mutants and lanes 




2.3.3. Assessment of C2 mutants’ capacity to dimerise 
The C2 mutants’ capacity to dimerise was assessed by PhastGel® SDS-PAGE. Dimerisation of 
the mutants is observed on the PhastGel® (Fig. 2.20). The non-boiled and non-reduced C2 
(H43W) was observed as a multimer with a mobility shift at 60 kDa (Fig. 2.20, lane 2). The 
electrophoretic mobility of the C2 (H43W) mutants was unexpected as this mutant is supposed to 
be a dimer mimicking cathepsin W. Therefore, it is expected to exhibit electrophoretic mobility 
similar to that of wild-type C2 and migrate at 42 kDa (Fig. 2.20, lane 8). The non-boiled and 
non-reduced C2 (K39F; E44P) was observed as a multimer at 50 kDa. This relative shift is also 
peculiar as this mutant is supposed to be a monomer regardless of pH, mimicking cruzipain. 
Hence, it is expected to migrate at 27 kDa like monomeric wild-type C2. Multimeric 
conformations of the mutants was abolished by either boiling or reduction with 2-
mercaptoethanol. The monomers were observed as doublets at 24 kDa (Fig. 2.20, lanes 3 and 4 
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Figure 2.20. Assessment of C2 mutants’ capacity to dimerise by PhastGel® SDS-PAGE. The mutants were 
analysed by 12.5% PhastGel® SDS-PAGE and the gel was stained with Coomassie blue R. Lane 1, BioRad LMWM; 
lanes 2 and 5, non-boiled and non-reduced C2 mutants; lanes 3 and 6, boiled and non-reduced C2 mutants and lanes 
4 and 7, boiled and reduced C2 mutants and lane 8, non-boiled and non-reduced wild-type C2. 
 
Dimerisation of wild-type C2 is a pH dependant phenomenon (Boulangé et al., submitted). 
Hence, it was necessary to subject the C2 mutants and wild-type C2 to different pH-values to 
assess this phenomenon. Multimerisation was observed to occur at physiological/neutral pH (Fig. 
2.21, lanes 2, 4 and 6). Subjecting both mutants and wild-type C2 to acidic pH (pH 3.5) 
completely abolished multimerisation. Thus, the proteins migrated as monomers at 24 kDa (Fig. 















Figure 2.21. pH treatment of the C2 mutants and wild-type C2. The C2 mutants and wild-type C2 samples were 
analysed by electrophoresis on a 12.5% homogeneous PhastGel® SDS-PAGE and the gel was stained with 
Coomassie blue R. Lane 1, BioRad LMWM; lanes 2, 4 and 6, samples incubated at pH 7.4 and lanes 3, 5 and 7, 
samples incubated at pH 3.5. 
 
Gelatin SDS-PAGE analysis was performed to determine the activity of the C2 mutants against 
gelatin. Both C2 mutants were observed to be active as doublets at 41 kDa (Fig. 2.22, lanes 2 and 
3) represented by the clearing on the gel. The C2 (K39F; E44P) mutant was observed to be more 
active than the C2 (H43W) mutant as indicated by the relative clearing on the gel (Fig. 2.22, 
lanes 2 and 3). C2 activity was observed as the single band clearing at 41 kDa (Fig. 2.22, lane 4).  
 
  






Figure 2.22. Gelatin-containing non-reducing SDS-PAGE (12%) showing activity of the C2 mutants. Non-
boiled and non-reduced samples were subjected to electrophoresis on a SDS-PAGE (12%) gel containing 1% 





2.3.4 Enzymatic characterisation of the C2 mutants. 
Enzymatic characterisation of the C2 mutants was performed to assess the effects of the 
mutations on activity compared to activity of wild-type C2. Firstly, the active concentration of 
the enzymes was determined by active site titration using E-64. The C2 (H43W) mutant 
exhibited 20% activity whereas the C2 (K39F; E44P) mutant contained 50% active enzyme. 
Wild-type C2 contained 10% active enzyme. Activity of the mutants was assayed against a 
standard substrate for cathepsin L-like cysteine proteases, Z-Phe-Arg-AMC. 
 
Michaelis-Menten curves were plotted for both the C2 mutants [C2 (H43W) and C2 (K39F; 
E44P)] and wild-type C2 (Fig. 2.23). These curves were used to determine the affinity constant 
(Km) of each protease form for Z-Phe-Arg-AMC. The Km of C2 (H43W) was determined to be 
11.7 µM, 10.3 µM for C2 (K39E44ΔFP) and 9.82 µM for wild-type C2 (Table 2.4). Therefore, it 
can be concluded that the mutants and wild-type C2 have similar Km-values for the hydrolysis of 
Z-Phe-Arg-AMC.  
 
The specificity constant (kcat/Km) of the C2 mutants and wild-type C2 for the hydrolysis of Z-
Phe-Arg-AMC was determined. The C2 mutants displayed similar specificity constants of 1.02 
s 1.μM-1 for C2 (H43W) and 0.62 s-1.μM-1 for C2 (K39F; E44P) while wild-type C2 displayed a 
very different specificity constant for the hydrolysis of Z-Phe-Arg-AMC of 90.51 s-1.M-1 (Table 
2.3). Differences in the rate of substrate turnover by the C2 mutants compared to wild-type C2 








Figure 2.23. Michaelis-Menten curves for the hydrolysis of Z-Phe-Arg-AMC by C2 mutants and wild-type C2. 
(A) C2 (H43W), (B) C2 (K39F; E44P) and (C) wild-type C2 Michaelis-Menten curves. The activity of the proteases 
was assayed against Z-Phe-Arg-AMC in congopain assay buffer [100 mM Bis-Tris buffer, pH 6.0, 4 mM EDTA, 
0.02% (w/v) NaN3, 6 mM DTT]. The curves were plotted using the Hyper® 32 software (J.S. Easterby). The curves 
were used to determine the kinetic constants (Km, kcat and kcat/Km).  
 
Table 2.3. Kinetic constants for the hydrolysis of Z-Phe-Arg-AMC by the C2 mutants and 
wild-type C2. Assays were carried out in congopain assay buffer [100 mM Bis-Tris buffer, pH 
6.0, 4 mM EDTA, 0.02% (w/v) NaN3, 6 mM DTT] with 1.5 ng of active enzyme at 37ºC. The 
kinetic constants were calculated using the Hyper® 32 software (J. S Easterby). 
Enzyme  Km (μM) Vmax (μM.s-1)  kcat (s-1) kcat/Km (s-1.μM-1) 
C2   9.82  2.85   0.89  90.57 
C2 (H43W)  11.7  0.93   0.012  1.02 
C2 (K39F; E44P) 10.3  1.79   0.0064  0.62 
 
The optimum pH for maximal activity of both mutants and wild-type C2 was determined using 
constant ionic strength AMT buffers at different pH-values (Ellis and Morrison, 1982) before 
measuring enzyme activity against Z-Phe-Arg-AMC. The pH activity profiles for C2 (H43W), 
C2 (K39F; E44P) and wild-type C2 are shown (Fig. 2.24). All the C2 forms share a pH optimum 




activity remaining at physiological pH. Activity of the proteases is completely abolished at pH-





Figure 2.24. pH activity profiles of the C2 mutants and wild-type C2 over a pH range of 4.0-9.0. (A) C2 
(H43W), (B) C2 (K39F; E44P) and (C) C2 pH profiles. The constant ionic strength AMT buffers were used to 
determine optimum pH of the proteases. The curves were plotted using the GraphPad® Prism software. 
 
2.4 DISCUSSION 
Vaccination of animals with the pathogenic factors secreted or released by dying parasites has 
been shown to be the most viable avenue for controlling trypanosomosis in cattle. Authié et al. 
(2001) conducted an immunisation trial in cattle using the recombinant catalytic domain of 
congopain (C2) as an antigen. Although the protective effects of immunisation were limited, the 
study revealed the role played by cysteine proteases in the disease process. Analysis of P. 
pastoris expressed C2 by PhastGel® SDS-PAGE revealed unexpected dimerisation of the 
protease at physiological pH. More relevant to vaccine development was the fact that antibodies 
from trypano-tolerant cattle specifically recognised the dimeric conformation. Therefore, a 
hypothesis was formulated that protective epitopes are associated with the dimer. For these 




elucidate the dimerisation mechanism of congopain in order to develop an effective anti-disease 
vaccine for trypanosomosis.  
 
A dimerisation model was proposed based on the crystal structure of cruzipain, a monomer and 
cathepsin W that is always a dimer. In the present study the author embarked on mutating certain 
amino acid residues located in the dimerisation motif of congopain to mimick either cruzipain or 
cathepsin W using PCR-based site-directed mutagenesis. The mutants were successfully 
expressed in the P. pastoris expression system and their dimerisation capacity was assessed by 
PhastGel® SDS-PAGE. In addition, the enzymatic characteristics of the mutants were determined 
to assess the effects of mutations on enzyme catalysis. 
 
In the present study, high level expression of the C2 mutants and wild-type C2 was achieved in 
the P. pastoris expression system. In addition, each protease form remained stable in expression 
supernatants over an expression period. Although full-length congopain has been expressed in 
high yields (2 to 4 mg of protein per litre of culture) in yeast, the protease was shown to be 
highly unstable in the culture supernatants (Boulangé et al., submitted). This is the major 
obstacle encountered with the expression of the full length protein in eukaryotic systems. The 
stability problem observed with congopain seems to occur in all Trypanosomatidae cathepsin L-
like cysteine proteases with the exception of cruzipain (Alvarez et al., 2002). Expression of 
functionally active full-length cruzipain was achieved in insect cells, although the yield was low 
(Alvarez et al., 2002). The catalytic domain of parasite cysteine proteases had been successfully 
expressed in the P. pastoris expression system. These include the cathepsin L-like cysteine 
protease of Gnathostoma spinigerum, a mammalian parasite (Kongkerd et al., 2008), cathepsin B 
of T. congolense (Mendoza-Palomares et al., 2008), rhodesain, a major cysteine protease of T. b. 
rhodesiense (Caffrey et al., 2001), and multiple isoforms of cathepsin B-like cysteine proteases 
from Trichobilharzia regenti (Dvořák et al., 2005).  
 
Heterologous expression of functionally active cysteine proteases has been achieved in E. coli 
cells. These include full-length cruzipain, the major cysteine protease of T. cruzi (Eakin et al., 
1993), a cysteine proteinase B of Leishmania braziliensis (Lanfranco et al., 2008), and cysteine 
proteinase B of L. mexicana (Sanderson et al., 2000). Attempts to express functionally active 




2001). Functionally active truncated congopain was successfully expressed in a baculovirus 
expression system with very low yields (Boulangé et al., 2001). Therefore, these systems could 
not be used in this study due to the above mentioned limitations. 
 
Expression of the truncated protease devoid of the highly immunogenic C-terminal domain 
drastically improved the expression efficiency of cruzipain (Eakin et al., 1993; McGrath et al., 
1995). Similar findings were obtained with heterologous expression of truncated congopain in 
yeast (Boulangé et al., submitted). Truncated congopain was expressed at five fold higher levels 
than the full-length protease (Boulangé et al., submitted). The truncated form of congopain 
retained its activity, indicating that the C-terminal domain is not essential for activity of the 
parasite cysteine proteases (Boulangé et al., submitted). Sanderson et al., (2000) showed that the 
recombinant cysteine protease B of L. mexicana is active in the absence of the C-terminal 
domain. Thus, the C-terminal domain of parasite cysteine protease plays no role in activity of the 
enzymes.  
 
The P. pastoris expression system allows for post-translational modification i.e. proteolytic 
processing, folding, disulfide bond formation and glycosylation of proteins (Wu and Letchworth, 
2004). This is the main advantage of this system over the bacterial system. Bacterial systems 
express cysteine proteases as insoluble inclusion bodies that require solubulisation and 
renaturation for recovery of active protein (Sanderson et al., 2000; Aloulou et al., 2006; 
Lanfranco et al., 2008). The yeast system allows for extracellular secretion of the proteins, thus 
significantly simplifying the purification process. This desirable feature is brought about by the 
presence of the Saccharomyces cerevisae α-factor signal peptide in P. pastoris expression 
vectors.  
 
Analysis of P. pastoris expression supernatants revealed processing of the proregion of the C2 
mutants yielding an active mature enzyme. Processing of the proregion was expected to occur 
autocatalytically at acidic pH as shown for papain (Vernet et al., 1995). The pH of the expression 
supernatant decreased to pH 5.0. Therefore, the drop in pH of the expression supernatants 
facilitated the cleavage of the proregion by changing the tertiary structure of the protease, 
circumventing the inhibition of active site residues by the propeptide (Menard et al., 1998). 




sulfate, an unusual feature amongst papain-like enzymes (Serveau et al., 2003). This suggests 
that congopain might be processed in the bloodstream of the infected host to its active form and 
can contribute to the pathogenesis of the disease (Serveau et al., 2003). 
 
The propeptide of cysteine proteases has been shown to play a dual role in the protease. The 
propeptide has been empirically shown to be essential for the correct folding of the parent 
enzyme and inhibits proteolytic activity of the parent enzyme, thereby maintaining it in the 
inactive zymogen state (Vernet et al., 1995; Lalmanach et al., 1998; Menard et al., 1998; Brooks 
et al., 2000; Sanderson et al., 2000; Lanfranco et al., 2008). The inhibitory property of the 
proregion against congopain was shown to be conferred by the conserved “YHNGA” motif. A 
similar motif “YLNGA” is present in the cysteine protease B of L. mexicana (Sanderson et al., 
2000). The inhibitory motif of trypanosomal and mammalian cysteine proteases was exploited to 
derive potent inhibitors against the protease with potential chemotherapeutic use (McGrath et al., 
1995; McKerrow et al., 1995; Chowdhury et al., 2002).  
 
Processing of the propeptide takes place at several cleavage sites within the protease as shown 
for the central domain of CP1 (C1), cruzipain and cysteine protease B of L. mexicana (Eakin et 
al., 1993; Sanderson et al., 2000; Boulangé et al., 2001). C1 was observed to migrate as a 
doublet of 27 kDa (Boulangé et al., 2001). The monomeric forms of the C2 mutants exhibited 
similar behaviour in the present study migrating as doublets of 24 kDa. N-terminal sequencing of 
C1 revealed inconsistency in the in vitro maturation site of the proenzyme (Boulangé et al., 
2001). The N-terminal sequence of the top band was TGKAPPA and KAPPA for the bottom 
band (Boulangé et al., 2001). The N-terminal sequence of cruzipain consists of APAA while that 
for the cathepsin L-like cysteine protease of T. carassii comprises of APDE (Eakin et al., 1993; 
Ruszczyk et al., 2008). Therefore, this evidence confirms that maturation of parasite cysteine 
proteases occur at different maturation sites, although there are some parasites that share the 
same maturation site (Lanfranco et al., 2008).  
 
Dimerisation of the C2 mutants has been shown to be a pH dependant phenomenon (Boulangé et 
al., submitted). In the present study, both C2 mutants exhibited a higher molecular weight than 
wild-type C2 at physiological pH. However, at acidic pH, the C2 mutants and wild-type C2 




was different from that of wild-type C2, K39, H43 and E44 are indeed involved in the dimerisation 
process. However, the mobility shift of the C2 mutants on a PhastGel® suggests that more amino 
acid residues are involved in the dimerisation mechanism of congopain. This hypothesis was 
corroborated by the proposed dimerisation mechanism of cathepsin W (Brinkworth et al., 2000). 
Brinkworth et al. (2000) identified amino acid residues located at positions 1-10, 40-80 and 170-
200 in each monomer to be involved in the dimerisation process. Furthermore, the motif 
consisting of R40I41S42F43W44D45F46 was shown to form part of the dimer interface (Brinkworth 
et al., 2000). The work done by Chen et al. (2008) in elucidating the dimerisation mechanism of 
the SARS 3C-like protease confirms involvement of many amino acid residues in the 
dimerisation process. Seven amino acid residues including S1, F3, R4, S10, E14, S139 and F140 were 
shown to be involved in the dimerisation process of the protease (Chen et al., 2008; Shi et al., 
2008). Substitution of these amino acid residues with alanine was shown to alter the dimer-
monomer equilibria of the protease and catalytic activity of the 3C-like protease. 
 
The proposed dimerisation mechanism of congopain was based on the 3D structure of cathepsin 
W and cruzipain (Prof J. Hoebeke, IBMC, Strasbourg, France, personal communication). 
Although cruzipain has been demonstrated to exist as a monomer in vitro, there is no evidence 
demonstrating the dimerisation of cathepsin W in vitro (McGrath et al., 1995; Brinkworth et al., 
2000). In fact, it was assumed that cathepsin W is a dimer based on a theoretical model that was 
constructed from the cruzipain central domain (C1) structure (Brinkworth et al., 2000). 
Mammalian cathepsin C is the only cathepsin that has been shown to exist as a multimer in vitro 
(Dahl et al., 2001; Horn et al., 2002). Analysis of cathepsin C isolated from bovine spleen by gel 
chromatography revealed that the mature protease is a tetramer (Horn et al., 2002). These 
findings were corroborated by crystallisation of a baculovirus expressed cathepsin C in the 
presence of the inhibitor Gly-Phe-diazomethane (Molgaard et al., 2007). Thus, such flaws in the 
proposed dimerisation model of congopain explain the unexpected electrophoretic mobility of the 
C2 mutants on a PhastGel®.  
 
Sera from trypano-tolerant cattle were previously shown to better recognise the dimeric 
conformation of congopain than the monomeric conformation (Boulangé et al., submitted). 
Elucidation of the dimerisation mechanism of congopain was expected to assist in the 




allowed for the design of peptidomimotopes that specifically target the dimer interface of 
congopain. A similar strategy has been explored for developing inhibitors against the SARS 3C-
like protease (Chen et al., 2008). An inhibitor targeting the N-terminal finger of the SARS 3C-
like protease was shown to specifically bind and competitively inhibit the activity of the protease 
(Ding et al., 2005). Therefore, understanding of the dimerisation mechanism of congopain is 
crucial for the design and development of an effective inhibitor against the protease.  
 
The C2 mutants exhibited affinity constants (Km) similar to wild-type C2. The mutants [C2 
(H43W) and C2 (K39F; E44P)] and wild-type C2 used as a control had affinity constants around 
10.61 µM. These compared favourably to the Km-values obtained previously for native 
congopain of 1.5 µM, 4.4 µM, and 7.3 µM for the hydrolysis of Z-Phe-Arg-AMC (Authié et al., 
1992; Mbawa et al., 1992; Chagas et al., 1997). Similarity in the affinity constants of wild-type 
C2, C2 mutants and native congopain suggests that the mutations did not affect the affinity of the 
protease for the substrate. However, the mutation did affect the proteolytic activity of the 
protease as indicated by significant differences in the specificity constants for the hydrolysis of 
Z-Phe-Arg-AMC by the C2 mutants compared to that by wild-type C2. A two-fold difference in 
the specificity constant was observed between the C2 mutants and wild-type C2. 
 
The C2 mutants exhibited pH profiles similar to that of wild-type C2. They were all active over a 
broad pH range with optimum activity at pH 6.5 and 80% activity remaining at physiological pH. 
Similar findings were previously obtained with native congopain (Mbawa et al., 1992; Chagas et 
al., 1997). Significant activity at physiological pH suggests that the protease is active in the 
bloodstream of infected cattle (Serveau et al., 2003). This bears interesting consequences for 
host-parasite interactions.  
 
The focus of the present study was to elucidate the dimerisation mechanism of congopain with 
the aim of identifying protective epitopes associated with the dimer conformation. Amino acid 
residues located in the dimerisation motif of congopain (K39, H43 and E44) were mutated 
successfully by PCR-based site-directed mutagenesis to mimick cruzipain and cathepsin W. The 
mutant forms of C2 were heterologously expressed in P. pastoris and purified by three phase 
partitioning and molecular exclusion chromatography. The effects of mutations on the 




mutations altered the electrophoretic mobility of the C2 mutants compared to wild-type C2. The 
C2 (H43W) mutant was expected to migrate as a dimer of 42 kDa like wild-type C2 but 
displayed a mobility shift at 60 kDa. The C2 (K39F; E44P) mutant did not behave as postulated 
in the model as it was observed to migrate at 50 kDa in a PhastGel®. Multimerisation of the C2 
mutants was prevented by subjecting C2 mutants to denaturing conditions and acidic pH. The C2 
mutants and wild-type C2 displayed similar pH profiles but different kinetic constants for the 
hydrolysis of Z-Phe-Arg-AMC. Although this study did not completely elucidate the 
dimerisation mechanism of congopain, it confirmed the involvement of the dimerisation motif in 
the dimerisation process. Crystallisation of congopain is required in order to identify surface 
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ABSTRACT 
Congopain, the major cathepsin L-like cysteine protease of Trypanosoma congolense is an 
attractive candidate for an “anti-disease” vaccine, and target for the design and development of 
chemotherapeutic drugs. Structural studies are the most powerful tool for gaining access to the 3-
D structure of a protein. The 3-D structure of congopain has not yet been elucidated. Hence, 
wild-type catalytic domain of congopain (C2), as well as mutant forms, were heterologously 
expressed in P. pastoris and purified by a combination of three phase partitioning, molecular 
exclusion chromatography and cation exchange chromatography, to crystallisation purity levels. 
The catalytically active wild-type C2 and the C2 dimer mutants were inhibited with E-64 to 
prevent self-degradation of the proteases during the purification process. Then, each protease 
form was concentrated to 5-10 mg/ml per batch, and sent for crystallisation. As crystallisation of 
these proteases is still underway, we embarked on virtual 3-D modelling. The 3-D structure of 
congopain was constructed based on the crystal structure of cruzipain using in silico homology 
modelling. The 3-D structure of congopain is similar to the structure of papain-like enzymes, 
with α-helices and β-sheets forming the L and the R domains. The dimerisation motif was shown 
to be located on the surface of the protease. While awaiting the crystallographic results, 
molecular docking studies can be conducted using the 3-D model of congopain to define and 
construct mimotopes for immunisation studies, or design and development of structure-based 
inhibitors of the protease.  
 





Trypanosoma congolense is the major causative agent of African animal trypanosomosis, or 
nagana in sub-Saharan Africa. In search for new drug targets, cysteine proteases were extensively 
studied in this group of parasites (Authié et al., 1992; Coombs and Mottram, 1997; Mottram et 
al., 2004). Analysis of T. congolense cDNA revealed two genes coding for related enzymes, 
namely CP1 (Fish et al., 1995, EMBL accession Z25813) and CP2 (Jaye et al. 1994, EMBL 
accession L25130). A functionally active, CP2 type enzyme, named congopain, was purified 
from T. congolense bloodstream lysates by immuno-affinity chromatography (Authié et al., 
1992; Mbawa et al., 1992). 
 
Congopain is a cathepsin L-like cysteine protease with a classical papain-like catalytic triad 
consisting of C25, H159 and N175 (papain numbering). The enzyme is synthesised as an inactive 
zymogen by the parasites (Authié et al., 1992; Mbawa et al., 1992). The propeptide is essential 
for correct folding of the protease and inhibits the parent enzyme (Vernet et al., 1995). 
Autocatalytic processing of the propeptide at acidic pH produces a mature enzyme consisting of 
a catalytic domain (217 residues) and a C-terminal domain (105 residues) (Boulangé et al., 2001; 
Serveau et al., 2003). The C-terminal domain is unique to Trypanosomatidae cysteine proteases 
(Mottram et al., 1989). Although the C-terminal domain is highly immunogenic, its exact 
function still remains to be elucidated (Jaye et al., 1994; Chagas et al., 1997).  
 
Congopain is active over a broad pH range with optimal activity at physiological pH. The 
enzyme exhibits endopeptidolytic activity against natural protein substrates such as fibrinogen, 
serum albumin, immunoglobulins and trypanosome variant surface glycoprotein (Mbawa et al., 
1992). However, the protease has little or no activity against casein and elastin (Mbawa et al., 
1992). The protease prefers basic amino acid residues such as arginine at P1 and bulky 
hydrophobic residues like phenylalanine in P2. The choice of synthetic substrate for congopain 
(and all papain-like enzymes) is Z-Phe-Arg-AMC (Authié et al., 1992; Chagas et al., 1997). 
However, substrates such as the dibasic Z-Arg-Arg-AMC and monobasic, N-terminally 
unblocked Arg-AMC are not hydrolysed by congopain (Authié et al., 1992; Mbawa et al., 1992). 
The protease is inhibited by the mechanistic class specific inhibitor, trans-epoxysuccinyl-4-





Congopain has been shown to be circulating in the bloodstream of infected cattle (Authié et al., 
1992). Furthermore, it was found that antibodies from trypano-tolerant, but not trypano-
susceptible, cattle recognise congopain in vitro (Authié et al., 1992). Inhibition of congopain 
activity by antibodies from trypano-tolerant cattle was thought to contribute to disease resistance 
of this breed of cattle. Therefore, congopain is a good candidate for an anti-disease vaccine for 
cattle trypanosomosis. Recombinant catalytic domain of congopain (C2) was heterologously 
expressed in a baculovirus expression system (Boulangé et al., 2001). Cattle were immunised 
with C2 and challenged with T. congolense (Authié et al., 2001). This study revealed that C2 
partially protected the animals against the disease caused by an infection with T. congolense 
(Authié et al., 2001). This study confirmed the role played by cysteine proteases in disease 
pathology (Authié et al., 2001). 
 
The 3-D structure of congopain is yet to be elucidated. However, cruzipain, the congopain 
homologue from T. cruzi, has been crystallised. The crystal structure of cruzipain allowed 
researchers to develop numerous structure-based peptide inhibitors. McGrath et al. (1995) 
showed that cruzipain activity was inhibited by peptidly-fluoromethylketone inhibitors. The 
inhibition of cruzipain activity by the inhibitors was correlated with death of parasites in both ex 
vivo tissue culture and in vivo mouse models of the disease (Harth et al., 1993; McGrath et al., 
1995). Thus, it is hoped that elucidation of the 3-D structure of congopain will facilitate both the 
design of structure-based inhibitors of the protease for prophylaxis of animal trypanosomosis and 
development of mimotopes for use in immunisation studies.  
 
The catalytic domain of congopain (C2) and the mutant proenzyme [proC2 (C25A)] were 
heterologously expressed in a P. pastoris expression system (Boulangé et al., submitted). 
Analysis of recombinant C2 by PhastGel® SDS-PAGE revealed unexpected dimerisation of the 
protease at physiological pH (Boulangé et al., submitted). Moreover, antibodies from trypano-
tolerant cattle recognised dimer-specific epitopes (Boulangé et al., submitted). Thus, it is 
important to understand the dimerisation mechanism of congopain in order to design and develop 
an effective vaccine against the disease. In this study, both C2 and proC2 (C25A) were 
heterologously expressed in the P. pastoris expression system. The proteases were purified by 




chromatography. Crystallisation of the different protease forms of congopain is currently 
underway at the Institut de Biologie Structurale (Grenoble, France).  
 
3.2 MATERIALS AND METHODS 
3.2.1. Materials 
Glycerol stocks of P. pastoris containing recombinant pPic9-proC2 and pPic9- proC2 (C25A) 
were obtained from Dr A Boulangé (University of KwaZulu-Natal, Pietermaritzburg). P. pastoris 
containing the pPic9-proC2 (H43W) and pPic9-proC2 (K39F; E44P) were generated as described 
in Chapter 2. Sephacryl S-300 and SP Sephadex C-25 were purchased from Sigma (Munich, 
Germany). Anti-peptide antibodies were produced in chickens against a peptide corresponding to 
the 22 N-terminal residues of congopain (Mkhize, 2003). IgG anti-dimer C2 antibodies were 
raised in rabbits against the dimeric form of C2 that was expressed in P. pastoris (A. Boulangé, 
unpublished). Goat anti-rabbit IgG-HRPO conjugate was obtained from Jackson 




3.2.2.1 Expression of C2 and proC2 (C25A) in P. pastoris 
The glycerol stocks of P. pastoris strain GS 115 containing pPic9-proC2 and pPic9-proC2 
(C25A) were streaked on YPD plates [1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) 
dextrose, 15 g/l bacteriological agar] containing ampicillin (50 µg/ml). It is important to mention 
that addition of ampicillin was purely to minimise the risk of bacterial contamination of the 
culture. The plates were incubated at 30ºC for 2-3 days until the colonies were sizable. Liquid 
YPD (100 ml) containing ampicillin (50 µg/ml) was inoculated with a single colony of yeast. The 
culture was incubated at 30ºC in a baffled flask with agitation for two days. This pre-culture was 
transferred into 1 L BMGY [1% (w/v) yeast extract, 2% (w/v) peptone, 100 mM potassium 
phosphate buffer, pH 6.5, containing 1.34% (w/v) yeast nitrogen base without amino acids 
(YNB)]. The culture was grown at 30ºC for a further two days to increase biomass. The cells 
were pelleted (6000×g, 10 min, RT) and resuspended in 500 ml buffered minimal media [BMM, 




biotin, 5% (v/v) methanol]. The culture was grown in a baffled flask covered with cheesecloth to 
facilitate aeration, in an orbital shaking incubator at 30ºC for four to six days to allow for protein 
expression. The culture was supplemented with 0.5% (v/v) methanol daily to induce protein 
expression. P. pastoris secretes proteins into the expression media. Cells were pelleted (6000×g, 
10 min, RT) and supernatants were kept at -20ºC until required for purification. 
 
3.2.2.2 Purification of the proteins 
Three phase partitioning (TPP) 
Three phase partitioning (TPP) was carried out as described by Pike and Dennison (1989). The 
expression supernatants were thawed and filtered through Whatman No 1 filter paper. Pro-C2 
was autocatalytically processed to mature C2 by lowering the pH to 4.2 with phosphoric acid. 
Tertiary butanol was added to 500 ml supernatant (1/3 final volume, 250 ml). The proteins were 
precipitated with 40% (w/v) ammonium sulfate (40% of final volume, 300 g) (Pike and 
Dennison, 1989). Ammonium sulfate was dissolved by gentle stirring with a magnetic stirrer. 
The precipitated protein mixture was centrifuged (6000×g, 10 min, 4ºC) using a pre-chilled 
swing-out rotor. The protein layer was collected at the interface between the tertiary butanol and 
aqueous phases and re-dissolved in dialysis buffer (PBS, pH 7.2). Excess salt and tertiary butanol 
were removed from the purified protein by overnight dialysis at 4ºC (PBS, pH 7.2) using a 10 
kDa cut-off dialysis membrane. The diluted protein was concentrated by dialysis against solid 
polyethylene glycol Mr 20 000 (PEG 20 000) until 5-10 ml remained in the dialysis bag.  
 
Molecular Exclusion Chromatography 
Molecular exclusion chromatography (MEC) was used to remove the higher molecular weight 
contaminants. The Sephacryl S-300 HR column (25 × 840 mm) was equilibrated with one 
column volume of 50 mM sodium acetate buffer, pH 4.2 (25 cm.h-1, 4ºC). The column was 
calibrated as described in Section 2.2.2.6. The TPP concentrated protein sample (2.5% of column 
volume, 8 ml) was applied to the column and eluted with 50 mM sodium acetate buffer, pH 4.2. 
Protein elution was monitored by measuring absorbance at 280 nm. 
 
Cation exchange chromatography 
Cation exchange chromatography was performed as a further purification step for C2 and proC2 




with 50 mM sodium acetate buffer, pH 4.2. The pooled MEC fractions were cycled overnight 
through the column at 4ºC (0.5 cm/min). The column was washed with 50 mM sodium acetate 
buffer, pH 4.2 (5 column volumes) and eluted with a linear gradient of NaCl from 0 to 1 M over 
5 column volumes. The A280nm was measured for all the eluted fractions (1.5 ml). The fractions 
containing C2 or proC2 (C25A) were pooled and concentrated by ultrafiltration using an Amicon 
PM 10 membrane. The column was washed with 1 M NaCl (5 column volumes) to remove traces 
of bound proteins. The column was regenerated using one column volume each of 0.1 M HCl 
and 0.1 M NaOH and finally re-equilibrated with Na-acetate buffer (50 mM, pH 4.2, 5 column 
volumes). 
 
3.2.2.3. Protein Quantitation 
Two methods were used to determine protein concentration, i.e. BCA™ Protein Assay kit 
(Pierce, Rockford, IL, USA) and direct visualisation on reducing SDS-PAGE. The BCA assay 
was performed following the manufacturer’s instructions. This quantification method is based on 
the binding of bicinchoninic acid to proteins. Briefly, the working reagent was prepared by 
combining reagent B with reagent A in a 1:20 ratio. Bovine serum albumin (BSA) standards 
were prepared as described in the manual. The standards were mixed with working reagent 
solution (200 µl) in a Nunc® 96 microtiter plate and incubated at 37ºC for 30 min. Development 
of the purple colour was monitored by measuring absorbance at 562 nm (A562nm). A standard 
























Figure 3.1. Standard curve for the determination of protein concentration. Increasing concentrations of BSA 
were plotted against absorbance at 562 nm. The equation of the trend line is y = 0.000279 + 0.230, with a correlation 





For the second method of quantification, BSA standards (0.5 mg/ml to 2 mg/ml) were prepared. 
Equal volumes of the standards and proteins of unknown concentration (5 µl) were run on a 
reducing 12% Laemmli SDS-PAGE gel. The gel was stained with Coomassie blue R-250 
[0.1255 (w/v) Coomassie blue R-250, 50% (v/v) methanol, 10% (v/v) glacial acetic acid]. Protein 
concentration was estimated by comparing band intensity of proteins of unknown concentration 
with the standards (Fig. 3.2).  
 
  







Figure 3.2. Coomassie stained 12% reducing SDS-PAGE gel for direct estimation of protein concentration. 
The BSA standards were run alongside the proteins of unknown concentration. Comparison of band intensity was 
used to estimate protein concentration. Lane 1, BioRad LMWM; lane 2, 0.5 mg/ml BSA; lane 3, 0.75 mg/ml BSA; 
lane 4, 1 mg/ml BSA; lane 5, 1.5 mg/ml BSA; lane 6, 2 mg/ml BSA; lane 7, 1:100 diluted proC2 (C25A) and lane 8, 
1:100 diluted wild-type C2. 
 
3.2.2.4 Protein Visualisation 
Laemmli SDS-PAGE 
Reducing SDS-PAGE was performed using a discontinuous buffer system consisting of running 
(pH 8.8) and stacking (pH 6.8) Tris-glycine buffers (Laemmli, 1970). The samples were treated 
with either non-reducing treatment buffer [125 mM Tris-Cl buffer, pH 6.8, 4% (w/v) SDS, 20 
(v/v) glycerol] or reducing treatment buffer (10% (v/v) 2-mercaptoethanol added to the non-
reducing treatment buffer) in a 1:1 ratio. Electrophoresis was conducted at 20 mA/gel in tank 
buffer [250 mM Tris-Cl buffer, pH 8.3, 192 mM glycine, 0.1% (w/v) SDS]. The proteins were 
stained with Coomassie blue R-250 [0.125% (w/v) Coomassie blue R-250, 50% (v/v) methanol, 








Proteins were transferred to a nitrocellulose membrane from the Laemmli SDS-PAGE gels using 
a semi-dry blotter (Sigma, Steinhem, Germany), run at 7 V overnight (Towbin et al., 1979). The 
nitrocellulose was transiently stained with Ponceau S [0.1% (w/v) Ponceau S in 1% (v/v) glacial 
acetic acid] and the positions of molecular weight marker bands marked with a pencil after 
destaining the membrane with distilled water. The unoccupied sites on the membrane were 
blocked with low fat milk [5% (w/v) low fat milk in TBS (20 mM Tris-Cl buffer, pH 7.4, 200 
mM NaCl)] for one hour. The membrane was washed with TBS (3 × 5 min) and incubated in 
primary antibody diluted in 0.5% (w/v) BSA-TBS for two hours. The membrane was washed 
with TBS (3 × 5 min) and incubated with horse radish peroxidase (HRPO) conjugated secondary 
antibody for one hour. Finally, the membrane was washed with TBS and incubated in substrate 
solution [0.006% (w/v) 4-chloro-1-napthol, 10% (v/v) methanol, 0.0015 (v/v) H2O2] until bands 
became visible. 
 
3.2.2.5 Deglycosylation of proC2 (C25A) 
The proC2 (C25A) sample was incubated with endoglycosidase H according to Caffrey et al. 
(2001). Mutant proenzyme was mixed with 5 M NaCl containing 5% (w/v) SDS. The mixture 
was reduced with 10% (v/v) 2-mercaptoethanol and boiled for 5 min. The mixture was allowed 
to cool to room temperature and 0.5 M sodium citrate (one-tenth volume) was added. The 
samples were split into two tubes and endoglycosidase H (500 U) was added to one of the tubes. 
Both tubes were incubated at 37ºC for three hours to allow for hydrolysis by endoglycosidase H. 
Following incubation, the samples were analysed on a 12% reducing SDS-PAGE gel as 
described in Section 3.2.2.4. 
 
3.2.2.6 In silico homology modelling of congopain 
The 3-D structure of the catalytic domain of congopain (C2, GeneBank accession number L 
25130) was predicted using comparative modelling methods. Firstly, the template protein with 
protein data bank (PDB) coordinates was chosen for construction of the 3-D structure. In this 
case, cruzipain (PDB accession number 2aim) was chosen as a template (Gillmor et al., 1997). 
The C2 amino acid sequence was aligned with the template sequence using the ClustalW2™ 




MODEL™ server for prediction of protein structure (Schwede et al., 2003; Kopp and Schwede, 
2004). The programme models the 3-D structure of the target based on the resolved X-ray 
crystallographic structure of the template. The predicted model of congopain based on the crystal 
structure of cruzipain was referred to as C2 and the positive control model was referred to as 
cruzipain+. The SWISS-MODEL™ server verified the accuracy of the predicted model using 
ANOLEA™ and GROMOS™ algorithms (Melo and Feytmans, 1998). The verified model was 
downloaded as a PDP file with PDB coordinates. The predicted model was viewed using the 
SWISS-PDP viewer (spdbv) programme that was downloaded from the SWISS-MODEL™ 
server (www.swissmodel.expasy.org//SWISS-MODEL.html, accessed on 16/02/2009). The 
predicted model was refined using the spdbv programme by performing two steepest descent 
energy minimisation steps (1:20 and 1:100) to improve the stereochemical geometry of the 
predicted model. The PROCHECK™ algorithm available on the PDB web site 
(http://deposit.pdb.org/adit, accessed on 16/02/2009) was used to validate the refined 3-D model.  
 
3.3 RESULTS 
3.3.1 Expression and purification of C2 and proC2 (C25A) 
High level expression of C2 and proC2 (C25A) was achieved in P. pastoris. C2 was observed as 
a band of approximately 27 kDa while proC2 (C25A) was observed as a prominent band of 36 
kDa (Fig. 3.3, lanes 2 and 3). C2 was processed into a mature enzyme through autocatalytic 
cleavage of the propeptide at acidic pH (Vernet et al., 1995; Boulangé et al., 2001; Serveau et al., 
2003). Functional activity of the enzyme is necessary for processing of the propeptide (Menard et 
al., 1998; Boulangé et al., submitted). The bulk of proC2 (C25A) existed as a zymogen of 36 
kDa (Fig. 3.3, lane 3). Two other bands corresponding to different forms of proC2 (C25A) were 















Figure 3.3. Coomassie stained 12% reducing SDS-PAGE gel showing the expression of C2 and proC2 (C25A) 
by P. pastoris. The protein samples were boiled and reduced prior to loading. Lane 1, BioRad low molecular weight 
marker (LMWM); lane 2, C2 expression supernatant and lane 3, proC2 (C25A) expression supernatant. 
 
Higher levels of the inactive mutant [proC2 (C25A)] were expressed than the functionally active 
C2 (Fig. 3.3, lanes 2 and 3), as described previously (Boulangé et al., submitted). The two higher 
molecular weight bands (58 kDa and 78 kDa) observed for proC2 (C25A) were thought to 
correspond to different forms of the protease (Fig. 3.3, lane 3). The hazy 58 kDa band is 
proposed to be the glycosylated form of proC2 (C25A) and the less conspicuous 78 kDa band is 
proposed to be the multimeric form of proC2 (C25A).  
 
Three phase partitioning was applied as an initial purification step. The expressed proteins were 
precipitated with 40% ammonium sulfate in the presence of tertiary butanol. C2 migrated at 27 
kDa on a reducing SDS-PAGE gel (Fig. 3.4, lanes 2-9). The protein was observed to be pure 
except for the presence of higher molecular weight contaminants. Hence, further purification of 
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Figure 3.4. Purification of recombinantly expressed C2 by three phase partitioning (TPP). The precipitated 
proteins were subjected to analysis on a 12% reducing SDS-PAGE gel. Lane 1, BioRad LMWM and lanes 2-9, 




Concerning proC2 (C25A), four bands were observed on a SDS-PAGE gel after TPP (Fig. 3.5, 
lanes 2-10). The bands were observed at 27, 36, 58 and 78 kDa. The 27 kDa band corresponds to 
the expected size of the mature enzyme. Although processing of the inactive proenzyme was not 
expected (Boulangé et al., submitted), similar results were obtained with the inactive mutant 
cruzipain expressed in a bacterial system (Eakin et al., 1993). Although the mechanism of 
processing is not fully understood, it was proposed that secreted bacterial proteases might be 
involved in the processing of the proregion of cruzipain (Eakin et al., 1993). The presence of 
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Figure 3.5. Purification of recombinantly expressed proC2 (C25A) by three phase partitioning (TPP). The 
precipitated proteins were analysed on a SDS-PAGE (12%) gel. Lane 1, BioRad LMWM and lanes 2-10, 
precipitated proC2 (C25A) fractions from different expression supernatants. 
 
The higher molecular weight contaminants were removed by molecular exclusion 
chromatography. These contaminants correspond to the first peak on the elution profile of C2 
(Fig. 3.6A). C2 eluted at 45 kDa from the column confirming that the protease might have a 
dimeric conformation (Fig. 3.6A). However, the protease of 27 kDa was shown on a reducing 
SDS-PAGE gel (Fig. 3.6B and C). It is likely that the presence of reducing or denaturing agents 
in the treatment buffer disrupts the protease dimer conformation. Analysis of the peak fractions 
by reducing SDS-PAGE gel confirmed the removal of higher molecular weight contaminants 
























































Figure 3.6. Purification of C2 by molecular exclusion chromatography on a Sephacryl S-300 HR column. 
Panel A, elution profile of C2 on a Sephacryl S-300 HR column (25 × 840 mm, 25 cm.h-1) equilibrated with 50 mM 
sodium acetate buffer, pH 4.2. The column was calibrated with blue dextran (2000 kDa), phosphorylase b (97 kDa), 
bovine serum albumin (66 kDa) and ovalbumin (44 kDa). Panels B and C, reducing SDS-PAGE gel analysis of C2 
peak fractions. The fractions were boiled and reduced prior to loading. Panel B, lane 1, BioRad LMWM and lanes 2-
10, C2 MEC peak fractions 58-66. Panel C, lane 1, BioRad LMWM and lanes 2-10, C2 MEC fractions 67-75. 
 
The MEC elution pattern of proC2 (C25A) showed two peaks (Fig. 3.7A). The first peak 
contained higher molecular weight contaminants while proC2 (C25A) eluted in the second peak 
at 66 kDa confirming the existence of a dimeric protease. Analysis of the fractions in the second 
peak by reducing SDS-PAGE revealed that the 58 and 78 kDa bands of proC2 (C25A) co-eluted 
with the 36 kDa band of proC2 (C25A) (Fig. 3.7B, lanes 4-10). This was not surprising as these 
proteins have a molecular weight that is close to each other. A minor 27 kDa band corresponding 
to the mature enzyme was observed on the reducing SDS-PAGE gels (Fig. 3.7B, lanes 3-9 and C, 




















































Figure 3.7. Purification of proC2 (C25A) by molecular exclusion chromatography on a Sephacryl S-300 HR 
column. Panel A, elution profile of proC2 (C25A) on a Sephacryl S-300 HR column (25 × 840 mm, 25 cm.h-1) 
equilibrated with 50 mM sodium acetate buffer, pH 4.2. The column was calibrated with blue dextran (2000 kDa), 
phosphorylase b (97 kDa), bovine serum albumin (66 kDa) and ovalbumin (44 kDa). Panels B and C, reducing SDS-
PAGE gel analysis of proC2 (C25A) peak fractions. The fractions were boiled and reduced prior to loading. Panel B, 
lane 1, BioRad LMWM and lanes 2-10, proC2 (C25A) MEC peak fractions 43-51. Panel C, lane 1, BioRad LMWM 
and lanes 2-10, proC2 (C25A) MEC peak fractions 52-60. 
 
Upon concentration of C2 and proC2 (C25A), the protein samples appeared yellowish, 
suggesting non-protein contamination of the samples. This was undesirable for crystallography, 
hence, a third purification step, cation exchange chromatography, was performed. C2 eluted at 
200 mM NaCl from a SP Sephadex C-25 column (Fig. 3.8A, fractions 4-8). SP Sephadex C-25 
purification of the proteins was achieved as shown by the presence of a single band at 27 kDa on 

































































Figure 3.8. Purification of C2 by cation exchange chromatography on a SP Sephadex C-25 column. Panel A, 
elution of C2 from SP Sephadex C-25 column (1.5 × 10 cm, 0.5 cm/min) using a 0-1 M NaCl gradient in 50 mM 
sodium acetate buffer, pH 4.2. Elution of the proteins was followed by measuring absorbance at 280 nm for each 
fraction. Panel B, assessment of the purity of the peak fractions by reducing SDS-PAGE (12%). The gel was stained 
with Coomassie blue R-250. The samples were boiled and reduced prior to loading. Lane 1, BioRad LMWM and 
lanes 2-10, C2 IEC peak fractions. 
 
The mutant proenzymes eluted with 300 mM salt from the SP Sephadex C-25 column (Fig. 3.9A, 
fractions 8-16). A single band corresponding to the mutant proenzyme was observed at 36 kDa 
on a SDS-PAGE gel (Fig. 3.9B, lanes 2-10). The two larger protein bands (58 kDa and 78 kDa) 
were not observed. There is an apparent difference in the pI of C2 and proC2 (C25A), indicated 
by the difference in elution profiles. This is in line with the theoretical pI of the two proteins, of 
4.6 for C2 and 8.66 for proC2 (C25A). The higher pI of the proenzyme is due to the presence of a 































































Figure 3.9. Purification of proC2 (C25A) by cation exchange chromatography on a SP Sephadex C-25 
column. Panel A, elution of proC2 (C25A) from SP Sephadex C-25 column (1.5 × 10 cm, 0.5 cm/min) using 0-1 M 
NaCl gradient in 50 mM sodium acetate buffer, pH 4.2. Elution of the proteins was followed by measuring 
absorbance at 280 nm for each fraction. Panel B, assessment of the purity of the peak fractions by reducing SDS-
PAGE (12%). The samples were boiled and reduced prior to loading. The gel was stained with Coomassie blue R-




The cation exchange chromatography fractions of C2 and proC2 (C25A) were separately 
concentrated by ultrafiltration using an Amicon PM 10 membrane. The concentrate appeared 
colourless, indicating the separation of the non-protein contaminants. Concentrated C2 migrated 
as a single intense band of 27 kDa (Fig. 3.10, lane 2). The mutant proenzymes migrated at 36 
kDa (Fig. 3.10, lane 4). The two higher molecular weight bands (58 kDa and 78 kDa) of proC2 
(C25A) re-appeared after concentration. The concentration of C2 was determined to be 10 mg/ml 
and that for proC2 (C25A) was 15 mg/ml. The yield was 10× higher than that obtained for the 
expression of C2 in baculovirus (Boulangé et al., 2001). 
 
   








Figure 3.10. Analysis of concentrated C2 and proC2 (C25A) by 12% reducing SDS-PAGE. The samples were 
boiled, reduced and subjected to electrophoresis on a 12% reducing SDS-PAGE gel. Lane 1, BioRad LMWM; lane 
2, concentrated C2; lane 3, C2 ultrafiltration filtrate; lane 4, concentrated proC2 (C25A) and lane 5, proC2 (C25A) 
ultrafiltration filtrate. 
 
The effects of different treatment conditions on the migration of C2 and proC2 (C25A) was 
assessed by SDS-PAGE (Fig. 3.11A). The non-boiled and non-reduced C2 migrated as a smear 
from 36 kDa to 24 kDa (Fig. 3.11A, lane 2). Boiling C2 improved the resolution of the protein on 
a SDS-PAGE gel. The boiled and non-reduced C2 migrated at 24 kDa (Fig. 3.11A, lane 3). 
Boiling and reduction changed the mobility of C2 on a SDS-PAGE gel. The reduced protein 
migrated at 31 kDa (Fig. 3.11A, lane 4). Reduction and boiling serve to relax the structure of the 
protein by disrupting the secondary and the tertiary structure of a protein, thus allowing for 
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Figure 3.11. Analysis of C2 and proC2 (C25A) treated under different conditions. Panel A, reducing SDS-
PAGE (12%) gel showing C2 and proC2 (C25A) subjected to different treatments. Panel B, western blot of C2 and 
proC2 (C25A) with congopain N-terminal peptide antibodies raised in chickens. The affinity purified peptide 
antibodies were used at 10 µg/ml. Lane 1, BioRad LMWM; lane 2, non-boiled and non-reduced C2; lane 3, boiled 
and non-reduced C2; lane 4, boiled and reduced C2; lane 5, non-boiled and non-reduced proC2 (C25A); lane 6, 
boiled and non-reduced proC2 (C25A)  and  lane 7, boiled and reduced proC2 (C25A). 
 
The non-boiled and non-reduced proC2 (C25A) was observed as a conspicuous band at 36 kDa 
(Fig. 3.11A, lane 5). The band corresponding to the mature mutant enzyme was observed at 24 
kDa (Fig. 3.11A, lane 5). A 33 kDa band was observed below the 36 kDa band corresponding to 
the zymogen proC2 (C25A). A faint 78 kDa band is proposed to correspond to the dimeric form 
of proC2 (C25A), although it does not disappear after boiling and reduction of the protease. 
Three bands with a Mr of 24, 36 and 58 kDa were observed for the boiled and non-reduced 
mutant (Fig. 3.11A, lane 6). Four bands were observed for boiled and reduced proC2 (C25A). 
The bands exhibited a Mr of 27, 36, 58 and 78 kDa (Fig. 3.11A, lane 7). The 58 and 78 kDa 
bands were observed as very faint bands on a SDS-PAGE gel. A band corresponding to the 
mature mutant protease displayed a molecular shift of 27 kDa (Fig. 3.11A, lane 7). Thus, boiled 
and reduced proteins migrate more slowly than non-boiled and non-reduced proteins.  
 
Congopain N-terminal peptide antibodies recognised both C2 and proC2 (C25A) (Fig. 3.11B). 
The non-boiled and non-reduced C2 was observed as a smear from 36 to 24 kDa (Fig. 3.11B, 
lane 2). The dimer conformation of C2 was not visualised on a standard Laemmli SDS-PAGE 
system (Fig. 3.11B, lane 2). Boulangé et al., (submitted) showed that C2 does not resolve as a 
dimer on a standard Laemmli SDS-PAGE gel. Attempts to replicate the gel composition and 
buffer systems used for PhastGel® in the Laemmli system failed to resolve the dimeric form of 
C2 (Boulangé et al., submitted). The boiled and non-reduced C2 was recognised as a 24 kDa 




lanes 3 and 4). The antibodies recognised four bands of 24, 36, 58 and 78 kDa for non-boiled and 
non-reduced proC2 (C25A) (Fig. 3.11B, lane 5). Similar bands were recognised by antibodies in 
boiled and non-reduced proC2 (C25A) (Fig. 3.11B, lane 6). Boiled and reduced proC2 (C25A) 
showed a band of 37 kDa (Fig. 3.11B, lane 7). The anti-peptide antibodies were used at a high 
concentration, thus non-specific recognition of proteins was expected.  
 
Treatment of proC2 (C25A) with endoglycosidase H (EndoH) revealed glycosylation of the 
mutant. In the presence of EndoH, the hazy 58 kDa band disappeared (Fig. 3.12, lane 3). 
However, a conspicuous 66 kDa band appeared in the EndoH treated proC2 (C25A). Caffrey et 
al. (2001) showed that rhodesain, the major cysteine protease of T. b. rhodesiense, is 
glycosylated. The glycosylation site was shown to be located in the catalytic domain. Another 
study showed that cruzipain, the congopain homologue from T. cruzi is glycosylated (Eakin et 
al., 1993). Therefore, glycosylation seems to be a common feature amongst cysteine proteases of 
parasitic protozoa. 
 








Figure 3.12. Analysis of deglycosylation of proC2 (C25A) on a reducing SDS-PAGE gel. The boiled and 
reduced proC2 (C25A) was treated with EndoH. Lane 1, BioRad LMWM; lane 2, untreated proC2 (C25A) and lane 
3, EndoH treated proC2 (C25A). 
 
Rabbit anti-dimer C2 antibodies recognised all the different multimer conformations of proC2 
(C25A), C2 (H43W), C2 (K39F; E44P) and wild-type C2 (Fig. 3.13). These antibodies 
recognised the 27, 36, 58, 79 and an extra 97 kDa band of the mutant proenzyme [proC2 
(C25A)]. The rabbit anti-dimer C2 antibodies were produced against P. pastoris expressed 
recombinant C2. Thus, these antibodies may recognise some of the contaminating yeast proteins. 




purification process. The monomeric forms of C2 (H43W) and C2 (K39F; E44P) were not 
recognised by these antibodies. These antibodies recognised the 97 kDa band of C2 (H43W) and 
did not recognise C2 (K39F; E44P).  
 
   






Figure 3.13. Western blot of C2, proC2 (C25A), C2 (H43W) and C2 (K39F; E44P) probed with rabbit anti-
dimer C2 antibodies. The samples were transferred to a nitrocellulose membrane from a Laemmli SDS-PAGE gel 
using a semi-dry blotter, run at 7 V overnight. Lane 1: BioRad LMWM; lanes 2-3, proC2 (C25A); lanes 4-5, wild-
type C2; lanes 6-7, C2 (H43W) and lanes 8-9, C2 (K39F; E44P). 
 
3.3.2 Homology modeling of congopain 
The primary structure of the catalytic domain of congopain (C2) was aligned with the catalytic 
domain of cruzipain, human cathepsin L and human cathepsin W using the CLUSTALW2™ 
programme. C2 displayed 68% identity with cruzipain catalytic domain, 46% identity with 
human cathepsin L and 37% identity with human cathepsin W (Fig. 3.14). Hence, cruzipain was 
chosen as a suitable template for constructing the 3-D model of congopain. The percentage 
identity shared by the template (cruzipain) and the target (C2) sequence is crucial for 
comparative modelling (Melo and Feytmans, 1998; Schwede et al., 2000; Schwede et al., 2003). 
In fact, the quality of the model is directly dependant on the quality of the sequence alignment 
(Melo and Feytmans, 1998). Alignment displaying lower than 40% identity generates errors in 
the modelling process (Schwede et al., 2000). The alignment of C2 is expected to produce a good 
quality model as sequence identity is above the 40% threshold limit. The CLUSTALW2™ 
alignment file was submitted to the SWISS-MODEL™ server for prediction of the 3-D structure 
of the protease. The SWISS-MODEL™ server modelled 214 amino acid residues for the C2 
model based on the cruzipain 3-D structure. The number of amino acids modelled by the SWISS-
MODEL™ server is dependant on the number of amino acid residues present in the template 





CLUSTAL 2.0.10 multiple sequence alignment 
 
 
congopain        -APEAVDWRKKG-AVTPVKDQGQCGSCWAFSAIGNIEGQWKVAGHELTSLSEQMLVSCD- 57 
cruzipain        -APAAVDWRARG-AVTAVKDQGQCGSCWAFSAIGNVECQWFLAGHPLTNLSEQMLVSCD- 57 
cathepsin L      -APRSVDWREKG-YVTPVKNQGQCGSCWAFSATGALEGQMFRKTGRLISLSEQNLVDCSG 58 
cathepsin W      SVPFSCDWRKVAGAISPIKDQKNCNCCWAMAAAGNIETLWRISFWDFVDVSVHELLDCG- 59 
                  .* : ***  .  ::.:*:* :*..***::* * :*         : .:* : *:.*.  
 
congopain        -TNDFGCEGGLMDDAFKWIVSSNKGNVFTEQSYPYASGGGNVPTCDKSGKVVGAKIRDHV 116 
cruzipain        -KTDSGCSGGLMNNAFEWIVQENNGAVYTEDSYPYASGEGISPPCTTSGHTVGATITGHV 116 
cathepsin L      PQGNEGCNGGLMDYAFQYVQ--DNGGLDSEESYPYEAT---EESCKYNPKYSVANDTGFV 113 
cathepsin W      -RCGDGCHGGFVWDAFITVL--NNSGLASEKDYPFQGKVR-AHRCHPKKYQKVAWIQDFI 115 
                    . ** **::  **  :   ::. : :*..**: .       *  .     *   ..: 
 
Congopain        DLPEDENAIAEWLAKNGPVAIAVDA--TSFQSYTGGVLTS----CISEHLDHGVLLVGYD 170 
cruzipain        ELPQDEAQIAAWLAVNGPVAVAVDA--SSWMTYTGGVMTS----CVSEQLDHGVLLVGYN 170 
cathepsin L      DIPKQEKALMKAVATVGPISVAIDAGHESFLFYKEGIYFEP--DCSSEDMDHGVLVVGYG 171 
cathepsin W      MLQNNEHRIAQYLATYGPITVTINM--KPLQLYRKGVIKATPTTCDPQLVDHSVLLVGFG 173 
                  : ::*  :   :*  **::::::    .   *  *:       * .: :**.**:**:. 
 
Congopain        DTSK--------------------PPYWIIKNSWSKGWGEEGYSALRR-HNQCLMKNLPS 209 
cruzipain        DSAA--------------------VPYWIIKNSWTTQWGEEGYIRIAKGSNQCLVKEEAS 210 
cathepsin L      FEST-------------------------------------------------------- 175 
cathepsin W      SVKSEEGIWAETVSSQSQPQPPHPTPYWILKNSWGAQWGEKGYFRLHRGSNTCGITKFPL 233 
                                                                              
 
congopain        SAVVSGPPPPPPTPTFT 226 
cruzipain        SAVVG------------ 215 
cathepsin L      ----------------- 
cathepsin W      TARVQKPDMKPRVSCPP 250 
 
Figure 3.14. ClustalW2™ alignment of congopain catalytic domain (C2). C2 was aligned with the sequences of 
cruzipain (PDB accession number 2aim), human cathepsin L (PDB accession number 1mhw) and human cathepsin 
W (GenBank accession number N 001335). * indicates 100% conserved amino acid residues. 
 
The total energy of the C2 model before energy minimisation was -7968.2 KJ/mol, which was 
85% of the total energy of the positive control, cruzipain+ (-9284.1 KJ/mol). Performance of two 
steps of energy minimisation using the GROMOS™ algorithm improved the stereochemical 
geometry of the model (Melo and Feytmans, 1998; Kopp and Schwede, 2004). The final energy 
of the C2 model was reduced to -9410.2 KJ/mol, resulting in 15% improvement in the packing 
quality of the predicted model. The total energy of the model was negative, confirming that the 
predicted model exists in the most relaxed conformation (Melo and Feytmans, 1998). The 
packing quality of the cruzipain+ model improved by 10% after energy minimisation. There was 
a slight improvement in the total energy of the positive control after refinement using the 
GROMOS™ algorithm, therefore, authenticating the modelling algorithm (Melo and Feytmans, 
1998). The positive control (cruzipain+) model displayed lower total energy than the C2 model 
before and after energy minimisation. The total energy of the X-ray resolved crystal structure 
was shown to be lower than the total energy of the predicted model (Melo and Feytmans, 1998). 





Ramachandran analysis of the C2 model using the PROCHECK™ algorithm revealed that 85.6% 
of the non-glycine and non-proline residues fall within the limits of Ф/ψ conformational angles 
(Fig. 3.15A). This compared very well with the cruzipain+ model that showed 84.7% of the non-
proline and non-glycine residues to be located within the most favoured regions of the 
Ramachandran plot (Fig. 3.15B). The C2 model contained 11.7%, 0.6% and 2.2% residues in the 
additionally allowed regions, generously allowed regions and the disallowed regions of the 
Ramachandran plot respectively (Fig. 3.15A). A good quality model should contain very few 
amino acid residues in the disallowed regions (Kleywegt and Jones, 1996; Kleywegt, 1997). 
Independent studies modelling P. falciparum transketolase and E. coli oligopeptidase B showed 
the presence of a few amino acid residues in the disallowed regions of the Ramachandran plot 





Figure 3.15. Validation of the C2 model by constructing Ramachandran plots using the PROCHECK™ 
algorithm. Ramachandran plots were derived after energy minimisation of (A) the C2 model and (B) the cruzipain+ 
model. The different coloured regions indicate the “most favoured regions” (red), “additionally allowed” (yellow), 
“generously allowed” (light yellow) and “disallowed” regions (white).  
 
The predicted 3-D topology of the C2 model consisted of antiparallel β-pleated sheets and α-
helices that folded to form the two domains of C2; namely the R and the L domains (Fig. 3.16A). 
The predicted 3-D structure of the C2 model is consistent with that of papain-like cysteine 
proteases (Lecaille et al., 2001). The secondary structure of the C2 model consisted of eight 
antiparallel β-pleated sheets and five α-helices that varied in length (Fig. 3.16A). This was 




model was shown to be composed of six of the eight antiparallel β-pleated sheets and two of the 
five α-helices (Fig. 3.16A). Therefore, it can be concluded that the R domain of the C2 model 









Figure 3.16. Predicted 3-D models of C2 and cruzipain+. Models, (A) C2 and (B) cruzipain+ were analysed using 
the spdbv viewer programme. The 3-D model was coloured according to the secondary structure. The antiparallel β-
pleated sheets are represented in yellow and the α-helices in red.  
 
The predicted 3-D structure of the C2 model followed the common framework of the positive 
control model (cruzipain+). This was revealed by performing an iterative magic fit between the 
chiral carbon (Cα) of the predicted model and the respective positive control. Root mean square 
deviation (RMSD) between the predicted backbone of the model and the experimental control 
model is another method for assessing the quality of the model (Chothia and Lesk, 1986; Wells 
et al., 2006). The C2 model deviated by 0.22 Å from the cruzipain+ model with 852 atoms 
superimposed. The minimal deviation between the C2 and cruzipain+ models could be due to the 
high percentage of sequence identity shared by the template (cruzipain+) and the target (C2). The 
RMSD values between the predicted model and the experimental positive control should not be 
more than 0.5 Å (Lesk, 1997). Therefore, the RMSD values of the C2 model further confirmed 
the quality of the predicted model. 
 
Assessment of the superimposed 3-D structures of the C2 model on the cruzipain+ control 
structure confirmed the high quality of the model (Fig. 3.17). Traces of a green colour indicating 
the secondary structure of the C2 model was observed throughout the secondary structure of the 
positive control (yellow colour) (Fig. 3.17). This confirms that the 3-D structure of congopain is 








Figure 3.17. Comparison of the 3-D structure of the C2 model with the cruzipain+ control model. The C2 
model was superimposed on the cruzipain+ model using the spdbv programme. The secondary structure of the C2 
model is indicated by the green colour and the yellow colour represents the secondary structure of the positive 
control.  
 
The predicted model of C2 obtained in this study was better than that available in the literature 
(Lecaille et al., 2001). The C2 model was constructed by homology modelling of congopain with 
the experimental 3-D structure of cruzipain (PDB accession number 1aim) (Lecaille et al., 2001). 
The predicted model deviated by 1.06 Å (190 Cα atoms superimposed) from the backbone of the 
positive control (Lecaille et al., 2001). The RMSD of the predicted model is above the 0.5 Å 
threshold limit, thus, the model could be considered inaccurate. The experimental conditions and 
method used to resolve the crystal structure of a protein impact greatly on the resulting 3-D 
structure (Harrison et al., 1995; Guex and Peitsch, 1997). Models constructed from experimental 
proteins resolved by nuclear magnetic resonance (NMR) displayed minimal deviation from the 
backbone structure of the template (Harrison et al., 1995; Guex and Peitsch, 1997). Therefore, 
the 3-D structures resolved by NMR are more relaxed since the protein is resolved in the solution 
state (Guex and Peitsch, 1997). The degree of resolution of the X-ray crystal structure influences 
the deviation of the predicted model backbone from the control (Kleywegt and Jones, 1996). The 
crystal structure of cruzipain was resolved to 2.1 Å in the presence of inhibitors (Gillmor et al., 
1997). Judging from the degree of resolution of the crystal structure of cruzipain, the generated 
model was not expected to deviate to a great degree from the backbone structure of the 
experimental control. Inhibitors used to stabilise the 3-D structure of a protein during 
crystallisation also contributes to the degree of deviation of the model from the control backbone 




that might have contributed to the stabilisation of the 3-D conformation of the enzyme, resulting 
in a more relaxed 3-D structure of cruzipain (Gillmor et al., 1997). Therefore, the model of C2 
constructed in the present study could be used to design structure-based inhibitors of the enzyme. 
 
The possible dimerisation motif of congopain has been identified based on the 3-D structures of 
cruzipain and cathepsin W (Brinkworth et al., 2000; Prof. J. Hoebeke, IBMC, France, personal 
communication). The dimerisation motif of congopain consists of W38K39V40A41G42H43E44L45 
(Prof. J. Hoebeke, IBMC, France, personal communication). This motif is similar to that of 
cathepsin W consisting of amino acid residues R40I41S42F43W44D45F46 (Brinkworth et al., 2000). 
There is no empirical evidence showing surface location of the dimerisation motif in congopain. 
Hence, the 3-D surface structure of the C2 model was analysed by the spdbv programme to 
identify the location of the dimerisation motif in the enzyme. Indeed, the dimerisation motif was 
located on the surface of the C2 model (Fig. 3.18A). The cruzipain+ model exhibited similar 
results, confirming surface location of the dimerisation motif, although the protease is known to 
exist as a monomer (Fig. 3.18B). The dimerisation motif of the C2 model was virtually 
superimposable on the cruzipain+ motif with a RMSD value of 0.22 Å (data not shown). Traces 
of a green colour representing the secondary structure of the C2 model were observed in the 
backbone and side chains of the cruzipain+ model except where K39 was substituted with F39 and 




Figure 3.18. Molecular surface structures of the models showing surface location of the dimerisation motif. 
(A) C2 model surface structure and (B) cruzipain+ surface structure. The molecular surface of both C2 model and 





Ever since the emergence of drug resistant parasites, vaccination has been explored as an 
alternative method for controlling trypanosomosis in animals. However, antigenic variation 
displayed by trypanosomes is a major impediment to vaccine development. The concept of an 
anti-disease vaccine was proposed based on targeting pathogenic factors contributing to the 
disease, rather than targeting the parasite itself (Playfair et al., 1991; Authié, 1994). Cysteine 
proteases such as congopain were implicated as pathogenic factors involved in the development 
of anaemia in infected animals (Authié et al., 2001). Immunisation studies conducted in cattle 
using baculovirus expressed congopain, administered in conjunction with RWL proprietary 
adjuvant from SmithKline-Beecham, provided partial protection to animals following a challenge 
with T. congolense (Authié et al., 2001). Although there were no significant differences in the 
development of infection between immunised and non-immunised animals, the immunised 
animals produced higher titres of antibodies against congopain, maintained or gained weight 
during infection and developed less severe anaemia. A subsequent study aimed at reproducing 
these results using P. pastoris expressed congopain co-administered with ISA206 oil-in-water 
adjuvant from Seppic was unsuccessful (E. Authié and A. Boulangé, personal communication). 
The objective of the present study was to elucidate the 3-D-structure of congopain in order to 
identify protective epitopes exposed at the surface of the protease. Once these epitopes have been 
identified, mimotopes could be designed, constructed and used in vaccination experiments.  
 
In the present study, the truncated wild-type catalytic domain of congopain (C2) and the mutant 
proenzyme [proC2 (C25A)] were heterologously expressed in the P. pastoris expression system 
for crystallisation purposes. Expression of trypanosomal cysteine proteases such as truncated 
cruzipain (Eakin et al., 1993), rhodesain (Caffrey et al., 2001), cathepsin B of T. congolense 
(Mendoza-Palomares et al., 2008) and congopain (Boulangé et al., 2001) had been conducted in 
either a bacterial or an eukaryotic system. Truncated cruzipain is the only trypanosomal cysteine 
protease that has been crystallised (Eakin et al., 1993; McGrath et al., 1995). Attempts to 
crystallise full-length cruzipain that includes the C-terminal domain have been unsuccessful 
(Alvarez et al., 2002). The difficulty to crystallise the functionally active full-length cruzipain 





High level heterologous expression of functionally active C2 and proC2 (C25A) was achieved in 
yeast. The yield of C2 was 10-20 mg/l of culture and 50-100 mg/l of culture for proC2 (C25A). 
The inactive mutant is expressed at levels five to ten times higher than its active counterpart. The 
inactive mutant is more stable in culture than active C2. Full-length active cysteine proteases 
such as congopain and cruzipain have been shown to be highly unstable (Alvarez et al., 2002).  
 
Both C2 and proC2 (C25A) were expressed as proenzymes by P. pastoris. However, the 
proregion of both enzymes was cleaved at acidic pH yielding a 27 kDa mature enzyme. The bulk 
of proC2 (C25A) remained as a zymogen. Maturation of the inactive enzyme was puzzling since 
enzyme activity is necessary for cleavage of the proregion. Processing of inactive cruzipain 
(C25A) was shown to involve bacterial proteases co-purified during preparation of inclusion 
bodies (Eakin et al., 1993). On the other hand, activation of lysosomal cysteine proteases such as 
cathepsin X and C was shown to be performed by cathepsins L and S (Dahl et al., 2001; Turk et 
al., 2001). Therefore, processing of the inactive proenzyme may have been conducted by P. 
pastoris proteases that are secreted into the culture media during protein expression. The 
cleavage sites for removal of the proregion differ depending on the parasite species (Sanderson et 
al., 2000). Congopain displays an “APEA” N-terminal sequence after removal of the propeptide 
while cruzipain displays “APAA” (Eakin et al., 1993; Authié, 1994; Fish et al., 1995). 
 
The proenzyme form of congopain [proC2 (C25A)] is glycosylated. The same is true for the 
cruzipain (Eakin et al., 1993) and rhodesain proenzymes (Caffrey et al., 2001). This could 
present major obstacles for the crystallisation of the protease. Glycosylation was shown to inhibit 
crystallisation of IL-10 (Hoover et al., 1999). This is because glycosylation alters size micro-
heterogeneity, flexibility of the protein and is a potential source of charge, thus, prevents proper 
packing of a protein necessary for crystallisation (Wyss and Wagner, 1996). However, 
glycoproteins such as proteinase A of Saccharomyces cerevisae and HIV gp120 envelope protein 
have been crystallised in spite of their carbohydrate heterogeneity (Aguilar et al., 1997; Kwong 
et al., 1998). The glycosylation site for congopain has not been identified whereas glycosylation 
of cruzipain occurs on Asn113 (Eakin et al., 1993) and Asn295 in rhodesain (Caffrey et al., 2001). 
Although the glycosylation site of rhodesain has been shown to be located in the central domain, 




of congopain contains four asparagine residues (N67, N78, N102 and N119) that could potentially be 
glycosylated.  
 
Crystallisation of the recombinant catalytic domain of congopain (C2) had been attempted (Dr A. 
Boulangé, University of KwaZulu-Natal, personal communication). Although the results were 
encouraging, the crystallisation process could not be completed due to shortage of the protease. 
In order to complete the crystallisation process, highly concentrated C2 (> 5 mg/ml) was 
required. Subsequent attempts to produce more protease to complete the crystallisation process 
were unsuccessful (Dr A. Boulangé, University of KwaZulu-Natal, personal communication). 
The major obstacle encountered was that the ion-exchange purification step could not be 
reproduced. Therefore, a new purification protocol had to be developed.  
 
To ensure homogeneity of the protease sent for crystallisation, proC2 expressed in P. pastoris 
was matured at pH 4.2 to ensure processing of the protease. Furthermore, the protease was 
treated with DTT to ensure complete activation of the protease. Following this, C2 as well as the 
C2 dimer mutants were irreversibly inhibited with E-64 to prevent self-degradation during the 
purification process. The purification regimen included three phase partitioning (TPP), molecular 
exclusion chromatography and cation exchange chromatography. Three phase partitioning 
described by Pike and Dennison (1989) for the purification of cathepsin L from sheep liver was a 
major breakthrough in the purification process. The method was successful in concentrating the 
congopain variants from large volumes of culture supernatant while removing the contaminating 
proteins. The main advantage of this technique was that it was reproducible, cheap and saved 
significant amount of time (Pike and Dennison, 1989). After TPP, the precipitated protein 
mixture appeared yellowish in colour indicating the presence of non-protein contaminants. 
Molecular exclusion chromatography was successfully applied to remove the non-protein 
contaminants as well as the higher molecular weight contaminants. Finally, cation exchange 
chromatography was used to ensure homogeneity of the proteins. The highly pure protein sample 
(> 99% purity) was concentrated to 5-10 mg/ml per batch for crystallisation. The proteins were 
sent for crystallisation at the Institut de Biologie Structurale as part of a collaborative agreement 
with Prof. F. Vellieux (Grenoble, France). During the preparation of this dissertation, 





While waiting for the crystallographic data, comparative homology modelling was employed to 
generate the 3-D structure of congopain. Crucial to comparative modelling of protein 3-D 
structures is the template used to construct the model (Melo and Feytmans, 1998; Schwede et al., 
2000; Schwede et al., 2003). The primary structure of congopain displayed a high level of 
sequence identity with cruzipain, the major cysteine protease of T. cruzi. Moreover, the crystal 
structure of cruzipain had been elucidated in the presence of various inhibitors (Eakin et al., 
1993; McGrath et al., 1995). Hence, cruzipain was chosen as a suitable template for the 
generation of the 3-D models of congopain. 
 
The 3-D model of congopain consisted of α-helices and β-sheets that formed the L and the R-
domains. The predicted 3-D structure of congopain displayed similar structural features as 
cruzipain. The 3-D model of congopain revealed surface location of the dimerisation motif as 
postulated by Prof. J. Hoebeke (IBMC, Strasbourg, France, personal communication). Although 
the models did not offer much information about how exactly the dimerisation of congopain 
unfolds, the dimerisation mechanism of cathepsin W was proposed based on a theoretical 3-D 
model of the protease constructed from the crystal structure of cruzipain and cathepsin K. 
Brinkworth et al. (2000) proposed that an extended loop composed of amino acid residues 40-46 
(RISFWDF) forms part of the dimer interface. The mechanism involves interaction between 
amino acid residues located in the dimer interface (residues 40-80), residues 1-10 and residues 
170-200 of each monomer facing opposite directions (Brinkworth et al., 2000). It was proposed 
that the presence of A11 in the cathepsin W structure contributes to dimer formation by adding 
twists to the structure of the protease. Crystallisation of the congopain variants (that is currently 
underway) and solving the crystal structures is expected to complete the puzzle regarding the 
dimerisation mechanism of congopain. This is critical for the development of an effective 
vaccine since protective epitopes have been shown to be dimer-associated (Boulangé et al., 
submitted).  
 
The objective of this study was to determine the 3-D structure of congopain in order to map 
protective epitopes exposed at the surface of the protease and develop mimotopes to be utilised in 
vaccination studies. We embarked on large-scale heterologous expression in P. pastoris of the 
wild-type catalytic domain of congopain (C2) as well as mutant forms of congopain. The proteins 




chromatography and cation exchange chromatography to purity standards required for 
crystallisation. At the time of writing of this thesis, the crystallographic data was not yet 
available. Hence, in silico homology modelling was performed using the cruzipain crystal 
structure to gain access to the 3-D structure of congopain. The 3-D model confirmed that the 
congopain structure is similar to that of papain-like enzymes. The structure is composed of α-
helices and β-sheets that fold to form the L and the R domains. Furthermore, the dimer motif 
identified by Brinkworth et al. (2000) in cathepsin W was shown to be located on the surface of 
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ABSTRACT 
Heat shock protein 70 (HSP70) family proteins are intracellular chaperones involved in the 
folding of denatured proteins. In addition, they have been found to be potent stimulators of innate 
and adaptive immune responses. A protein belonging to the HSP70 family had been identified in 
T. congolense. It was shown to be an immunodominant antigen homologous to mammalian 
immunoglobulin-heavy-chain binding protein (BiP). The current study aimed at elucidating the 
adjuvanticity of T. congolense BiP using C2, the recombinantly expressed catalytic domain of 
congopain, as a model antigen. Full-length BiP or truncated BiP devoid of the 10 kDa C-terminal 
domain was genetically fused to proC2 or C2. The BiP-C2 chimeras were heterologously 
expressed in P. pastoris and E. coli. SDS-PAGE analysis of P. pastoris expressed chimeras 
revealed poor expression levels. The quantity and purity was not sufficient for conducting 
immunisation experiments in mice. On the other hand, bacteria overexpressed the BiP-C2 
chimeras as fusion proteins with maltose binding protein. The chimeras were expressed as 
insoluble inclusion bodies that required solubilisation with 8 M urea, renaturation and 
purification. Although the chimeras were successfully renatured, purification proved to be a 
cumbersome task. Hence, the BiP-C2 chimeras need to be recloned into an expression system 
that would combine prolific expression and easy purification of the chimeras to allow testing of 
their adjuvant potential in a murine model challenged with T. congolense. Furthermore, the 
capacity of the produced antibodies to inhibit the activity of congopain in vitro will be assessed. 
 








Bovine trypanosomosis (nagana) is a parasitic disease caused by tsetse-transmitted Trypanosoma 
congolense, T. vivax and T. b. brucei (Stevens and Brisse, 2004). The disease is characterised by 
anaemia, loss of productivity and is often fatal if untreated, making it the major constraint to 
livestock production in tropical Africa (Eisler et al., 2004). Prevention and treatment of 
trypanosomosis relies heavily on vector control and the use of chemotherapeutic and 
prophylactic agents (Allsopp and Hursey, 2004). Large scale vector eradication is improbable; 
hence, for the time being treatment of cattle still relies on trypanocidal drugs and other measures 
of integrated control (Holmes et al., 2004). However, emergence of drug resistant parasites has 
been reported in Africa (Anene et al., 2001; Geerts et al., 2001). Consequently, vaccination has 
been considered. 
 
Conventional vaccines based on targeting parasites’ variable or invariable antigens such as 
variable surface glycoprotein (VSG), tubulin (Lubega et al., 2002; Li et al., 2007) and flagellar 
pocket antigens (Mkunza et al., 1995) have proven elusive. Hence, a new “anti-disease” vaccine 
approach has been devised based on mounting an immune response against pathogenic factors 
released by the parasites during infection (Playfair et al., 1990; Playfair et al., 1991; Authié, 
1994). Congopain, the major cysteine protease of T. congolense, has been shown to act as a 
pathogenic factor in the disease process (Authié et al., 2001). Inhibition of congopain activity 
with antibodies has been associated with resistance to the disease, a phenomenon known as 
trypanotolerance (Authié, 1994). For these reasons, congopain is an attractive target for an anti-
disease vaccine for cattle trypanosomosis. 
 
The functionally active catalytic domain of congopain (C2) had been heterologously expressed in 
the baculovirus expression system and used in immunisation trials in cattle to assess its role in 
the disease process (Authié et al., 2001; Boulangé et al., 2001). The antigen was co-administered 
with RWL proprietary adjuvant from SmithKline-Beecham to boost the immune response. 
Immunised cattle showed features similar to those of trypano-tolerant cattle, i.e. cattle that have 
an inherited genetic ability to control the disease upon infection with T. congolense (Paling et al., 
1991; Williams et al., 1991). These animals limited anaemia and produced a prominent IgG 





Initially, vaccination was conducted with live or attenuated pathogens that carried all the 
machinery necessary to stimulate a strong immune response (Storni et al., 2005). However, 
major drawbacks were encountered with the use of live or attenuated vaccines (Wilson-Welder et 
al., 2008). These are associated with the capability of the attenuated vaccines to undergo 
recombination and the threat of them reverting to the virulent forms. Molecular biology 
techniques have been applied to address this major problem. Now, subunit vaccines have been 
developed based on targeting a particular antigen of an organism (Wilson-Welder et al., 2008). 
Unlike live vaccines, subunit vaccines lack strong immunogenicity and required frequent 
boosting (Wilson-Welder et al., 2008). These vaccines were co-administered with adjuvants to 
enhance the immune response (Singh and O'Hagan, 2003). Adjuvants based on live or attenuated 
pathogens suspended in oil-water emulsion like Freund’s complete adjuvant have been shown to 
be effective immune boosters in livestock vaccines, however, their toxicity towards the host has 
limited their use (Singh and O'Hagan, 2003; Wilson-Welder et al., 2008). 
 
In this context, the development of safer and more effective adjuvants is necessary. Heat shock 
proteins (HSPs), more specifically the HSP70 family proteins, have been identified as potential 
stimulators of the immune response against cancers and infectious agents (Rico et al., 1998; 
Planelles et al., 2002; Ge et al., 2006). Ge et al. (2006) conducted an immunisation trial in mice 
comparing the immune response induced by immunisation with P. pastoris expressed Japanese 
encephalitis virus E-protein genetically fused with mycobacterial HSP70 and recombinant E-
protein co-administered with Freund’s adjuvant. The immune response stimulated by the 
Freund’s adjuvant was more pronounced than that stimulated by the HSP70 molecule. In 
addition, antibodies induced with Freund’s adjuvant were shown to be more effective in 
neutralising the growth of the virus in vitro (Ge et al., 2006). However, the immune response 
generated by immunisation with E-protein fused to HSP70 was better than that induced with E-
protein alone, the HSP70 molecule alone and the E-protein plus HSP70. Although the immune 
response induced by the Freund’s adjuvant was better, the low cost and low toxicity of the 
HSP70 molecule makes it an attractive adjuvant (Ge et al., 2006). 
 
A 69 kDa antigen was identified in T. congolense lysates using sera from trypano-tolerant and 
trypano-susceptible cattle in a western blot (Boulangé and Authié, 1994). Cloning of the 69 kDa 




identity to mammalian immunoglobulin heavy-chain binding protein (BiP) (Boulangé and 
Authié, 1994). Hence, the antigen was named T. congolense BiP (Boulangé and Authié, 1994). 
The cDNA of T. congolense BiP is 2.35 kb and encodes 653 amino acid residues (Boulangé and 
Authié, 1994). The protein is composed of a leader peptide, a N-terminal ATPase domain (44 
kDa), a protease sensitive site, a peptide binding domain (18 kDa) and a variable, immunogenic 
C-terminal domain (10 kDa) that harbours the trypanosome specific MDDL retention signal 
(Boulangé and Authié, 1994).  
 
Previous studies showed that immunisation of animals with C2 can lead to a partially protective 
immune response against a T. congolense infection (Authié et al., 2001). The partially protective 
immune response is linked to the poor antigenicity of congopain and the type of antigen delivery 
system used. The protective epitopes of congopain have been shown to be dimer-associated 
(Boulangé et al., submitted). Hence, the objective of the present study was to improve the 
delivery of C2 to the immune cells while maintaining the dimer conformation of the protease. 
The capacity of T. congolense BiP to deliver and maintain the antigen in the appropriate 
conformation was investigated. BiP was genetically fused to C2 using molecular biology 
techniques and the chimeras were expressed in P. pastoris and E. coli expression systems. High 
level expression of C2 had been achieved in P. pastoris (Boulangé et al., submitted). However, 
bacteria expressed C2 as insoluble inclusion bodies that were difficult to renature (Boulangé et 
al., 2001). Although BiP was expressed as a soluble fusion protein with maltose binding protein 
in E. coli (Boulangé et al., 2002), attempts to express it in P. pastoris failed (Dr A. Boulangé. 
University of KwaZulu-Natal, personal communication). Due to these reasons, expression of the 
BiP-C2 chimeras was attempted in both systems.  
 
Two constructs were designed for expression in each expression system. The constructs 
contained proC2 or C2 cloned 5’ or 3’ to either full-length BiP (R69) or truncated BiP lacking 
the 10 kDa C-terminal domain (R60). The proregion of cysteine proteases plays a crucial role in 
proper folding of the protease and inhibits proteolytic activity of the enzyme (Lalmanach et al., 
1998; Sanderson et al., 2000). Consequently, it was included in most constructs. The C-terminal 
domain (10 kDa) of BiP is highly variable and antigenic (Boulangé and Authié, 1994). 
Antibodies from infected animals were shown to specifically recognise epitopes located in the C-




response, the C-terminal domain of BiP was omitted in most constructs. Here we report on the 
cloning and expression of the BiP-C2 chimeras in eukaryotic and bacterial expression systems. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
Molecular Biology: EcoRI, NotI, XbaI, shrimp alkaline phosphatase (SAP), T4 DNA ligase, 
dNTP mix, X-gal, MassRuler™ DNA ladder mix, Middle Range™ DNA ladder mix, GeneJet™ 
plasmid miniprep kit and TransformAid™ bacterial transformation kit were purchased from 
Fermentas (Vilnius, Lithuania). Taq DNA polymerase was obtained from Solis Biodyne (Tartu, 
Estonia). DNA Clean and Concentrator kit was obtained from ZymoResearch™ (Orange, CA, 
USA). The E. Z. N. A® gel extraction kit was from peQLab (Erlangen, Germany). Competent E. 
coli (JM 109) and XhoI were purchased from New England Biolabs (Ipswitch, MA, USA). The 
pGEM-T® vector was purchased from Promega (Madison, WI, USA). The P. pastoris yeast 
strain GS 115 and pPic9 expression vector were obtained from Invitrogen (Carlsband, CA, 
USA). The BioRad GenePulser™ electroporator was purchased from BioRad (Hercules, CA, 
USA). 
 
Antibodies: The anti-congopain bovine polyclonal antibody was raised against the catalytic 
domain of CP1 (C1) that was expressed in bacteria (Boulangé et al., 2001). The rabbit anti-BiP 
polyclonal antibody raised against full-length BiP expressed in bacteria was obtained from Dr A. 
Boulangé (University of KwaZulu-Natal, Pietermaritzburg). 
 
4.2.2 Methods 
4.2.2.1 Cloning of BiP-C2 chimeras for expression in Pichia pastoris 
Amplification of truncated BiP 
The catalytic domain of congopain (C2) had been cloned into a pPic9 expression vector (Fig. 4.1) 
with its propeptide using EcoRI and NotI cloning sites (Boulangé et al., submitted). 
Immunoglobulin heavy-chain binding protein (BiP) of T. congolense had been cloned into the 
pMal-cRI vector (Boulangé et al., 2002). The glycerol stocks of E. coli containing pPic9-proC2 




0.5% (w/v) NaCl, 15 g/l bacteriological agar] containing ampicillin (50 µg/ml). Liquid 2× YT 
containing ampicillin (50 µg/ml) was inoculated with a single colony and the culture was 
incubated overnight at 37ºC. Plasmid DNA was isolated using the GeneJet™ plasmid miniprep 
kit according to the manufacturer’s instructions. The quality of isolated plasmid DNA was 
assessed by electrophoresis on a 1% (w/v) agarose gel in 1× TAE buffer (40 mM Tris-Cl buffer, 
0.1 mM EDTA, 20 mM acetic acid) run at 80 V for 30 min. 
 
    
Figure 4.1. Map of pPic9 expression vector. The pPic9 expression vector contains the ColE1 origin of replication 
(pBR322), 5’ AOX promoter (5’ AOX), a multiple cloning site, α-factor secretion signal (S), c-myc epitope (TT), 
ampicillin resistance gene, and his4 gene for the selection by complementation in his4 yeast strains.  
 
Enzymes cutting or not cutting the full-length BiP and proC2 open reading frames were 
identified using restriction maps (Fig. 4.2A and B). Therefore, EcoRI and NotI were chosen as 
restriction enzymes to be used in the cloning process. The primers were designed to contain 
either EcoRI or NotI sites at both ends to allow for 5’ or 3’ cloning of the PCR product into the 
pPic9-proC2 expression vector. Truncated BiP devoid of the variable and immunogenic C-
terminal domain was amplified by polymerase chain reaction (PCR) using specific primers from 
the pMal-R69 template DNA (Table 4.1). Amplification was carried out by denaturing plasmid 
DNA at 95ºC for 5 min followed by 25 cycles of denaturation at 95ºC for 1 min, primer 







Table 4.1. Primers used for amplification of R60 from pMal-R69 plasmid DNA. The 
amplicon was ligated into pGEM-T vector before being transformed into competent E. coli cells. 
The restriction sites are highlighted in bold. 
Primer       Sequence 
R60EcoRIFw   5’-GCCGAATTCGCGCCCGAGAGCGGCGGGAAG-3’ 
R60EcoRIRv   5’-GAGGAATTCCCGCGCCTCCACACGCTCCCC-3’ 
R60NotIFw   5’-CGCGCGGCCGCGCCCGAGAGCGGCGGGAAG-3’ 
R60NotIRv   5’-GAGGCGGCCGCCCGCGCCTCCACACGCTCC-3’ 
SP6    5’-CATATGATTTAGGTGACACTATA-3’ 





Cutters: ApaI, BamHI, BstXI, NcoI and PstI









Cutters: EcoRV, HindII, NcoI, PstI, SacII, SalI and XhoI












Figure 4.2. Restriction maps of CP2 (A) and BiP (B) showing cutting and not cutting enzymes. The enzymes 
highlighted in bold are those used in the cloning process.  
 
Subcloning of amplicons into pGEM-T vector 
The truncated PCR product (1.65 kb) was purified using the peQLab gel extraction kit. The 
purified amplicons were ligated into the pGEM-T vector (Fig. 4.3). The ligation mix (3 µl) was 
transformed into competent E. coli (JM 109) cells using the TransformAid™ bacterial 




ampicillin (50 µg/ml), X-gal (20 µg/ml) and IPTG (10 µg/ml) to allow for blue and white colony 
screening. The plates were incubated overnight at 37ºC. 
 
    
Figure 4.3. Map of the pGEM-T® vector (Promega). The vector contains a multiple cloning site, ampicillin 
resistance gene (Ampr) for selection of recombinants, f1 origin of replication (f1 ori) and the lacZ gene for blue and 
white colony screening. 
 
White colonies were screened by colony PCR using the vector-specific T7 and SP6 primers 
(Table 4.1). The amplification conditions applied for PCR screening are shown in Table 4.2. 
PCR-positive colonies were grown in selective media overnight at 37ºC. Plasmid DNA was 
isolated using the GeneJet™ plasmid miniprep kit. 
 
Subcloning of the inserts into pPic9-proC2 expression vector 
Recombinant pGEM-T vector containing R60 was digested with either EcoRI or NotI and the 
drop out product was purified using the E. Z. N. A.® gel extraction kit. pPic9-proC2 was also 
digested with either EcoRI or NotI in their respective enzyme buffers. The linearised vector 
(pPic9-proC2) was dephosphorylated with 1 U of SAP and concentrated using the 
ZymoResearch™ DNA Clean and Concentrator kit. The insert was ligated into linear pPic9-
proC2 vector to generate pPic9-proC2-R60 and pPic9-R60-proC2 (Fig. 4.4). The ligation mix 
was used to transform competent E. coli cells and the cells were plated onto 2× YT plates 
containing ampicillin (50 µg/ml). Transformants were screened with AOX primers (Table 4.3). 
The PCR conditions used during colony PCR screening of transformants are shown in Table 4.2. 





R60 (1.65 kb) proC2 (0.93kb)
EcoRIEcoRI NotI
proC2 (0.93kb) R60 (1.65 kb)
EcoRI NotI NotI
proC2-R60 (2.68 kb) R60-proC2 (2.68 kb)
R60 (60 kDa) R60 (60 kDa)
Expression Expression
proC2 (34 kDa)proC2 (34 kDa)  
Figure 4.4. Schematic representation of the cloning process for the generation of R60-proC2 and proC2-R60 
constructs in the pPic9 expression vector. The truncated BiP (R60) amplicon containing EcoRI sites was cloned 5’ 
to proC2 ORF and the amplicon containing NotI sites was cloned 3’ to proC2 ORF in pPic9-proC2 vector. 
 
Table 4.2. Colony PCR conditions for the different experiments. The master mix composed 
of PCR reaction buffer (1×), Taq DNA polymerase (0.1 U), primers (1 µM), dNTPs (0.2 mM), 
and subsequently dispensed into PCR tubes. All the PCR reactions were cycled 25 times. 
      Colony PCR   Colony PCR 
      (E. coli)   (P. pastoris) 
T7/SP6 AOX   AOX 
 
Denaturation    95ºC; 30 s 95ºC; 1 min  95ºC; 1 min 
Annealing    45ºC; 30 s 50ºC; 30 s  50ºC; 30 s 
Elongation    72ºC; 1 min 72ºC; 3 min  72ºC; 3 min 
Reaction volume (µl)   20  20   100 
 
Transformation of Pichia pastoris strain GS 115 cells 
The isolated plasmid DNA (pPic9-proC2-R60 and pPic9-R60-proC2) was linearised with SacI 
restriction enzyme for efficient recombination into the P. pastoris genome. The linearised 
plasmid DNA was concentrated using the ZymoResearch™ DNA Clean and Concentrator kit. P. 
pastoris strain GS 115 yeast cells were made competent by using the protocol described by Wu 
and Letchworth (2004). Briefly, cells were incubated in lithium acetate/DTT buffer (100 mM 
lithium acetate buffer pH 7.5, 10 mM DTT, 0.6 mM sorbitol) for 30 min, followed by several 
washes of the cell pellet in ice cold 1 M sorbitol. At the end, the cells (1010 cells/ml) were 
resuspended in ice cold 1 M sorbitol and frozen at -80ºC until required for use. 
 
Competent P. pastoris strain GS 115 cells (200 µl) were incubated with SacI-linearised plasmid 




BioRad® electroporator (Hercules, CA, USA) set at 1.5 kV, 25 µF and 186 Ω in 2 mm gap 
cuvettes. Immediately after electroporation, the cells were diluted with ice cold 1 M sorbitol (1 
ml). The cells were spread on minimal media plates [1.34% (w/v) yeast nitrogen base without 
amino acids (YNB), 0.0004% (w/v) biotin, 2% (w/v) glucose, 15 g/l bacteriological agar] 
containing ampicillin (50 µg/ml). The plates were incubates at 30ºC until the colonies were 
visible (generally 2-3 days).  
 
Colony PCR using AOX primers (Table 4.3) was performed on P. pastoris transformants using 
the adapted Ayra-Pardo et al. (1998) protocol as described in Table 4.2. Positive colonies were 
grown in liquid YPD media [1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v dextrose] 
containing antibiotics (generally ampicillin, 50 µg/ml). 
 
BiP-C2 chimeras expression in Pichia pastoris 
Liquid YPD (100 ml) containing antibiotics (generally ampicillin, 50 µg/ml) was inoculated with 
a single colony of recombinant P. pastoris and grown at 30ºC in a baffled flask with agitation for 
two to three days. This culture was used to inoculate 1 L BMGY media [1% (w/v) yeast extract, 
2% (w/v) peptone, 100 mM potassium phosphate buffer, pH 6.5] and incubated for a further two 
days to increase biomass. The cells were pelleted (6000×g, 10 min, RT) and resuspended in an 
equal volume of buffered minimal medium [BMM, 100 mM potassium phosphate buffer, pH 6.5, 
1.34% (w/v) YNB, 0.0004% (w/v) biotin, 5% (v/v) methanol]. The baffled flasks were covered 
with cheesecloth to facilitate aeration of the cultures. The cultures were supplemented with 
methanol [0.5% (v/v) methanol] daily for the entire duration of the expression period to induce 
protein expression. 
 
4.2.2.2 Cloning of BiP-C2 chimeras for bacterial expression 
Amplification and subcloning of inserts into pGEM-T vector 
T. congolense full-length BiP (R69) had been cloned into pMal-cRI expression vector (Boulangé 
et al., 2002). Thus it was convenient, simple and cost effective to clone congopain catalytic 
domain (C2) into the pMal-R69 expression vector. The truncated catalytic domain of congopain 
(C2) and C2 containing the proregion (proC2) were amplified with specific primers (Table 4.3) 
from the pPic-proC2 vector used as a template. PCR was performed by denaturing plasmid DNA 




50ºC for 30 s, elongation at 72ºC for 1 min and final elongation at 72ºC for 7 min. The proC2 
amplicon contained EcoRI cloning sites on both ends whereas the C2 amplicon contained one 
XhoI site on the 5’ end and one XbaI site plus the engineered stop codon on the 3’ end. The 
cloning sites determined whether congopain was to be cloned upstream or downstream of the 
R69 open reading frame in the pMal-R69 expression vector. Two constructs, proC2-R69 (full-
length BiP) and R60-C2 (truncated BiP) were generated (Fig. 4.5) 
 
Table 4.3. Primers used to amplify proC2 and C2 from pPic9-proC2 template DNA. 
Plasmid DNA was isolated using the GeneJet™ plasmid miniprep kit from an overnight culture 
of cells. The restriction sites are underlined. 
Primer      Sequence 
 
proCDEcoRIFw 5’-GCCGAATTCGCGTGCTTTGTTCCCGTGGCG-3’ 
CDEcoRIRv  5’-GTGGAATTCCGGAGTCGGGGGTGGAGGCGG-3’ 
CDXhoIFw  5’-CCACCCTCGAGGCACCTGAGGCAGTTGACTGGCG-3 
CDXbaIRv  5’-CTGTCTAGATTACGGAGTCGGGGGTGGAGGCGG-3’ 
AOXFw  5’-ACTGGTTCCAATTGACAAGC-3’ 
AOXRv  5’-GCAAATGGCATTCTGACATCC-3’ 
 
2.83 kb 2.25 kb
42 kDa 33 kDa 69 kDa 60 kDa 24 kDa42 kDa
Expression Expression
MBP proC2 R69 MBP C2R60
C2 (0.6 kb)R60 (1.65 kb)R69 (1.9 kb)proC2 (0.93 kb)
EcoRI EcoRI BamHI EcoRI XhoI XbaI




Figure 4.5. Design of proC2-R69 (A) and R60-C2 (B) for expression in bacteria. The constructs were generated 
using different cloning sites. ProC2-R69 was generated using EcoRI cloning sites and R60-C2 was generated using 
XhoI and XbaI cloning sites. The MBP-proC2-R69 fusion chimera is expected to be 144 kDa and MBP-R60-C2 is 
expected to be 126 kDa.  
 
The amplicons were purified and ligated into the pGEM-T vector. Recombinant colonies were 




from positive colonies and digested with either EcoRI or XhoI/XbaI to drop out proC2 and C2 
respectively. The inserts were purified using the peQLab gel extraction kit.  
 
Subcloning of inserts into pMal expression vector 
Recombinant pMal-R69 was digested with either EcoRI or XhoI/XbaI to generate linear plasmid 
DNA. Linear plasmid DNA was dephosphorylated with SAP and concentrated using the 
ZymoResearch® DNA Clean and Concentrator kit. The proC2 (EcoRI/EcoRI) and C2 
(XhoI/XbaI) inserts were ligated into linear pMal-R69 plasmid DNA. The ligation mix (3 µl) was 
transformed into competent E. coli (JM 109) cells (50 µl) using the TransformAid™ bacterial 
transformation kit. The transformed cells were plated onto 2× YT plates containing ampicillin 
(50 µg/ml). Colony PCR was performed with pMal and insert specific primer pairs on 
transformants to screen for recombinant colonies. Positive colonies were used to make glycerol 
stocks. 
 
Expression of the BiP-C2 chimeras in bacteria. 
Expression of the BiP-C2 chimeras was carried out as described in the pMal manual (NEB pMal 
instruction manual). An overnight culture was prepared by inoculating terrific broth, 
supplemented with glucose, with a single colony of bacteria containing the respective 
recombinant plasmid DNA. Glucose represses the expression of amylase from the maltose genes, 
thus, prevents degradation of amylose in the resin in subsequent purification steps (NEB pMal 
instruction manual). In addition, glucose exerts additional repression of the lac Z promoter in the 
absence of the inducer IPTG (NEB pMal instruction manual). This pre-culture was transferred 
into fresh terrific broth (500 ml) containing ampicillin (50 µg/ml) and incubated at 37ºC in a 
shaking incubator until the culture reached an OD600 of 0.6. The culture was induced with 0.1 
mM IPTG and incubated at 37ºC for 4 h for protein expression in an orbital shaking incubator. 
The cells were collected by centrifugation (5000×g, 10 min, RT) and resuspended in TE buffer 
(100 mM Tris-Cl buffer, pH 7.4, 10 mM EDTA). Lysozyme was added to the lysate to facilitate 
degradation of the bacterial cell wall. The lysate was frozen overnight at -80ºC.  
 
4.2.2.3 Solubilisation and renaturation of bacterial-expressed chimeras 
The inclusion bodies were solubilised and renatured using the protocol described by Sijwali et 




with 2 M urea, 20 mM Tris-Cl, 2.5% Triton X-100, pH 8, followed by subsequent washes with 
20% (w/v) sucrose, 20 mM Tris-Cl, pH 8. The inclusion bodies were pelleted (17000×g, 30 min, 
4ºC) and solubilised with 8 M urea. The crude insoluble material was separated by centrifugation 
(27000×g, 30 min, 4ºC) from the soluble protein. 
 
The fusion chimeras (MBP-R69-C2 and MBP-proC2-R69) were reduced with 10 mM DTT to 
ensure complete activation of the cysteine protease. Renaturation was performed by drop-wise 
dilution of the fusion chimera with refolding buffer (100 mM Tris-Cl buffer, pH 9.0, 1 mM 
EDTA, 30% (v/v) glycerol, 250 mM L-arginine, 1 mM GSH, 1 mM GSSG) at 4ºC. The fusion 
chimera was diluted a 100 fold in refolding buffer. The renatured chimera was concentrated by 
ultrafiltration using an Amicon PM 10 filter membrane (10 kDa cut-off).  
 
4.2.2.4 Purification of BiP-C2 chimeras by three phase partitioning (TPP) 
Three phase partitioning (Pike and Dennison, 1989) was used to purify the BiP-C2 chimeras 
from expression supernatants. The supernatant was filtered through Whatman No 1 filter paper. 
The pH of the supernatant was lowered to pH 4.2 with phosphoric acid for autocatalytic 
processing of the cysteine protease to the mature form. The fusion chimeras were precipitated 
with 40% ammonium sulfate (40% of total volume) in the presence of tertiary butanol (1/3 final 
volume). The salt was dissolved by gentle stirring with a magnetic stirrer. The precipitated 
protein mixture was centrifuged (6000×g, 10 min, 4ºC) using a pre-chilled swing-out rotor. The 
protein layer at the interface between the aqueous and tertiary butanol phases was collected and 
dialysed against PBS, pH 7.2 using a 10 kDa cut-off dialysis membrane to remove traces of salt 
and tertiary butanol. The diluted protein was concentrated using polyethylene glycol Mr 20 000 
until 1-2 ml remained in the dialysis bag. 
 
4.2.2.5 Purification of BiP-C2 chimeras by amylose affinity chromatography 
Maltose binding protein (MBP) affinity for amylose was exploited to purify the fusion chimeras 
from the crude bacterial lysate. Amylose resin (NEB pMal instruction manual) was packed into a 
column (10 ml). The column was washed with 8 column volumes of column buffer (20 mM Tris-
Cl buffer, pH 7.4, 0.2 M NaCl, 10 mM 2-mercaptoethanol) before the renatured protein sample 




The fusion chimera was eluted with 10 mM maltose in column buffer and protein elution was 
monitored by measuring A280nm of each 1.5 ml fraction. The fractions containing proteins were 
pooled and concentrated by ultrafiltration using an Amicon PM 10 filter membrane. The resin 
was regenerated by sequential washes with distilled water, 0.1% (w/v) SDS, distilled water and 
column buffer.  
 
4.2.2.6 Protein Visualisation 
Laemmli SDS-PAGE 
Proteins were visualised by discontinuous SDS-PAGE (Laemmli, 1970). The proteins were 
resolved through a large pore size stacking gel (pH 6.8) and a small pore size running gel (pH 
8.8). For accurate determination of protein molecular weight, the fusion chimeras were treated 
with reducing treatment buffer [125 mM Tris-Cl buffer, pH 6.8, 4% (w/v) SDS, 20% (v/v) 
glycerol, 10% (v/v) 2-mercaptoethanol] in a 1:1 ratio. SDS and 2-mercaptoethanol present in the 
treatment buffer facilitate denaturation and reduction of the proteins and give the protein a net 
negative charge. Consequently, when an electric field is applied, the proteins separate based 
solely on molecular weight. For our purpose, proteins were run at 20 mA/gel for 2 h in tank 
buffer [250 mM Tris-Cl buffer, 192 mM glycine, 0.1% (w/v) SDS, pH 8.3]. Coomassie blue R-
250 [0.125 (w/v) Coomassie blue R-250, 50% (v/v) methanol, 10% (v/v) glacial acetic acid] was 
used to stain proteins.  
 
Silver staining 
Silver staining was performed when more sensitive staining was required (Blum et al., 1987). 
The gel was immersed in fixing solution [50% (v/v) methanol, 12% (v/v) acetic acid, 0.5% (v/v) 
formaldehyde] for one hour and subsequently washed (3 × 5 min) in 50% (v/v) ethanol. The gel 
was incubated in pre-treatment solution (4 mg Na2S2O3.5H2O dissolved in 200 ml of water) for 1 
min, rinsed with distilled water (3 × 5 min) and soaked in impregnation solution [0.2% (w/v) 
AgNO3, 0.28% (v/v) formaldehyde] for 20 min. The gel was rinsed with distilled water (2 × 20 s) 
and incubated in developing solution [0.019% (v/v) formaldehyde, 0.004% Na2S2O3.5H2O, 60 
g/l Na2CO3] until the first bands became visible. The gel was then placed in distilled water to 
allow for complete development of the bands. When the desired intensity of the bands was 






The proteins separated by Laemmli SDS-PAGE were electroblotted to a nitrocellulose membrane 
using a semi-dry blotter, run at 7 V overnight (Towbin et al., 1979). The unoccupied sites on the 
membrane were blocked with low fat milk [5% (w/v) in TBS]. The membrane was washed with 
TBS (3 × 5 min) and probed with bovine anti-congopain and rabbit anti-full-length BiP 
antibodies diluted in 0.5% (w/v) BSA in TBS for 2 h. The membrane was washed with TBS (3 × 
5 min) and subsequently incubated with rabbit anti-bovine IgG and goat anti-rabbit IgG 
conjugated to horse radish peroxidase (HRPO) for 1 hour. Finally, the membrane was washed 
with TBS (3 × 5 min) and incubated in substrate solution [0.06% (w/v) 4-chloro-1-naphthol, 10% 
(v/v) methanol, 0.0015% (v/v) H2O2 in TBS] until bands appeared.  
 
4.3 RESULTS 
4.3.1 Cloning, expression and purification of P. pastoris expressed BiP-C2 chimeras 
Truncated BiP (R60) lacking the C-terminal domain was amplified from pMal-R69 DNA using 
specific primers. The two amplicons were observed as prominent bands of 1.65 kb (Fig. 4.6. 
lanes 2 and 3). This is consistent with the predicted size of the amplicons. The products were 
excised from the agarose gel and purified using the peQLab gel extraction kit. 
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Figure 4.6. Amplification of truncated BiP (R60) from the pMal-R69 template DNA. The PCR product was 
analysed by electrophoresis on a 1% (w/v) agarose gel in 1× TAE buffer. Lane 1, MassRuler™ DNA ladder mix; 
lane 2, R60NotI amplicon and lane 3, R60EcoRI amplicon.  
 
The purified PCR product (R60) was ligated into the pGEM-T vector and the ligation mix was 




attempted to identify recombinant colonies. However, no recombinants were observed using this 
method. Two colonies per transformation were grown in selective media overnight and plasmid 
DNA isolated. The isolated plasmid DNA appeared as two bands above 10 kb (Fig. 4.7A, lanes 
2-5). This means that the plasmid exists in two conformations. Miniprep DNA was digested with 
either EcoRI or NotI to confirm the presence of the inserted fragment (Fig. 4.7B). All the 
plasmids were recombinant as indicated by the drop out of a 1.65 kb product after digestion. 
Digestion of plasmid DNA with NotI was incomplete as indicated by the presence of bands 
slightly below and above 5 kb (Fig. 4.7B, lanes 4 and 5). The dropped out insert was purified 
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Figure 4.7. Screening of pGEM-T vector recombinants. Panel A, isolation of recombinant pGEM-T-R60EcoRI or 
pGEM-T-R60NotI plasmid DNA. Plasmid DNA was analysed by electrophoresis on a 1% (w/v) agarose gel in 1× 
TAE buffer. Lane 1, FastDNA™ Ruler High Range; lane 2, pGEM-T-R60EcoRI clone 1; lane 3, pGEM-T-
R60EcoRI clone 2; lane 4, pGEM-T-R60NotI clone 1 and lane 5, pGEM-T-R60NotI clone 2. Panel B, restriction 
digest of pGEM-T vector recombinants with either EcoRI or NotI. Lane 1, FastDNA™ Ruler High Range; lane 2, 
EcoRI restricted pGEM-T-R60EcoRI clone 1; lane 3, EcoRI restricted pGEM-T-R60EcoRI clone 2; lane 4, NotI 
restricted pGEM-T-R60NotI clone 1 and lane 5, NotI restricted pGEM-T-R60NotI clone 2. 
 
The catalytic domain of congopain (C2) had been cloned into pPic9 expression vector (Boulangé 
et al., submitted). The pPic9-proC2 expression vector was prepared by miniprep and used to 
clone the truncated BiP open reading frame upstream or downstream from the proC2 open 
reading frame. Therefore, pPic9-proC2 was digested with either EcoRI or NotI. Linear vector 
DNA was observed as a single band around 9 kb (Fig. 4.8, lanes 2 and 3). Linear plasmid DNA 
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Figure 4.8. Purification of the pPic9-proC2 expression vector DNA after linearisation with either EcoRI or 
NotI. The digestion mixture was analysed by agarose gel electrophoresis. Lane 1, MassRuler™ DNA ladder mix; 
lane 2, EcoRI restricted pPic9-proC2 and lane 3, NotI restricted pPic9-proC2.  
 
Purified R60EcoRI and R60NotI were ligated into the pPic9-proC2 expression vector. The 
ligation mix was used to transform competent E. coli cells. Colony PCR using three sets of 
primers was performed to screen for recombinant colonies per cloning experiment. To screen for 
pPic9-R60-proC2 recombinants, colony PCR was performed using an AOX primer pair, the 
insert-specific primers (R60EcoRIFw and CDEcoRIRv) and a combination of R60EcoRIFw and 
AOXRv primers (Fig. 4.9A). Amplification with a combination of insert-specific and vector-
specific primers was performed to confirm the ligation of the insert into the vector. Screening of 
colonies with AOX primers produced a 3 kb PCR product (Fig. 4.9A, lanes 8 and 11). The PCR 
product (R60-proC2) was bigger than the expected 2.8 kb due to the 200 bp vector sequence 
amplified by the AOX primers on both ends. Screening of pPic9-R60-proC2 with insert-specific 
primers produced an expected 2.8 kb product (Fig. 4.9A, lanes 9 and 12). However, a 
combination of R60EcoRIFw and AOXRv primers amplified a 2.85 kb PCR product (Fig. 4.9A, 
lanes 10 and 13). Differences in the size of PCR product amplified by insert-specific primers and 
a combination of R60EcoRIFw and AOXRv primers was expected due to the capacity of the 
AOX primers to amplify some of the vector sequence. Two positive clones were obtained for 
pPic9-R60-proC2. 
 
A screening process similar to the above was applied to screen for pPic9-proC2-R60 
recombinants. The colonies were screened with the AOX primer pair, insert-specific primers 
(proCDEcoRIFw and R60NotIRv) and a combination of proCDEcoRIFw and AOXRv primers 




product (proC2-R60) in recombinant colonies (Fig. 4.9B, lanes 8 and 11). Screening with insert-
specific primers produced an expected 2.8 kb PCR product (Fig. 4.9B, lanes 9 and 12). However, 
screening with a combination of proCDEcoRIFw and AOXRv primers amplified a 2.85 kb 
product (Fig. 4.9B, lanes 10 and 13). This product was slightly bigger due to the 200 bp vector 
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Figure 4.9. Colony PCR screening of pPic9-proC2 recombinants. Panel A, colony PCR screening of pPic9-R60-
proC2 recombinant colonies with AOX primers, R60EcoRIFw-CDEcoRIRv specific primers and a combination of 
R60EcoRIFw and AOXRv primers. Lane 1, FastDNA™ Ruler High Range; lanes 2, 5, 8, 11 and 14, AOX screening 
of colonies 1-5; lanes 3, 6, 9, 12, and 15, R60EcoRIFw-CDEcoRIRv screening of colonies 1-5 and lanes 4, 7, 10, 13 
and 16, R60EcoRIFw-AOXRv screening of colonies 1-5. Panel B, colony PCR screening of pPic9-proC2-R60 
recombinant colonies with AOX primers, proCDEcoRIFw-R60NotIRv specific primers and a combination of 
proCDEcoRIFw and AOXRv primers. PCR products were analysed by agarose gel electrophoresis. Lane 1, 
FastDNA™ Ruler High Range; lanes 2, 5, 8, 11 and 14, AOX screening of colonies 1-5; lanes 3, 6, 9, 12 and 15, 
proCDEcoRIFw-R60NotIRv screening of colonies 1-5 and lanes 4, 7, 10, 13 and 16, proCDEcoRIFw-AOXRv 
screening of colonies 1-5. 
 
Recombinant expression vector DNA was isolated by miniprep and digested with the SacI 
restriction enzyme (Fig. 4.10). Miniprep plasmid DNA was observed as two bands above 10 kb 
(Fig. 4.10, lanes 2 and 4). Linear plasmid DNA migrated as a single band slightly above 10 kb 
(Fig. 4.10, lanes 3 and 5). Linear plasmid DNA migrated faster than miniprep DNA (Fig. 4.10). 




(Sambrook and Russell, 2001). Plasmid DNA was linearised and used to transform P. pastoris 
strain GS 115 cells. Colony PCR was performed on transformants to confirm successful 
integration of recombinant vector DNA into the P. pastoris genome. 
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Figure 4.10. Linearisation of recombinant plasmid DNA with the SacI restriction enzyme. The digestion 
mixture was analysed by electrophoresis on a 1% (w/v) agarose gel in 1× TAE buffer. Lane 1, FastDNA™ Ruler 
High Range; lane 2, uncut pPic9-R60-proC2; lane 3, SacI cut pPic9-R60-proC2; lane 4, uncut pPicp-proC2-R60 and 
lane 5, SacI cut pPic9-proC2-R60. 
 
Recombinant P. pastoris transformants were used to inoculate minimal media for protein 
expression. Protein expression was induced by daily supplementation of the media with methanol 
for the entire duration of the expression period. Analysis of the expression of the proteins by 
SDS-PAGE revealed a poor level of expression by the yeast cells (Fig. 4.11). The bands 
corresponding to the expected chimeras were not visible on the gel (Fig. 4.11, lanes 2 and 3). 
Both chimeras (proC2-R60 and R60-proC2) were expected to migrate at 84 kDa on a SDS-
PAGE gel. However, the presence of the 27 kDa band corresponding to the processed mature 
protease (C2) in the proC2-R60 lane suggested some degradation of the chimera (Fig. 4.11, lane 
2). The cleavage of proC2 from R60 was unexpected because cleavage was expected to occur at 
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Figure 4.11. Silver staining of reducing SDS-PAGE (12%) gel analysing expression supernatants of the BiP-
C2 by P. pastoris. The samples were boiled and reduced before loading. Lane 1, BioRad LMWM; lane 2, proC2-
R60 expression supernatant and lane 3, R60-proc2 expression supernatant.  
 
Three phase partitioning was used to concentrate the chimeras from the large volumes of 
expression supernatant. The proteins were precipitated with a kosmotropic ammonium sulfate 
salt in the presence of tertiary butanol. The predicted 84 kDa band corresponding to the full-
length chimeras (proC2-R60 and R60-proC2) became visible after TPP (Fig. 4.12A, lanes 2 and 
3). The identity of the band was confirmed by rabbit anti-BiP antibodies that weakly recognised 
the 84 kDa band (Fig. 4.12B, lanes 2 and 3). The bovine anti-congopain antibodies failed to 
recognise the chimeras. However, these particular antibodies specifically recognised bands at 27 
kDa and 33 kDa corresponding to mature and immature congopain respectively (Fig. 4.12B, 
lanes 2 to 4). This indicates cleavage of the chimeras into their constituent proteins. The poor 
yields and low purity of both chimeras did not warrant immunisation experiments in mice. 
 
bovine anti-CP1/3 Rabbit anti-BiP
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Figure 4.12. Analysis of BiP-C2 chimera purification by reducing SDS-PAGE and western blot. Panel A, 
reducing SDS-PAGE (12%) gel showing the purification of BiP-C2 chimeras. The BiP-C2 chimeras were boiled and 
reduced prior to loading. Lane 1, Fermentas LMWM; lane 2, proC2-R60; lane 3, R60-proC2 and lane 4, C2. Panel 
B, detection of the BiP-C2 chimeras with bovine anti-congopain and rabbit anti-BiP antibodies following blotting of 
the proteins to a nitrocellulose membrane. The antigen-antibody reaction was visualised using anti-species 
antibodies labelled with HRPO, followed by incubation with 4-chloro-1-naphthol/H2O2. Lane 1, Fermentas LMWM; 




4.3.2 Cloning, expression and purification of bacterial expressed C2-BiP chimeras 
Truncated catalytic domain of congopain containing or lacking the proregion (proC2 or C2) was 
amplified by PCR using Taq DNA polymerase. The amplicons migrated at 0.6 kb and 0.93 kb, as 
expected for C2 and proC2 open reading frames respectively (Fig. 4.13). The proregion is 
essential for correct folding of the protease, hence, its inclusion in the proC2 construct (Vernet et 
al., 1995). The proregion was omitted in the R60-C2 constructs because during maturation of the 
protease, the proregion will be cleaved leading to the loss of the antigen C2. The PCR products 
were purified by gel extraction to remove the PCR buffers that contains high salt concentrations.  
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Figure 4.13. PCR amplification of C2 and proC2 from pPic9-proC2 template DNA. The amplicons were 
analysed by electrophoresis on a 1% (w/v) agarose gel. Lane 1, MassRuler™ DNA ladder mix; lane 2, C2 amplicon 
and lane 3, proC2 amplicon.  
 
The purified PCR products (proC2 and C2) were ligated into the pGEM-T vector and the ligation 
mix was used to transform competent E. coli cells. White colonies were screened by colony PCR 
using T7/SP6 primers. Colony PCR was unsuccessful for pGEM-T-proC2 screening. Therefore, 
two random colonies were used to inoculate selective media and grown overnight to isolate 
plasmid DNA. Plasmid DNA migrated as three clearly visible bands at 2.8, 5.6 and 10 kb (Fig. 
4.14A, lanes 2 and 3). Plasmid DNA was digested with EcoRI to confirm successful ligation of 
the insert into the vector (Fig. 4.14B, lanes 4 and 7). The plasmids dropped out a 1.2 kb product 
corresponding to the cloned fragment. The dropped out product migrated higher than the 
expected 0.93 kb for the proC2 open reading frame. This might be due to the high salt 
concentration present in restriction enzyme buffers. Plasmid DNA linearised with XbaI migrated 
as a single band around 5 kb (Fig. 4.14B, lanes 3 and 6). The band corresponding to the insert 
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Figure 4.14. Screening of pGEM-T-proC2 recombinants by miniprep and restriction digestion. Panel A, 
isolation of recombinant pGEM-T-proC2 plasmid DNA using the GeneJet™ plasmid miniprep kit.  Plasmid DNA 
was analysed by electrophoresis on a 1% (w/v) agarose gel in 1× TAE buffer. Lane 1, FastDNA™ Ruler High 
Range; lane 2, pGEM-T-proC2 clone 1 and lane 3, pGEM-T-proC2 clone 2. Panel B, digestion analysis of the 
pGEM T- vector recombinants with EcoRI or XbaI restriction endonucleases. The digested plasmid DNA was 
analysed by electrophoresis on a 1% (w/v) agarose gel in 1× TAE buffer. Lane 1, FastDNA™ Ruler High Range; 
lane 2, unrestricted pGEM-T-proC2 clone 1; lane 3, XbaI restricted pGEM-T-proC2 clone 1; lane 4, EcoRI restricted 
pGEM-T-proC2 clone 1; lane 5, unrestricted pGEM-T-proC2 clone 2; lane 6, XbaI restricted pGEM-T-proC2 clone 
2 and lane 7, EcoRI restricted pGEM-T-proC2 clone 2.  
 
Colony PCR screening of pGEM-T-C2 transformants with T7/SP6 primers produced a 0.7 kb 
PCR product (Fig. 4.15, lanes 6, 7, 8, 10 and11) corresponding to the cloned C2 fragment. Five 
recombinant clones were obtained for pGEM-T-C2, two colonies (7 and 11) were chosen to 
inoculate selective media for subsequent plasmid DNA isolation by miniprep. Plasmid DNA was 
digested with XhoI/XbaI and the dropped out insert was purified by gel extraction. (Fig. 4.15B, 
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Figure 4.15. Screening of pGEM-T-C2 recombinants by colony PCR. Panel A, colony PCR screening of pGEM-
T-C2 recombinants using T7 and SP6 universal primers. The PCR products were analysed by electrophoresis on a 
1% (w/v) agarose gel in 1× TAE buffer. Lane 1, MassRuler™ DNA ladder mix; lanes 2-11, pGEM-T-C2 clones 1-
10. Panel B, purified C2 inserts after digestion of recombinant plasmid DNA with XhoI/XbaI. The inserts were 
purified by gel extraction and analysed by electrophoresis on a 1% (w/v) agarose gel. Lane 1, MassRuler™ DNA 




The pMal-R69 vector DNA was prepared by miniprep (Fig. 4.16, lane 2). Plasmid DNA 
migrated as two bands above 10 kb (Fig. 4.16, lane 2). Plasmid DNA was digested with either 
EcoRI or XhoI/XbaI to produce linear plasmid DNA (Fig. 4.16, lanes 3 and 4). Linear plasmid 
DNA migrated slightly above 10 kb as expected (Fig. 4.16, lanes 3 and 4). Linear plasmid DNA 
migrated slower than closed circular uncut DNA. 
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Figure 4.16. Preparation of the pMal-R69 vector by restriction with either EcoRI or XhoI/XbaI. The linear 
vector was analysed by agarose gel electrophoresis. Lane 1, MassRuler™ DNA ladder mix; lane 2, uncut pMal-R69; 
lane 3, EcoRI cut pMal- R69 and lane 4, XhoI/XbaI cut pMal-R69. 
 
The purified inserts (proC2 and C2) were ligated into linear pMal-R69 or pMal-R60 DNA. 
Colony PCR screening for recombinants was attempted using the vector specific primers. Colony 
PCR was unsuccessful, hence, two random colonies per transformation were grown overnight in 
selective media. Plasmid DNA was isolated using the GeneJet™ plasmid miniprep kit. The 
pMal-proC2-R69 DNA migrated as a band at approximately 10 kb (Fig. 4.17, lanes 2 and 3). The 
yield was very low for plasmid DNA isolated using a commercial kit. 
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Figure 4.17. Analysis of isolated recombinant plasmid DNA of the pMal-proC2-R69 construct. Plasmid DNA 
was analysed by electrophoresis on a 1% (w/v) agarose gel in 1× TAE buffer. Lane 1, MassRuler DNA™ ladder 




A single band above 10 kb was observed for pMal-R60-C2 plasmid DNA (Fig. 4.18A, lanes 2 
and 3). The yields of plasmid DNA were better than those obtained for pMal-proC2-R69. The 
isolated plasmid DNA was used as a template for PCR amplification of R60-C2 using pMal 
primers, a combination of R60EcoRIFw/pMalRv primers and CDEcoRIFw/CDXhoIRv specific 
primers (Table 4.1 and Table 4.3). PCR amplification of R60-C2 with pMal primers was 
unsuccessful (Fig. 4.18B, lanes 2 and 5). This may be due to the fact that the primers were too 
old, thus could not anneal properly to the template DNA. A combination of 
R60EcoRIFw/pMalRv primers (Table 4.1 and Table 4.3) amplified a 2.2 kb product 
corresponding to the expected full-length R60-C2 chimera (Fig. 4.18B, lanes 3 and 6) whereas 
CDEcoRIFw/CDXhoIRv specific primer pair amplified a 0.7 kb fragment corresponding to the 
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Figure 4.18. Screening of pMal-R60-C2 recombinant colonies by miniprep and PCR. Panel A, miniprep of 
recombinant pMa-R60-C2 plasmid DNA. The DNA was analysed by agarose gel electrophoresis. Lane 1, 
MassRuler™ DNA ladder mix; lane 2, pMal-R60-C2 clone 1 and lane 3, pMal-R60-C2 clone 2. Panel B, PCR 
amplification of insert fragments in pMal-R60 vector with pMal primers, a combination of R60EcoRIFw/pMalRv 
primers and CDEcoRIFw/CDXhoIRv specific primers. The PCR products were analysed by electrophoresis on a 1% 
(w/v) agarose gel in 1× TAE buffer. Lane 1, MassRuler™ DNA ladder mix; lanes 2 and 5, amplification of pMal-
60-C2 with pMal primers; lanes 3 and 6, amplification of pMal-60-C2 with R60EcoRIFw/pMalRv primers and lanes 
4 and 7, amplification of pMal-R60-C2 with CDEcoRIFw/CDXhoIRv specific primer pair. 
 
High level expression of both chimeras was achieved in the bacterial expression system. The 
chimeras were expressed as fusion proteins with maltose binding protein (MBP). Hence, the 
proC2-R69 chimera was observed at 144 kDa (Fig. 4.19A, lane 3). The size is consistent with the 
predicted molecular mass of the full-length MBP-proC2-BiP fusion chimera. The full-length 




with bovine anti-congopain antibodies confirmed expression of the fusion chimera (Fig. 4.19B, 
lane 3). These antibodies recognised two other bands at 45 kDa and 77 kDa respectively. This 
suggest possible degradation of the MBP-proC2-BiP fusion chimera (144 kDa) to yield MBP-
proC2 (77 kDa) and MBP (45 kDa). Recognition of MBP by the antibodies was unsurprising 
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Figure 4.19. Analysis of MBP-proC2-R69 fusion chimera expression by reducing SDS-PAGE and western 
blotting. Panel A, reducing SDS-PAGE analysis of MBP-proC2-R69 expression by bacterial cells. The samples 
were boiled and reduced prior to loading. Lane 1, Fermentas protein marker; lane 2, insoluble uninduced MBP-
proC2-R69; lane 3, insoluble induced MBP-proC2-R69; lane 4, soluble uninduced MBP-proC2-R69 and lane 5, 
soluble induced MBP-proC2-R69. Panel B, detection of the fusion chimera with bovine anti-congopain antibodies 
following blotting of the proteins to a nitrocellulose membrane. The antigen-antibody reaction was visualised using 
anti-species antibodies labelled with HRPO, followed by incubation with 4-chloro-1-napthol/H2O2. Lane 1, 
Fermentas protein marker; lane 2, insoluble uninduced MBP-proC2-R69; lane 3, insoluble induced MBP-proC2-
R69; lane 4, soluble uninduced MBP-proC2-R69 and lane 5, soluble induced MBP-proC2-R69. The arrow indicates 
the band corresponding to MBP-proC2-R69. 
 
The MBP-R60-C2 fusion chimera was overexpressed by E. coli as an insoluble protein at 126 
kDa (Fig. 4.20A, lane 5). This reflects the expected size of the chimeras after fusion to MBP. The 
identity of the chimera band was proven by western blotting with bovine anti-congopain 
antibodies. These polyclonal antibodies recognised a prominent band at 126 kDa. As compared 


















Figure 4.20. Analysis of MBP-R60-C2 fusion chimera expression by reducing SDS-PAGE and western 
blotting. Panel A, reducing SDS-PAGE analysis of MBP-R60-C2 expression by bacterial cells. The samples were 
boiled and reduced prior to loading. Lane 1, Fermentas protein marker; lane 2, soluble uninduced MBP-R60-C2; 
lane 3, soluble induced MBP-R60-C2; lane 4, insoluble uninduced MBP-R60-C2 and lane 5, insoluble induced 
MBP-R60-C2. Panel B, detection of the MBP-R60-C2 fusion chimera with bovine anti-congopain antibodies 
following blotting of the proteins to a nitrocellulose membrane. The antigen-antibody reaction was visualised using 
anti-species antibodies labelled with HRPO, followed by incubation with 4-chloro-1-napthol/H2O2. Lane 1, 
Fermentas protein marker; lane 2, soluble uninduced MBP-R60-C2; lane 3, soluble induced MBP-R60-C2; lane 4, 
insoluble uninduced MBP-R60-C2 and lane 5, insoluble induced MBP-R60-C2. 
 
The inclusion bodies were successfully purified from crude cell lysates using the protocol 
described by Sijwali et al. (2001). This protocol involves successive washes of crude cell lysate 
with 2 M urea and 20% sucrose. The purified inclusion bodies migrated at 144 kDa 
corresponding to the MBP-proC2-R69 fusion chimera and 126 kDa for MBP-R60-C2 fusion 
chimera (Fig. 4.21, lanes 2 and 3). The MBP-proC2-R69 inclusion bodies underwent significant 
degradation during purification. MBP-proC2-R69 degradation products were observed at 116 
kDa, 70 kDa and a faint band around 45 kDa (Fig. 4.21, lane 2).  
 
  






Figure 4.21. Analysis of purified inclusion bodies by reducing SDS-PAGE. The samples were boiled and reduced 
prior to loading. Lane 1, Pharmacia High Range protein marker; lane 2, MBP-proC2-R69 inclusion bodies and lane 
3, MBP-R60-C2 inclusion bodies. The arrows indicate the bands corresponding to the fusion chimeras at 144 kDa 




The inclusion bodies were solubilised with 8 M urea before renaturation. The denatured soluble 
fusion chimeras were refolded by drop-wise dilution of urea with the optimised renaturation 
buffer (Sijwali et al., 2001). The slow dilution of urea facilitated correct folding of the chimera to 
yield soluble protein. The MBP-proC2-R69 chimera was completely degraded after renaturation 
and concentration by ultrafiltration (Fig. 4.22, lane 3). Degradation of the chimera suggests that 
proC2 was properly refolded and underwent maturation to the proteolytically active C2. The 
MBP-R60-C2 chimera was successfully renatured. The chimera migrated as a prominent band at 
116 kDa (Fig. 4.22, lane 4). This indicated that the chimera is not properly refolded. This 
chimera was subjected to further purification by affinity chromatography. 
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Figure 4.22. Coomassie blue R-250 staining of a reducing SDS-PAGE (12%) gel showing the renatured 
chimeras. The samples were boiled and reduced prior to loading. Lane 1, Pharmacia High Range protein marker; 
lane 2, BioRad LMWM; lane 3, renatured MBP-proC2-R69 and lane 4, MBP-R60-C2. 
 
The renatured MBP-R60-C2 chimera was cycled through the amylose column for optimal 
binding to the resin. The chimera eluted with 10 mM maltose as a single peak (Fig. 4.23A). 
Analysis of peak fractions by SDS-PAGE revealed relatively poor purification of the chimera 
(Fig. 4.23B, lanes 5-10). The higher molecular weight contaminants (212 kDa) co-eluted with the 
chimera from the column. Other small molecular weight contaminants were still present after 











































Figure 4.23. Purification of MBP-R60-C2 fusion chimera by amylose affinity chromatography. Panel A, 
elution profile of MBP-R60-C2 with 10 mM maltose. Elution of the fractions was monitored by measuring 
absorbance at 280 nm. Panel B, analysis of the elution fractions by reducing SDS-PAGE (12%) and staining with 
Coomassie blue R-250. Lane 1, Pharmacia High Range protein marker; lane 2, diluted renatured chimera, lane 3, 
unbound protein; lane 4, column wash and lanes 5-10, fractions (3-8) eluted from the amylose affinity column.  
 
The elution fractions were pooled and concentrated using ultrafiltration. The concentrated 
chimera migrated at 126 kDa on a reducing SDS-PAGE gel (Fig. 4.24, lane 2). However, 
contaminating bands were still observed signifying failure of the purification process. The 
apparent impurity of the MBP-R60-C2 fusion chimera prevented the conduction of immunisation 
trials in mice. Thus, future work in this regards involves re-cloning of the chimeras into a pET-
28a expression vector. This expression system will allow for overexpression and easy 
purification of the BiP-C2 chimeras using Nickel affinity chromatography. The purified BiP-C2 
chimera will be used in immunisation studies to determine the adjuvant capacity of BiP. 
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Figure 4.24. Analysis of the pooled affinity chromatography fraction of MBP-R60-C2 by reducing SDS-PAGE 
(12%) gel stained with Coomassie blue R-250. The samples were reduced and boiled prior to loading. Lane 1, 





Immunisation of cattle with an anti-disease vaccine containing recombinant C2 co-administered 
with the RWL proprietary adjuvant from SmithKline-Beecham provided limited protection 
against trypanosomosis (Authié et al., 2001). The pathological effects associated with congopain 
activity were less pronounced in immunised animals. Since the production of the RWL adjuvant 
was discontinued by SmithKline-Beecham, subsequent studies conducted in cattle using 
recombinant C2 expressed in P. pastoris co-administered with ISA206 oil-in-water adjuvant 
from Seppic failed to induce a protective immune response (E. Authié and A. Boulangé, personal 
communication). This failure is attributed to the low antigenicity of congopain, the expression 
system used to produce the antigen and the type of adjuvant used. Recombinant C2 expressed in 
P. pastoris has been shown to dimerise at physiological pH (Boulangé et al., submitted). The fact 
that sera from trypano-tolerant cattle recognised dimer associated epitopes had significant 
implications for the development of an effective anti-disease vaccine. In the present study, the 
ability of T. congolense BiP to deliver antigens to cells of immune system while maintaining the 
correct conformation of the antigen was investigated.  
 
Previous studies investigating the adjuvanticity of mycobacterial HSP70 revealed the need to 
genetically fuse the antigen to the HSP70 molecule (Tobian et al., 2005; Ge et al., 2006; Su et 
al., 2007). In this study, different constructs were designed to contain BiP genetically fused to 
C2. The constructs were designed for expression in P. pastoris and E. coli. Since vectors 
containing the proC2 open reading frame (pPic9-proC2) (Boulangé et al., submitted) and full-
length BiP ORF (pMal-R69) (Boulangé et al., 2002) were already available, it was cheap, 
convenient and less tedious to use these vectors to clone and express the chimeras. Two 
constructs were designed for expression in each expression system. ProC2-R60 and R60-proC2 
were designed for expression in P. pastoris. In both constructs, the proregion of congopain was 
included because of its importance in proper folding of the protease and in maintaining the 
protease in the inactive zymogen state (Lalmanach et al., 1998; Sanderson et al., 2000; 
Lanfranco et al., 2008). Truncated BiP (R60), where the C-terminal domain was omitted due to 
its high antigenicity, was used in these constructs (Boulangé and Authié, 1994). For bacterial 
expression, proC2-R69 and R60-C2 constructs were designed. The construct containing full-
length BiP (R69) was designed to assess the role played by the 10 kDa C-terminal domain in the 




The two chimeras (proC2-R60 and R60-proC2) were successfully expressed by P. pastoris, 
although the yields were very poor. Protein bands corresponding to proC2-R60 and R60-proC2 
chimeras were not visible in SDS-PAGE gels analysing expression supernatants. This is possibly 
due to the large volumes of the expression supernatants. Faint bands corresponding to proC2-R60 
and R60-proC2 chimeras (84 kDa) became visible after concentration of the expression 
supernatants by three phase partitioning. Bovine anti-congopain antibodies recognised bands at 
27 kDa and 33 kDa corresponding to mature C2 and immature proC2. The exact mechanism for 
the maturation of proC2 is not clear since the cultures were maintained at neutral pH (pH 7.0) 
during the entire expression period whereas maturation usually occurs at low pH (Vernet et al., 
1995; Serveau et al., 2003). Processing of the protease is proposed to be conducted by proteases 
secreted or released by dead P. pastoris cells in the culture. Cathepsins L and S have been shown 
to play a role in the activation of lysosomal proteases such as cathepsins X and C (Dahl et al., 
2001; Turk et al., 2001). The rabbit anti-BiP antibodies weakly recognised the 84 kDa bands 
corresponding to the chimeras. Weak recognition displayed by these antibodies may be due to the 
fact that these antibodies recognise epitopes located in the C-terminal domain of BiP (Boulangé 
et al., 2001). Due to the insufficient quantity and impurity of the chimeras, immunisation 
experiments were not conducted in the murine model. 
 
High level expression of functionally active C2 had been achieved in P. pastoris (Boulangé et 
al., submitted). The yeast cells produced 10-20 mg of protein per litre of culture. The poor 
expression level of the chimeras in P. pastoris is unlikely to be associated with the cysteine 
protease ORF. In fact, attempts to express BiP of T. congolense in P. pastoris failed (Dr A. 
Boulangé, University of KwaZulu-Natal, personal communication). Therefore, genetic fusion of 
the BiP ORF to the C2 ORF significantly altered codon usage by P. pastoris, resulting in poor 
expression of the chimeras. Similar results were obtained with the expression of mycobacterial 
HSP70 fused to E-protein of the Japanese encephalitis virus in P. pastoris (Ge et al., 2006). It 
can therefore be concluded that the P. pastoris expression system is not suitable for the 
expression of heat shock proteins including BiP.  
 
High level expression of the chimeras was achieved in E. coli cells. The chimeras were expressed 
as fusion proteins with the carrier protein, maltose binding protein. The MBP-proC2-R69 fusion 




indicated that the chimeras were expressed as insoluble inclusion bodies by the bacterial cells. 
Unfortunately, expression of the chimeras as insoluble inclusion bodies was a major drawback. 
This necessitated solubilisation and renaturation of the chimeras in order to yield soluble protein 
that could be used in the immunisation trials. Both chimeras were successfully solubilised with 8 
M urea. The next step was to attempt to renature the chimeras using the protocol described by 
Sijwali et al. (2001). The large size of the chimeras and the presence of disulfide bridges made 
refolding a cumbersome task. Renaturation was performed using a buffer optimised for 
appropriate refolding of falcipain-2 (Sijwali et al., 2001). The buffer contained both reduced and 
oxidised glutathione in a 1:1 ratio to aid formation of correct disulfide bridges in the chimera 
(Sijwali et al., 2001). In addition, the refolding buffer contained additives such as L-arginine and 
glycerol to prevent incorrect folding of the protein and to maintain the stability of the folded 
protein during renaturation (Yasuda et al., 1998; Jaspard, 2000). The presence of EDTA in the 
refolding buffer prevents inappropriate metal-catalysed oxidation of the cysteine residues (Singh 
and Panda, 2005). 
 
The chimeras were successfully renatured by slow dilution with refolding buffer and 
concentrated by ultrafiltration using an Amicon PM 10 membrane. SDS-PAGE analysis of the 
chimeras after renaturation revealed complete degradation of the MBP-proC2-R69 fusion 
chimera. Degradation of this chimera indicated proper folding of the protease and processing of 
the proenzyme to the mature forms that is possibly responsible for the degradation of the 
chimera. The renatured MBP-R60-C2 chimera was not degraded after renaturation. The presence 
of low molecular weight contaminants necessitated a further purification step. The affinity of 
maltose binding protein for amylose was exploited to purify the fusion chimera using amylose 
affinity chromatography. Although the chimera was successfully eluted from the column, several 
contaminants were still present after concentration of the chimera by ultrafiltration using an 
Amicon PM 10 membrane. The failure to attain pure chimera prevented immunisation studies in 
mice to determine the adjuvanticity of T. congolense BiP.  
 
Although it was desirable to express the chimeras in a eukaryotic system, the low yields and high 
cost of the expression media were major drawbacks. Therefore, future work will involve re-
cloning of the chimeras into a bacterial system that would allow for high level expression and 




the expressed protein is fused with a small histidine tag. The histidine tag does not interfere with 
the activity of the serine protease, oligopeptidase B (Morty et al., 1999; Morty et al., 2005). The 
advantage of using this approach is that affinity purification can be performed using nickel-
nitrilotriacetic acid (Ni-NTA) resin under denaturing conditions (Sijwali et al., 2001). 
Purification of the inclusion bodies under denaturing conditions will possibly remove associated 
contaminants and drastically improve refolding efficiency as was found for renaturation of egg 
white lysozyme (Maachupalli-Reddy et al., 1997). The soluble pure chimeric protein will be 
renatured and the endotoxins removed using the EndoTrap™ column. Finally, immunisation 
experiments will be conducted in mice with the purified chimera to assess the capacity of BiP to 
efficiently deliver the antigen to the immune system. 
 
In the present study, the BiP-C2 chimeras were cloned and successfully expressed in both P. 
pastoris and E. coli. The yield and purity of the P. pastoris expressed chimeras was very low 
while technical problems associated with purification were encountered with the bacterial 
expressed chimeras. Time constraints did not allow for re-cloning of the chimeras into a pET-28a 
expression vector. Due to these reasons, the immunisation experiments were not conducted in 
mice to assess the capacity of T. congolense BiP to act as an adjuvant that stimulates an enhanced 






















African bovine trypanosomosis (nagana) is a devastating parasitic disease responsible for severe 
loss in livestock production in many parts of the developing world. The disease is estimated to 
cost US $ 5 billion per annum in Africa alone (Kristjanson et al., 1999; Shaw, 2004). The 
symptoms of the disease include fever, anaemia, loss of productivity and ultimately death if the 
infected animals are left untreated. Control of animal trypanosomosis critically relies on three 
principal strategies: vector (tsetse fly) control, chemotherapy and exploitation of trypano-tolerant 
cattle (McDermott and Coleman, 2001). The negative impact of insecticides on the environment 
has significantly limited vector control measures. Emergence of drug resistant parasites has 
rendered trypanocidal drugs ineffective (Anene et al., 2001; Geerts et al., 2001). Therefore, there 
is an urgent need to develop new strategies for controlling the disease in animals.  
 
In this context, vaccination has been explored by researchers as an alternative for controlling 
trypanosomosis in cattle. Initial vaccination studies targeting the variable surface glycoprotein 
coat (VSG) of the parasite were proven to be ineffective (Morrison et al., 1982; Wells et al., 
1982). This is due to the fact that the parasite has the capacity to change its surface coat during 
infection, a process known as antigenic variation (Donelson, 2003; Barry and Carrington, 2004). 
This necessitated a shift towards targeting invariant parasite antigens such as flagellar pocket 
antigen (Mkunza et al., 1995) or tubulin (Lubega et al., 2002; Li et al., 2007). Although the 
structural components of the parasite provided partial protection against the disease, attempts to 
reproduce the results were unsuccessful and controversy lingered. A new approach is needed to 
develop an effective vaccine for animal trypanosomosis.  
 
The concept of an “anti-disease” vaccine was proposed based on targeting the pathogenic factors 
released by the parasites, rather than targeting the parasite itself (Playfair et al., 1990; Authié, 
1994; Schofield, 2007). Cysteine proteases have been implicated in the development of the 
disease in animals. Congopain, the major cysteine protease of T. congolense is a circulating 
antigen found in the bloodstream of infected animals (Serveau et al., 2003). Antibodies inhibiting 
the activity of congopain are associated with resistance to the disease (Authié et al., 2001). 




Congopain is a cathepsin L-like cysteine protease belonging to Clan CA of the cysteine protease 
family. Maturation of congopain takes place through autocatalytic removal of the propeptide at 
acidic pH (Serveau et al., 2003). The resulting catalytic domain contains the classical papain-like 
catalytic triad of C25, H159 and N175 (papain numbering) linked to the C-terminal domain by a 
polyproline hinge region (Fish et al., 1995; Chagas et al., 1997). The C-terminal domain is 
unique to Trypanosomatidae cysteine proteases, being absent in mammalian homologues such as 
cathepsins L and B (Mottram et al., 1989; Hellman et al., 1991). Besides its high 
immunogenicity, hence a potential “smoke-screen” effect, the function of the C-terminal domain 
is yet to be elucidated.  
 
The vaccine potential of congopain had been assessed in cattle immunised with the baculovirus 
expressed C2, administered in conjunction with RWL, a saponin-based proprietary adjuvant from 
SmithKline-Beecham. The immunised and control animals were challenged with T. congolense. 
Although immunisation of animals did not prevent the onset of an infection, the immunised 
animals were partially protected against the disease (Authié et al., 2001). Disease protection was 
characterised by a prominent IgG response to congopain and recovery of leukocyte counts 2-3 
months post infection. Subsequent immunisation studies conducted in cattle immunised with 
recombinant C2 expressed in P. pastoris and administered with ISA206 oil-in-water adjuvant 
from Seppic failed to provide protection against the disease (E. Authié and A. Boulangé, personal 
communication). It was suggested that the failure of the study could be due to the poor 
antigenicity of congopain, the type of adjuvant used and the expression system used to produce 
the antigen, all boiling down to an incorrect presentation of protective epitopes. Protective 
epitopes of congopain seem to be associated with the dimeric conformation of the protease 
(Boulangé et al., submitted). Therefore, identification of the dimer-associated protective 
epitopes, and improving the delivery of congopain to the immune system, while maintaining the 
native conformation of the protease, are crucial for the development of an effective anti-disease 
vaccine.  
 
Understanding the dimerisation mechanism of congopain is necessary for the identification of the 
dimer-associated protective epitopes. Prof. J. Hoebeke (IBMC, Strasbourg, France, personal 
communication) proposed a dimerisation model for congopain based on the 3-D structure of 




dimeric (Brinkworth et al., 2000). The model identified a stretch of charged and uncharged 
amino acid residues that form salt bridges depending on the pH. This stretch of amino acid 
residues is composed of W38K39V40A41G42H43E44L45. In the present study, the proposed 
dimerisation model was tested by altering certain amino acid residues located within the 
proposed dimerisation motif by site-directed mutagenesis to mimick proteases of differing 
dimerisation capabilities. To mimick cruzipain, K39 and E44 were replaced with F39 and P44 
whereas H43 was substituted with W43 to mimick cathepsin W.  
 
The functionally active C2 mutants were heterologously expressed in P. pastoris alongside wild-
type C2. The capacity of the C2 mutants and wild-type C2 to dimerise was assessed by 
PhastGel® SDS-PAGE. The electrophoretic mobility of the C2 mutants on a PhastGel® was 
different from that of wild-type C2. The mutant mimicking cathepsin W [C2 (H43W)] was 
expected to be a dimer regardless of pH, thus exhibiting electrophoretic mobility similar to wild-
type C2. Analysis of this mutant under non-denaturing conditions revealed a mobility shift at 60 
kDa while wild-type C2 migrated at 42 kDa. The mutant mimicking cruzipain [C2 (K39F; 
E44P)] was expected to be a monomer regardless of pH. However, under non-denaturing 
conditions the mutant was observed at 50 kDa. The effects of pH on the multimerisation of the 
C2 mutants as well as wild-type C2 were assessed. All the congopain variants were observed as 
multimers at physiological pH. This includes the C2 (K39F; E44P) mutant that was expected to 
be a monomer regardless of pH. Incubation of the congopain variants at acidic pH prevented 
multimerisation of the proteases. Therefore, the proposed dimerisation model of congopain is 
partially valid. The results obtained in this study suggest that the dimerisation mechanism of 
congopain involves more amino acid residues than postulated in the model. Brinkworth et al. 
(2000) showed that the dimerisation mechanism of cathepsin W involves amino acid residues 1-
10, 40-80 and 170-200. Due to the fact that the dimerisation mechanism of congopain was not 
completely elucidated, the dimer associated protective epitopes were not identified.  
 
Mutagenesis of amino acid residues located on the surface of congopain altered the enzymatic 
characteristics of the C2 mutants compared to wild-type C2. Significant differences were 
observed in the specificity constants (kcat/Km) of wild-type C2 and the C2 mutants. The 
introduced mutations decreased the catalytic specificity of C2, even though the mutated amino 




obtained by Chen et al. (2008) whereby mutagenesis of amino acid residues located in the dimer 
interface of the SARS 3C-like protease altered the catalytic activity by the protease and changed 
the dimer-monomer equilibria. An inhibitor targeting the N-terminal finger of the SARS 3C-like 
protease prevented the catalytic activity of the protease (Ding et al., 2005). Therefore, 
development of an inhibitor preventing the dimerisation of congopain could significantly limit 
the catalytic activity of the protease. Inhibition of congopain activity could limit the pathological 
effects associated with the activity of the protease in vivo.  
 
Crystallisation of congopain is necessary to map protective epitopes located at the surface of the 
protease and provide information regarding the dimerisation mechanism of congopain. In this 
second part of the present study, high level expression of wild-type C2 as well as the mutant 
forms of C2 was conducted in P. pastoris. The proteases were successfully purified to 
crystallisation standards using a combination of three phase partitioning, molecular exclusion 
chromatography and cation exchange chromatography. The proteases were sent for 
crystallisation at the Institut de Biologie Structurale (Grenoble, France) as part of a collaborative 
agreement with Prof. F. Vellieux. At the time of writing this dissertation, crystallisation of the 
proteases was still underway. The information obtained from the crystallisation of C2 as well as 
the mutant forms of C2 will be crucial for the design and construction of peptidomimotopes that 
could be used in vaccination studies in cattle. While awaiting the crystallographic data, in silico 
homology modelling was used as an alternative method for determining the 3-D structure of 
congopain. The 3-D model of congopain was constructed based on the crystal structure of 
cruzipain (McGrath et al., 1995). The 3-D structure of congopain is similar to that of papain-like 
cysteine proteases. The structure consisted of α-helices and β-sheets that folded to form the two 
domains of the protease delineated L and R domains (Lecaille et al., 2001).  
 
The last part of the study involved improving the delivery of C2 to the cells of the immune 
system while maintaining the native conformation of the protease, to improve the likelihood of 
producing catalytic activity-inhibiting antibodies (anti-disease vaccine). Although the chemically 
formulated adjuvants such as the Freund’s adjuvant are potent stimulators of the immune system 
(Wilson-Welder et al., 2008), their capacity to maintain the native conformation of the antigen is 
unknown. In addition, Freund’s adjuvant is often toxic to the immunised animals due to the 




O'Hagan, 2003). In the past few years, a large amount of literature reported the adjuvant potential 
of HSP70. Close collaborators were already working on T. congolense HSP70/BiP (Boulangé 
and Authié, 1994; Garzòn et al., unpublished). Therefore, the capacity of T. congolense BiP to 
efficiently deliver C2 to the immune system and induce the production of antibodies inhibiting 
the activity of congopain was investigated. Genetic fusion of an antigen with the HSP70/BiP is a 
prerequisite for efficient delivery of the antigen to cells of the immune system (Basu and 
Srivastava, 2000; Srivastava, 2002; Ge et al., 2006). Therefore, in this part of the study, C2 or 
proC2 was genetically fused to full-length BiP or truncated BiP. The quantity and purity of the P. 
pastoris expressed BiP-C2 chimeras was low, hence immunisation studies were not conducted in 
mice to determine the adjuvanticity of BiP. The chimeras were overexpressed in a bacterial 
expression system. However, problems were encountered regarding the renaturation and 
purification of the insoluble proteins preventing again performing the immunisation studies in 
mice.  
 
Future work in this regard involves re-cloning of the chimeras in an expression vector that would 
combine overexpression and ease of purification. The pET-28a expression vector would be a 
good choice since it expresses proteins as fusion proteins with a small histidine tag. The 
advantage of this system is that the proteins can be easily purified using nickel-chelate 
chromatography under denaturing conditions due to the insoluble nature of the proteins. The 
expressed chimeras will be passed through an EndoTrap™ column to remove 
lipopolysaccharides present in the bacterial lysates that are highly immunogenic. Immunisation 
studies using the purified chimeras will be conducted in mice to assess the adjuvanticity of T. 
congolense BiP.  
 
In the present study, the mutant forms of congopain were successfully cloned and recombinantly 
expressed in yeast. The introduced mutations altered the tertiary structure of the C2 mutants 
compared to wild-type C2. The observed differences in the electrophoretic mobility of the mutant 
forms of C2 and wild-type C2 conferred partial validity to the proposed dimerisation model, 
confirming the involvement of the identified dimerisation motif in the dimerisation mechanism 
of congopain. In line with improving the protective potential of congopain, the 3-D structure of 
congopain was required for the identification of protective epitopes to be used to develop 




expressed and purified to standards required for crystallisation. Unfortunately, since 
crystallisation is a time consuming process, the results are not yet available. Once the crystal 
structure of congopain has been resolved and the mimotopes have been developed, further work 
will involve their testing in murine or bovine models of infection. In order to assess the adjuvant 
potential of T. congolense BiP, the BiP-C2 chimeras were successfully cloned and expressed in 
this study. Due to technical problems associated with purification and renaturation, immunisation 
studies could not be performed in mice.  
 
Mapping of protective epitopes associated with the dimer conformation of congopain is a big 
step towards development of an effective anti-disease vaccine for trypanosomosis. The present 
study was important as it confirmed the involvement of the proposed dimerisation motif in the 
dimerisation mechanism of congopain. Crystallisation of congopain is essential for the design 
and construction of mimotopes and possibly development of a chemotherapeutic inhibitor. Genes 
coding for a cathepsin L-like cysteine protease in T. congolense exist in a multi-copy tandem 
array (A. Boulangé, unpublished). The presence of multiple congopain variants has raised doubts 
about the effectiveness of one congopain-based anti-disease vaccine against all the circulating 
variants. The diversity of the congopain-like gene family and enzymatic characteristics of 
congopain-like variants have been studied (Pillay, 2008; Kakundi, 2009). Although the 
congopain variants exhibited significant differences in their kinetic constants, their exact role in 
host-parasite interactions still needs to be determined. Further studies need to be conducted, 
possibly using gene disruption technology (Mottram et al., 1996) to elucidate the role played by 
the multiple congopain-like variants in vivo. Other potentially pathogenic factors have been 
identified in the secretome of T. congolense using immuno-proteomics technology (Holzmüller 
et al., 2008). However, more work is still necessary to determine the exact role played by these 
pathogenic factors in host-parasite relationships. Once the role played by these pathogenic factors 
has been determined, a multi-component anti-disease vaccine may be formulated to possibly 





Aguilar, C.F., Cronin, N.B., Badasso, M., Dreyer, T., Newman, M.D., Hoover, D.J., Wood, S.P., Johnson, M.J., and 
Blundell, J.C. (1997). The three-dimensional structure at 2.4 angstroms resolution of glycosylated proteinase A from 
the lysosome-like vacuole of Saccharomyces cerevisae. J Mol Biol 267, 899-915. 
Aksoy, S. (2003). Control of tsetse flies and trypanosomes using molecular genetics. Vet Parasitol 115, 125-145. 
Alexander, J., Coombs, G.H., and Mottram, J.C. (1998). Leishmania mexicana cysteine proteinase-deficient mutants 
have attenuated virulence for mice and potentiate a Th1 response. J Immunol 161, 6794-6801. 
Allsopp, R., and Hursey, B.H. (2004). Insecticidal control of tsetse. In The Trypanosomiasis, I. Maudlin, P.H. 
Holmes, and M.A. Miles, eds. (Wallingford, CABI International), pp. 490-507. 
Aloulou, A., Grandval, P., De Caro, J., De Caro, A., and Carriere, F. (2006). Constitutive expression of human 
pancreatic lipase-related protein 1 in Pichia pastoris. Protein Expr Purif 47, 415-421. 
Alvarez, V., Parussini, F., Aslund, L., and Cazzulo, J.J. (2002). Expression in insect cells of active mature cruzipain 
from Trypanosoma cruzi, containing its C-terminal domain. Protein Expr Purif 26, 467-475. 
Anene, B.M., Onah, D.N., and Nawa, Y. (2001). Drug resistance in pathogenic African trypanosomes: what hopes 
for the future? Vet Parasitol 96, 83-100. 
Asea, A., Kraeft, S.K., Kurt-Jones, E.A., Stevenson, M.A., Chen, L.B., Finberg, R.W., Koo, G.C., and Calderwood, 
S.K. (2000). HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role 
as a chaperone and cytokine. Nat Med 6, 435-442. 
Authié, E., Muteti, D.K., Mbawa, Z.R., Lonsdale-Eccles, J.D., Webster, P., and Wells, C.W. (1992). Identification 
of a 33-kilodalton immunodominant antigen of Trypanosoma congolense as a cysteine protease. Mol Biochem 
Parasitol 56, 103-116. 
Authié, E., Duvallet, G., Robertson, C., and Williams, D.J. (1993a). Antibody responses to a 33 kDa cysteine 
protease of Trypanosoma congolense: relationship to 'trypanotolerance' in cattle. Parasite Immunol 15, 465-474. 
Authié, E., Muteti, D.K., and Williams, D.J. (1993b). Antibody responses to invariant antigens of Trypanosoma 
congolense in cattle of differing susceptibility to trypanosomiasis. Parasite Immunol 15, 101-111. 
Authié, E. (1994). Trypanosomiasis and trypanotolerance in cattle: a role for congopain? Parasitol Today 10, 360-
364. 
Authié, E., Boulangé, A., Muteti, D., Lalmanach, G., Gauthier, F., and Musoke, A.J. (2001). Immunisation of cattle 
with cysteine proteinases of Trypanosoma congolense: targetting the disease rather than the parasite. Int J Parasitol 
31, 1429-1433. 
Ayra-Pardo, C.C., Martinez, G., and de la Riva, G.A. (1998). A single step screening procedure for Pichia pastoris 




Bangs, J.D., Uyetake, L., Brickman, M.J., Balber, A.E., and Boothroyd, J.C. (1993). Molecular cloning and cellular 
localization of a BiP homologue in Trypanosoma brucei. Divergent ER retention signals in a lower eukaryote. J Cell 
Sci 105 1101-1113. 
Barrett, A.J., and Kirschke, H. (1981). Cathepsin B, Cathepsin H, and cathepsin L. Methods Enzymol 80, 535-561. 
Barrett, A.J., Kembhavi, A.A., Brown, M.A., Kirschke, H., Knight, C.G., Tamai, M., and Hanada, K. (1982). L-
trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases 
including cathepsins B, H and L. Biochem J 201, 189-198. 
Barry, J.D., and McCulloch, R. (2001). Antigenic variation in trypanosomes: enhanced phenotypic variation in a 
eukaryotic parasite. Adv Parasitol 49, 1-70. 
Barry, J.D., and Carrington, M. (2004). Antigenic variation. In The Trypanosomiasis, I. Maudlin, P.H. Holmes, and 
M.A. Miles, eds. (Wallingford, CABI International), pp. 25-37. 
Barry, J.D., Marcello, L., Morrison, L.J., Read, A.F., Lythgoe, K., Jones, N., Carrington, M., Blandin, G., Bohme, 
U., Caler, E., et al. (2005). What the genome sequence is revealing about trypanosome antigenic variation. Biochem 
Soc Trans 33, 986-989. 
Basu, S., and Srivastava, P.K. (2000). Heat shock proteins: the fountainhead of innate and adaptive immune 
responses. Cell Stress Chaperones 5, 443-451. 
Black, S.J., Sicard, E.L., Murphy, N., and Nolan, D. (2001). Innate and acquired control of trypanosome 
parasitaemia in Cape buffalo. Int J Parasitol 31, 562-565. 
Blum, H., Beier, H., and Gross, H.J. (1987). Improved silver staining of plants proteins, RNA and DNA in 
plyacrylamide gels. Electrophoresis 8, 93-99. 
Boulangé, A., and Authié, E. (1994). A 69 kDa immunodominant antigen of Trypanosoma (Nannomonas) 
congolense is homologous to immunoglobulin heavy chain binding protein (BiP). Parasitology 109, 163-173. 
Boulangé, A., Serveau, C., Brillard, M., Minet, C., Gauthier, F., Diallo, A., Lalmanach, G., and Authié, E. (2001). 
Functional expression of the catalytic domains of two cysteine proteinases from Trypanosoma congolense. Int J 
Parasitol 31, 1435-1440. 
Boulangé, A., Katende, J., and Authié, E. (2002). Trypanosoma congolense: expression of a heat shock protein 70 
and initial evaluation as a diagnostic antigen for bovine trypanosomosis. Exp Parasitol 100, 6-11. 
Boulangé, A., Khamadi, S., Coetzer, T., and Authié, E. (submitted). Production of congopain, the major cysteine 
protease of Trypanosoma (Nannomonas) congolense, in Pichia pastoris reveals unexpected dimerisation at 
physiological pH. 
Brinkworth, R.I., Tort, J.F., Brindley, P.J., and Dalton, J.P. (2000). Phylogenetic relationships and theoretical model 
of human cathepsin W (lymphopain), a cysteine proteinase from cytotoxic T lymphocytes. Int J Biochem Cell Biol 
32, 373-384. 
Brooks, D.R., Tetley, L., Coombs, G.H., and Mottram, J.C. (2000). Processing and trafficking of cysteine proteases 




Bukau, B., Weissman, J., and Horwich, A. (2006). Molecular chaperones and protein quality control. Cell 125, 443-
451. 
Caffrey, C.R., Hansell, E., Lucas, K.D., Brinen, L.S., Alvarez Hernandez, A., Cheng, J., Gwaltney, S.L., 2nd, 
Roush, W.R., Stierhof, Y.D., Bogyo, M., et al. (2001). Active site mapping, biochemical properties and subcellular 
localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense. Mol Biochem Parasitol 
118, 61-73. 
Castellino, F., Boucher, P.E., Eichelberg, K., Mayhew, M., Rothman, J.E., Houghton, A.N., and Germain, R.N. 
(2000). Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility 
complex class I antigen presentation via two distinct processing pathways. J Exp Med 191, 1957-1964. 
Cazzulo, J., Stoka, V., and Turk, V. (2001). The major cysteine proteinase of Trypanosoma cruzi: a valid target for 
chemotherapy for Chagas disease. Curr Pharm Des 7, 1143-1156. 
Chagas, J.R., Authié, E., Serveau, C., Lalmanach, G., Juliano, L., and Gauthier, F. (1997). A comparison of the 
enzymatic properties of the major cysteine proteinases from Trypanosoma congolense and Trypanosoma cruzi. Mol 
Biochem Parasitol 88, 85-94. 
Chen, S., Zhang, J., Hu, T., Chen, K., Jiang, H., and Shen, X. (2008). Residues on the dimer interface of SARS 
coronavirus 3C-like protease: dimer stability characterization and enzyme catalytic activity analysis. J Biochem 143, 
525-536. 
Chothia, C., and Lesk, A.M. (1986). The relation between the divergence of sequence and structure in proteins. 
Embo J 5, 823-826. 
Chowdhury, S.F., Sivaraman, J., Wang, J., Devanathan, G., Lachance, P., Qi, H., Menard, R., Lefebvre, J., Konishi, 
Y., Cygler, M., et al. (2002). Design of noncovalent inhibitors of human cathepsin L. From the 96-residue proregion 
to optimized tripeptides. J Med Chem 45, 5321-5329. 
Coombs, G.H., and Mottram, J.C. (1997). Parasite proteinases and amino acid metabolism: possibilities for 
chemotherapeutic exploitation. Parasitology 114, S61-80. 
d'Ieteren, G.D., Authié, E., Wissocq, N., and Murray, M. (1998). Trypanotolerance, an option for sustainable 
livestock production in areas at risk from trypanosomosis. Rev Sci Tech 17, 154-175. 
Dahl, S.W., Halkier, T., Lauritzen, C., Dolenc, I., Pedersen, J., Turk, V., and Turk, B. (2001). Human recombinant 
pro-dipeptidyl peptidase I (cathepsin C) can be activated by cathepsins L and S but not by autocatalytic processing. 
Biochemistry 40, 1671-1678. 
Daugaard, M., Rohde, M., and Jaattela, M. (2007). The heat shock protein 70 family: Highly homologous proteins 
with overlapping and distinct functions. FEBS Lett 581, 3702-3710. 
Dehrmann, F.M., Coetzer, T.H.T., Pike, R.N., and Dennison, C. (1995). Mature cathepsin L is substantially active in 
the ionic milieu of the extracellular medium. Arch Biochem Biophys 324, 93-98. 
Delespaux, V., Geysen, D., Van den Bossche, P., and Geerts, S. (2008). Molecular tools for the rapid detection of 
drug resistance in animal trypanosomes. Trends Parasitol 24, 236-242. 




Desquesnes, M., and Davila, A.M. (2002). Applications of PCR-based tools for detection and identification of 
animal trypanosomes: a review and perspectives. Vet Parasitol 109, 213-231. 
Dieu, M.C., Vanbervliet, B., Vicari, A., Bridon, J.M., Oldham, E., Ait-Yahia, S., Briere, F., Zlotnik, A., Lebecque, 
S., and Caux, C. (1998). Selective recruitment of immature and mature dendritic cells by distinct chemokines 
expressed in different anatomic sites. J Exp Med 188, 373-386. 
Ding, L., Zhang, X.X., Wei, P., Fan, K., and Lai, L. (2005). The interaction between severe acute respiratory 
syndrome coronavirus 3C-like proteinase and a dimeric inhibitor by capillary electrophoresis. Anal Biochem 343, 
159-165. 
Dolečková, K., Kašný, M., Mikeš, L., Cartwright, J., Jedelský, P., Schneider, E.L., Dvořák, J., Mountford, A.P., 
Craik, C.S., and Horák, P. (2009). The functional expression and characterisation of a cysteine peptidase from the 
invasive stage of the neuropathogenic schistosome Trichobilharzia regenti. Int J Parasitol 39, 201-211. 
Donelson, J.E. (2003). Antigenic variation and the African trypanosome genome. Acta Trop 85, 391-404. 
Duggan, A.J. (1977). Bruce and the African Trypanosomes. Am J Trop Med Hyg 26, 1080-1083. 
Dvořák, J., Delcroix, M., Rossi, A., Vopálenskỳ, V., Pospíšek, M., Šedinová, M., Mikeš, L., Sajid, M., Sali, A., 
McKerrow, J.H., et al. (2005). Multiple cathepsin B isoforms in schistosomula of Trichobilharzia regenti: 
identification, characterisation and putative role in migration and nutrition. Int J Parasitol 35, 895-910. 
Eakin, A.E., McGrath, M.E., McKerrow, J.H., Fletterick, R.J., and Craik, C.S. (1993). Production of crystallizable 
cruzain, the major cysteine protease from Trypanosoma cruzi. J Biol Chem 268, 6115-6118. 
Eisler, M.C., Lessard, P., Masake, R.A., Moloo, S.K., and Peregrine, A.S. (1998). Sensitivity and specificity of 
antigen-capture ELISAs for diagnosis of Trypanosoma congolense and Trypanosoma vivax infections in cattle. Vet 
Parasitol 79, 187-201. 
Eisler, M.C., Dwinger, R.H., Majiwa, P.A.O., and Picozzi, A.S. (2004). Diagnosis and epidemiology of African 
animal trypanosomiasis. In The Trypanosomiasis, I. Maudlin, P.H. Holmes, and M.A. Miles, eds. (Wallingford, 
CABI International). 
El-Sayed, N.M., and Donelson, J.E. (1997). A survey of the Trypanosoma brucei rhodesiense genome using shotgun 
sequencing. Mol Biochem Parasitol 84, 167-178. 
El-Sayed, N.M., Hegde, P., Quackenbush, J., Melville, S.E., and Donelson, J.E. (2000). The African trypanosome 
genome. Int J Parasitol 30, 329-345. 
Ellis, K.J., and Morrison, J.F. (1982). Buffers of constant ionic strength for studying pH-dependent processes. 
Methods Enzymol 87, 405-426. 
Ersfeld, K., Asbeck, K., and Gull, K. (1998). Direct visualisation of individual gene organisation in Trypanosoma 
brucei by high-resolution in situ hybridisation. Chromosoma 107, 237-240. 
Fearon, D.T., and Locksley, R.M. (1996). The instructive role of innate immunity in the acquired immune response. 




Fish, W.R., Nkhungulu, Z.M., Muriuki, C.W., Ndegwa, D.M., Lonsdale-Eccles, J.D., and Steyaert, J. (1995). 
Primary structure and partial characterization of a life-cycle-regulated cysteine protease from Trypanosoma 
(Nannomonas) congolense. Gene 161, 125-128. 
Franke, C.R., Greiner, M., and Mehlitz, D. (1994). Investigations on naturally occurring Trypanosoma evansi 
infections in horses, cattle, dogs and capybaras (Hydrochaeris hydrochaeris) in Pantanal de Pocone (Mato Grosso, 
Brazil). Acta Trop 58, 159-169. 
Ge, F.F., Qiu, Y.F., Gao, X.F., Yang, Y.W., and Chen, P.Y. (2006). Fusion expression of major antigenic segment 
of JEV E protein-hsp70 and the identification of domain acting as adjuvant in hsp70. Vet Immunol Immunopathol 
113, 288-296. 
Geerts, S., Holmes, P.H., Eisler, M.C., and Diall, O. (2001). African bovine trypanosomiasis: the problem of drug 
resistance. Trends Parasitol 17, 25-28. 
Gérczei, T., Keserü, G.M., and Náray-Szabó, G. (2000). Construction of a 3D model of oligopeptidase B, a potential 
processing enzyme in prokaryotes. J Mol Graph Model 18, 7-17, 57-18. 
Germain, R.N. (1994). MHC-dependant antigen processing and peptide presentation: providing ligands for T 
lymphocytes activation. Cell 76, 287-299. 
Gillmor, S.A., Craik, C.S., and Fletterick, R.J. (1997). Structural determinants of specificity in the cysteine protease 
cruzain. Protein Sci 6, 1603-1611. 
Guex, N., and Peitsch, M.C. (1997). SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative 
protein modeling. Electrophoresis 18, 2714-2723. 
Gullo, C.A., and Teoh, G. (2004). Heat shock proteins: to present or not, that is the question. Immunol Lett 94, 1-10. 
Harmala, L.A., Ingulli, E.G., Curtsinger, J.M., Lucido, M.M., Schmidt, C.S., Weigel, B.J., Blazar, B.R., Mescher, 
M.F., and Pennell, C.A. (2002). The adjuvant effects of Mycobacterium tuberculosis heat shock protein 70 result 
from the rapid and prolonged activation of antigen-specific CD8+ T cells in vivo. J Immunol 169, 5622-5629. 
Harrison, R.W., Chatterjee, D., and Weber, I.T. (1995). Analysis of six protein structures predicted by comparative 
modeling techniques. Proteins 23, 463-471. 
Harth, G., Andrews, N., Mills, A.A., Engel, J.C., Smith, R., and McKerrow, J.H. (1993). Peptide-fluoromethyl 
ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi. Mol Biochem Parasitol 
58, 17-24. 
Hartl, F.U. (1996). Molecular chaperones in cellular protein folding. Nature 381, 571-579. 
Hellman, U., Wernstedt, C., and Cazzulo, J.J. (1991). Self-proteolysis of the cysteine proteinase, cruzipain, from 
Trypanosoma cruzi gives a major fragment corresponding to its carboxy-terminal domain. Mol Biochem Parasitol 
44, 15-21. 
Heussen, C., and Dowdle, E.B. (1980). Electrophoretic analysis of plasminogen activators in poly-acrylamide gels 




Holmes, P.H., Eisler, M.C., and Geerts, S. (2004). Current chemotherapy of animal trypanosomiasis. In The 
Trypanosomiasis, I. Maudlin, P.H. Holmes, and M.A. Miles, eds. (Wallingnford, CABI International), pp. 431-451. 
Holzmüller, P., Grebaut, P., Peltier, J.B., Brizard, J.P., Perrone, T., Gonzatti, M., Bengaly, Z., Rossignol, M., Aso, 
P.M., Vincendeau, P., et al. (2008). Secretome of animal trypanosomes. Ann N Y Acad Sci 1149, 337-342. 
Hoover, D.M., Schalk-Hihi, C., Chou, C., Menon, S., Wlodawer, A., and Zdenov, A. (1999). Purification of receptor 
complexes of interleuken-10:Stoichiometry and the importance of deglycosylation in their crystallisation. Eur J 
Biochem 262, 134-141. 
Horn, M., Baudys, M., Voburka, Z., Kluh, I., Vondrasek, J., and Mares, M. (2002). Free-thiol Cys331 exposed 
during activation process is critical for native tetramer structure of cathepsin C (dipeptidyl peptidase I). Protein Sci 
11, 933-943. 
Huang, R., Que, X., Hirata, K., Brinen, L.S., Lee, J.H., Hansell, E., Engel, J., Sajid, M., and Reed, S. (2009). The 
cathepsin L of Toxoplasma gondii (TgCPL) and its endogenous macromolecular inhibitor, toxostatin. Mol Biochem 
Parasitol 164, 86-94. 
Jaspard, E. (2000). Role of protein-solvent interaction in refolding: Effects of cosolvents additives on the 
renaturation of porcine pancreatic elastase at various pHs. Biochem Biophys 375, 220-228. 
Jaye, A.B., Nantulya, V.M., Majiwa, P.A.O., Urakawa, T., Masake, R.A., Wells, C.W., and Ole-MoiYoi, O. (1994). 
A Trypanosoma (Nannomonas) congolense-specific antigen released into the circulation of infected animals is a 
thiol protease precursor. EMBL accession L25130. 
Jonak, C., Klosner, G., and Trautinger, F. (2009). Significance of heat shock proteins in the skin upon UV exposure. 
Front Biosci 14, 4758-4768. 
Joshi, S., Singh, A.R., Kumar, A., Misra, P.C., Siddiqi, M.I., and Saxena, J.K. (2008). Molecular cloning and 
characterization of Plasmodium falciparum transketolase. Mol Biochem Parasitol 160, 32-41. 
Kakundi, E.M. (2009). Molecular analysis of the congopain gene family. MSc Thesis. University of KwaZulu-Natal, 
Pietermaritzburg. 
Kang, H.K., Lee, H.Y., Lee, Y.N., Jo, E.J., Kim, J.I., Aosai, F., Yano, A., Kwak, J.Y., and Bae, Y.S. (2004). 
Toxoplasma gondii-derived heat shock protein 70 stimulates the maturation of human monocyte-derived dendritic 
cells. Biochem Biophys Res Commun 322, 899-904. 
Klemba, M., and Goldberg, D.E. (2002). Biological roles of proteases in parasitic protozoa. Annu Rev Biochem 71, 
275-305. 
Kleywegt, G.J., and Jones, T.A. (1996). Phi/psi-chology: Ramachandran revisited. Structure 4, 1395-1400. 
Kleywegt, G.J. (1997). Validation of protein models from Calpha coordinates alone. J Mol Biol 273, 371-376. 
Kongkerd, N., Uparanukraw, P., Morakote, N., Sajid, M., and McKerrow, J.H. (2008). Identification and 





Kopp, J., and Schwede, T. (2004). The SWISS-MODEL Repository of annotated three-dimensional protein structure 
homology models. Nucleic Acids Res 32, D230-234. 
Kristjanson, P.M., Swallow, B.M., Kruska, R.L., and Leeuw, P.N.D. (1999). Measuring the cost of African animal 
trypanosomosis, the potential benefits of control and returns to research. Agric Sys, 79-98. 
Kunkel, T.A. (1985). Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci 
U S A 82, 488-492. 
Kunkel, T.A., Roberts, J.D., and Zakour, R.A. (1987). Rapid and efficient site-specific mutagenesis without 
phenotypic selection. Methods Enzymol 154, 367-382. 
Kwong, P.D., Wyatt, R., Robinson, J., Sweet, R.W., Sodroski, J., and Hendrickson, W. (1998). Structure of an HIV 
gp120 envelope in complex with the CD4 receptor and a neutralising antibody. Nature 393, 648-659. 
Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 
227, 680-685. 
Lalmanach, G., Lecaille, F., Chagas, J.R., Authié, E., Scharfstein, J., Juliano, M.A., and Gauthier, F. (1998). 
Inhibition of trypanosomal cysteine proteinases by their propeptides. J Biol Chem 273, 25112-25116. 
Lalmanach, G., Boulange´ , A., Serveau, C., Lecaille, F., Scharfstein, J., Gauthier, F., and Authie´ , E. (2002). 
Congopain from Trypanosoma congolense: drug target and vaccine candidate. Biol Chem 383, 739-749. 
Lanfranco, M.F., Loayza-Muro, R., Clark, D., Nunez, R., Zavaleta, A.I., Jimenez, M., Meldal, M., Coombs, G.H., 
Mottram, J.C., Izidoro, M., et al. (2008). Expression and substrate specificity of a recombinant cysteine proteinase B 
of Leishmania braziliensis. Mol Biochem Parasitol 161, 91-100. 
Lazarevic, V., Myers, A.J., Scanga, C.A., and Flynn, J.L. (2003). CD40, but not CD40L, is required for the optimal 
priming of T cells and control of aerosol M. tuberculosis infection. Immunity 19, 823-835. 
Lecaille, F., Authie, E., Moreau, T., Serveau, C., Gauthier, F., and Lalmanach, G. (2001). Subsite specificity of 
trypanosomal cathepsin L-like cysteine proteases. Probing the S2 pocket with phenylalanine-derived amino acids. 
Eur J Biochem 268, 2733-2741. 
Lehner, T., Bergmeier, L.A., Wang, Y., Tao, L., Sing, M., Spallek, R., and van der Zee, R. (2000). Heat shock 
proteins generate beta-chemokines which function as innate adjuvants enhancing adaptive immunity. Eur J Immunol 
30, 594-603. 
Lesk, A.M. (1997). Extraction of well-fitting substructures: root-mean-square deviation and the difference distance 
matrix. Fold Des 2, S12-14. 
Li, S.Q., Fung, M.C., Reid, S.A., Inoue, N., and Lun, Z.R. (2007). Immunization with recombinant beta-tubulin 
from Trypanosoma evansi induced protection against T. evansi, T. equiperdum and T. b. brucei infection in mice. 
Parasite Immunol 29, 191-199. 




Lubega, G.W., Byarugaba, D.K., and Prichard, R.K. (2002). Immunization with a tubulin-rich preparation from 
Trypanosoma brucei confers broad protection against African trypanosomosis. Exp Parasitol 102, 9-22. 
Maachupalli-Reddy, J., Kelley, B.D., and De Bernardez Clark, E. (1997). Effect of inclusion body contaminants on 
the oxidative renaturation of hen egg white lysozyme. Biotechnol Prog 13, 144-150. 
Martinez, J., Campetella, O., Frasch, A.C., and Cazzulo, J.J. (1991). The major cysteine proteinase (cruzipain) from 
Trypanosoma cruzi is antigenic in human infections. Infect Immun 59, 4275-4277. 
Matthews, K.R., Ellis, J.R., and Paterou, A. (2004). Molecular regulation of the life cycle of African trypanosomes. 
Trends Parasitol 20, 40-47. 
Mbawa, Z.R., Gumm, I.D., Fish, W.R., and Lonsdale-Eccles, J.D. (1991a). Endopeptidase variations among 
different life-cycle stages of African trypanosomes. Eur J Biochem 195, 183-190. 
Mbawa, Z.R., Webster, P., and Lonsdale-Eccles, J.D. (1991b). Immunolocalization of a cysteine protease within the 
lysosomal system of Trypanosoma congolense. Eur J Cell Biol 56, 243-250. 
Mbawa, Z.R., Gumm, I.D., Shaw, E., and Lonsdale-Eccles, J.D. (1992). Characterisation of a cysteine protease from 
bloodstream forms of Trypanosoma congolense. Eur J Biochem 204, 371-379. 
McDermott, J.J., and Coleman, P.G. (2001). Comparing apples and oranges--model-based assessment of different 
tsetse-transmitted trypanosomosis control strategies. Int J Parasitol 31, 603-609. 
McGrath, M.E., Eakin, A.E., Engel, J.C., McKerrow, J.H., Craik, C.S., and Fletterick, R.J. (1995). The crystal 
structure of cruzain: a therapeutic target for Chagas' disease. J Mol Biol 247, 251-259. 
McKerrow, J.H., McGrath, M.E., and Engel, J.C. (1995). The cysteine protease of Trypanosoma cruzi as a model for 
antiparasite drug design. Parasitol Today 11, 279-282. 
McKerrow, J.H., Engel, J., and Caffrey, C.R. (1999). Cysteine protease inhibitors as chemotherapy for parasitic 
infections. Bioorg Med Chem 7, 639-644. 
McKerrow, J.H., Caffrey, C., Kelly, B., Loke, P., and Sajid, M. (2006). Proteases in parasitic diseases. Annu Rev 
Pathol 1, 497-536. 
Melo, F., and Feytmans, E. (1998). Assessing protein structures with a non-local atomic interaction energy. J Mol 
Biol 277, 1141-1152. 
Melville, S.E., Majiwa, P.A.O., and Tait, A. (2004). The African trypanosome genome. In The Trypanosomiasis, I. 
Maudlin, P.H. Holmes, and M.A. Miles, eds. (Wallingford, CABI International), pp. 39-57. 
Menard, R., Carmona, E., Takebe, S., Dufour, E., Plouffe, C., Mason, P., and Mort, J.S. (1998). Autocatalytic 
processing of recombinant human procathepsin L. Contribution of both intermolecular and unimolecular events in 
the processing of procathepsin L in vitro. J Biol Chem 273, 4478-4484. 
Mendoza-Palomares, C., Biteau, N., Giroud, C., Coustou, V., Coetzer, T., Authié, E., Boulangé, A., and Baltz, T. 
(2008). Molecular and biochemical characterization of a cathepsin B-like protease family unique to Trypanosoma 




Mewes, H.W., Albermann, K., Bahr, M., Frishman, D., Gleissner, A., Hani, J., Heumann, K., Kleine, K., Maierl, A., 
Oliver, S.G., et al. (1997). Overview of the yeast genome. Nature 387, 7-65. 
Michael, M., Gerber, S., Fetzer, J., and Folkers, G. (1997). Oligonucleotide-directed mutagenesis and subsequent 
expression of the corresponding recombinant proteins without changing the bacterial vector system. Pharm Acta 
Helv 72, 139-143. 
Michael, S.F. (1994). Mutagenesis by incorporation of a phosphorylated oligo during PCR amplification. 
Biotechniques 16, 410-412. 
Mkhize, P.P. (2003). Epitope mapping of a trypanosomal cysteine protease. MSc Thesis, University of KwaZulu-
Natal, Pietermaritzburg. 
Mkunza, F., Olaho, W.M., and Powell, C.N. (1995). Partial protection against natural trypanosomiasis after 
vaccination with a flagellar pocket antigen from Trypanosoma brucei rhodesiense. Vaccine 13, 151-154. 
Molgaard, A., Arnau, J., Lauritzen, C., Larsen, S., Petersen, G., and Pedersen, J. (2007). The crystal structure of 
human dipeptidyl peptidase I (cathepsin C) in complex with the inhibitor Gly-Phe-CHN2. Biochem J 401, 645-650. 
Momen, H. (2001). Some current problems in the systematics of Trypanosomatids. Int J Parasitol 31, 640-642. 
Morrison, W.I., Black, S.J., Paris, J., Hinson, C.A., and Wells, P.W. (1982). Protective immunity and specificity of 
antibody responses elicited in cattle by irradiated Trypanosoma brucei. Parasite Immunol 4, 395-407. 
Morty, R.E., Troeberg, L., Pike, R.N., Jones, R., Nickel, P., Lonsdale-Eccles, J.D., and Coetzer, T.H.T. (1998). A 
trypanosome oligopeptidase B as a target for the trypanocidal agents pentamidine, diminezene and suramin. FEBS 
Lett 433, 251-256. 
Morty, R.E., Authié, E., Troeberg, L., Lonsdale-Eccles, J.D., and Coetzer, T.H. (1999). Purification and 
characterisation of a trypsin-like serine oligopeptidase from Trypanosoma congolense. Mol Biochem Parasitol 102, 
145-155. 
Morty, R.E., Pelle, R., Vadasz, I., Uzcanga, G.L., Seeger, W., and Bubis, J. (2005). Oligopeptidase B from 
Trypanosoma evansi. A parasite peptidase that inactivates atrial natriuretic factor in the bloodstream of infected 
hosts. J Biol Chem 280, 10925-10937. 
Mottram, J.C., North, M.J., Barry, J.D., and Coombs, G.H. (1989). A cysteine proteinase cDNA from Trypanosoma 
brucei predicts an enzyme with an unusual C-terminal extension. FEBS Lett 258, 211-215. 
Mottram, J.C., Souza, A.E., Hutchison, J.E., Carter, R., Frame, M.J., and Coombs, G.H. (1996). Evidence from 
disruption of the lmcpb gene array of Leishmania mexicana that cysteine proteinases are virulence factors. Proc Natl 
Acad Sci U S A 93, 6008-6013. 
Mottram, J.C., Coombs, G.H., and Alexander, J. (2004). Cysteine peptidases as virulence factors of Leishmania. 
Curr Opin Microbiol 7, 375-381. 
Murray, M., d'Ieteren, G.D., and Taele, A.J. (2004). Trypanotolerance. In The Trypanosomiasis, I. Maudlin, P.H. 




Naessens, J. (2006). Bovine trypanotolerance: A natural ability to prevent severe anaemia and haemophagocytic 
syndrome? Int J Parasitol 36, 521-528. 
North, M.J., Mottram, J.C., and Coombs, G.H. (1990). Cysteine proteinases of parasitic protozoa. Parasitol Today 6, 
270-275. 
Otte, M.J., Abuabara, J.Y., and Wells, E.A. (1994). Trypanosoma vivax in Colombia: epidemiology and production 
losses. Trop Anim Health Prod 26, 146-156. 
Paling, R.W., Moloo, S.K., Scott, J.R., Gettinby, G., McOdimba, F.A., and Murray, M. (1991). Susceptibility of 
N'Dama and Boran cattle to sequential challenges with tsetse-transmitted clones of Trypanosoma congolense. 
Parasite Immunol 13, 427-445. 
Pamer, E., and Cresswell, P. (1998). Mechanism of MHC class I-restricted antigen processing. Annu Rev Immunol 
16, 323-358. 
Payne, R.C., Sukanto, I.P., Djauhari, D., Partoutomo, S., Wilson, A.J., Jones, T.W., Boid, R., and Luckins, A.G. 
(1991). Trypanosoma evansi infection in cattle, buffaloes and horses in Indonesia. Vet Parasitol 38, 109-119. 
Pelham, H.R. (1986). Speculations on the functions of the major heat shock and glucose-regulated proteins. Cell 46, 
959-961. 
Pike, R.N., and Dennison, C. (1989). Protein fractionation by three phase partitioning (TPP) in aqueous/t-butanol 
mixtures. Biotechnol Bioeng 33, 221-228. 
Pillay, D. (2008). A study of the variability of the congopain-like cysteine proteases of Trypanosoma congolense. . 
MSc Thesis. University of KwaZulu-Natal, Pietermaritzburg. 
Planelles, L., Thomas, M., Pulgar, M., Maranon, C., Grabbe, S., and Lopez, M.C. (2002). Trypanosoma cruzi heat-
shock protein-70 kDa,alone or fused to the parasite KMP11 antigen, induces functional maturation of murine 
dendritic cells. Immunol Cell Biol 80, 241-247. 
Playfair, J.H., Taverne, J., Bate, C.A., and de Souza, J.B. (1990). The malaria vaccine: anti-parasite or anti-disease? 
Immunol Today 11, 25-27. 
Playfair, J.H., Taverne, J., and Bate, C.A. (1991). Don't kill the parasite: control the disease. Acta Leiden 60, 157-
165. 
Prowse, R.K., Chaplin, P., Robinson, H.C., and Spithill, T.W. (2002). Fasciola hepatica cathepsin L suppresses 
sheep lymphocyte proliferation in vitro and modulates surface CD4 expression on human and ovine T cells. Parasite 
Immunol 24, 57-66. 
Quintas-Granados, L.I., Orozco, E., Brieba, L.G., Arroyo, R., and Ortega-Lopez, J. (2009). Purification, refolding 
and autoactivation of the recombinant cysteine proteinase EhCP112 from Entamoeba histolytica. Protein Expr Purif 
63, 26-32. 




Rico, A.I., Del Real, G., Soto, M., Quijada, L., Martinez, A.C., Alonso, C., and Requena, J.M. (1998). 
Characterization of the immunostimulatory properties of Leishmania infantum HSP70 by fusion to the Escherichia 
coli maltose-binding protein in normal and nu/nu BALB/c mice. Infect Immun 66, 347-352. 
Robert, J. (2003). Evolution of heat shock protein and immunity. Dev Comp Immunol 27, 449-464. 
Roditi, I., and Lehane, M.J. (2008). Interactions between trypanosomes and tsetse flies. Curr Opin Microbiol 11, 
345-351. 
Rogers, D.J., and Randolph, S.E. (2002). A response to the aim of eradicating tsetse from Africa. Trends Parasitol 
18, 1489-1499. 
Ruszczyk, A., Forlenza, M., Savelkoul, H.F., and Wiegertjes, G.F. (2008). Molecular cloning and functional 
characterisation of a cathepsin L-like proteinase from the fish kinetoplastid parasite Trypanosoma carassii. Fish 
Shellfish Immunol 24, 205-214. 
Saibil, H.R. (2008). Chaperone machines in action. Curr Opin Struct Biol 18, 35-42. 
Sajid, M., and McKerrow, J.H. (2002). Cysteine proteases of parasitic organisms. Mol Biochem Parasitol 120, 1-21. 
Sambrook, J., and Russell, D.W. (2001). Molecular Cloning: A Laboratory Manual. In, J. Sambrook, and D.W. 
Russell, eds. (Cold Springer Harbour: Cold Springer Harbour Laboratory Press), p. 1.53. 
Sanderson, S.J., Pollock, K.G., Hilley, J.D., Meldal, M., Hilaire, P.S., Juliano, M.A., Juliano, L., Mottram, J.C., and 
Coombs, G.H. (2000). Expression and characterization of a recombinant cysteine proteinase of Leishmania 
mexicana. Biochem J 347, 383-388. 
Sarkar, G., and Sommer, S.S. (1990). The "megaprimer" method of site-directed mutagenesis. Biotechniques 8, 404-
407. 
Sbicego, S., Vassella, E., Kurath, U., Blum, B., and Roditi, I. (1999). The use of transgenic Trypanosoma brucei to 
identify compounds inducing the differentiation of bloodstream forms to procyclic forms. Mol Biochem Parasitol 
104, 311-322. 
Schechter, I., and Berger, A. (1967). On the size of the active site in proteases. I. Papain. Biochem Biophys Res 
Commun 27, 157-162. 
Schijns, V.E. (2000). Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 12, 456-463. 
Schmidt, G.D., and Roberts, L.S. (1989). Order Kinetoplastida: Trypanosomes and their kin. In Foundations of 
Parasitology (USA, Times Mirror College Publishing), pp. 55-80. 
Schofield, C.J., and Maudlin, I. (2001). Trypanosomiasis control. Int J Parasitol 31, 614-619. 
Schofield, L. (2007). Rational approaches to developing an anti-disease vaccine against malaria. Microbes Infect 9, 
784-791. 
Schwede, T., Diemand, A., Guex, N., and Peitsch, M.C. (2000). Protein structure computing in the genomic era. Res 




Schwede, T., Kopp, J., Guex, N., and Peitsch, M.C. (2003). SWISS-MODEL: An automated protein homology-
modeling server. Nucleic Acids Res 31, 3381-3385. 
Serveau, C., Boulangé, A., Lecaille, F., Gauthier, F., Authié, E., and Lalmanach, G. (2003). Procongopain from 
Trypanosoma congolense is processed at basic pH: an unusual feature among cathepsin L-like cysteine proteases. 
Biol Chem 384, 921-927. 
Shaw, A.P.M. (2004). Economics of African trypanosomiasis. In The Trypanosomiasis, I. Maudlin, P.H. Holmes, 
and M.A. Miles, eds. (Wallingford, CABI International), pp. 369-402. 
Shi, J., Sivaraman, J., and Song, J. (2008). Mechanism for controlling the dimer-monomer switch and coupling 
dimerization to catalysis of the severe acute respiratory syndrome coronavirus 3C-like protease. J Virol 82, 4620-
4629. 
Sijwali, P.S., Brinen, L.S., and Rosenthal, P.J. (2001). Systematic optimization of expression and refolding of the 
Plasmodium falciparum cysteine protease falcipain-2. Protein Expr Purif 22, 128-134. 
Singh, M., and O'Hagan, D. (1999). Advances in vaccine adjuvants. Nat Biotechnol 17, 1075-1081. 
Singh, M., and O'Hagan, D.T. (2003). Recent advances in veterinary vaccine adjuvants. Int J Parasitol 33, 469-478. 
Singh, S.M., and Panda, A.K. (2005). Solubilisation and refolding of bacterial inclusion body proteins. J. Bio. 
Bioeng. 99, 303-310. 
Srivastava, P. (2002). Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of 
the innate and adaptive immune responses. Annu Rev Immunol 20, 395-425. 
Stevens, J.R., and Brisse, S. (2004). Systematics of trypanosomes of medical and veterinary importance. In The 
Trypanosomiasis, I. Maudlin, P.H. Holmes, and M.A. Miles, eds. (Wallingford, CABI International), pp. 1-23. 
Storni, T., Kundig, T.M., Senti, G., and Johansen, P. (2005). Immunity in response to particulate antigen-delivery 
systems. Adv Drug Deliv Rev 57, 333-355. 
Su, C., Duan, X., Wang, X., Wang, C., Cao, R., Zhou, B., and Chen, P. (2007). Heterologous expression of FMDV 
immunodominant epitopes and HSP70 in P. pastoris and the subsequent immune response in mice. Vet Microbiol 
124, 256-263. 
Suto, R., and Srivastava, P.K. (1995). A mechanism for the specific immunogenicity of heat shock protein-
chaperoned peptides. Science 269, 1585-1588. 
Suzue, K., and Young, R.A. (1996). Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune 
responses to HIV-1 p24. J Immunol 156, 873-879. 
Taylor, K.A. (1998). Immune responses of cattle to African trypanosomes: protective or pathogenic? Int J Parasitol 
28, 219-240. 
Taylor, K.A., and Authié, E. (2004). Pathogenesis of animal trypanosomiaisis. In The Trypanosomiasis, I. Maudlin, 




Thompson, J.D., Higgins, D.G., and Gibson, T.J. (1994). CLUSTAL W: improving the sensitivity of progressive 
multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. 
Nucleic Acids Res 22, 4673-4680. 
Tobian, A.A., Harding, C.V., and Canaday, D.H. (2005). Mycobacterium tuberculosis heat shock fusion protein 
enhances class I MHC cross-processing and -presentation by B lymphocytes. J Immunol 174, 5209-5214. 
Torr, S.J., Hargrove, J.W., and Vale, G.A. (2005). Towards a rational policy for dealing with tsetse. Trends Parasitol 
21, 537-541. 
Towbin, H., Staehelin, T., and Gordon, J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to 
nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76, 4350-4354. 
Turk, B., Turk, D., and Turk, V. (2000). Lysosomal cysteine proteases: more than scavengers. Biochim Biophys 
Acta 1477, 98-111. 
Turk, V., Turk, B., and Turk, D. (2001). Lysosomal cysteine proteases: facts and opportunities. Embo J 20, 4629-
4633. 
Uilenberg, G. (1998). A field guide for diagnosis, treatment and prevention of African animal Trypanosomosis. In  
(Rome, FAO Corporate document Repository). 
Urban, A., Neukirchen, S., and Jaeger, K.E. (1997). A rapid and efficient method for site-directed mutagenesis using 
one-step overlap extension PCR. Nucleic Acids Res 25, 2227-2228. 
Vale, G.A., and Torr, S.J. (2004). Development of bait technology to control tsetse. In The Trypanosomiasis, I. 
Maudlin, P.H. Holmes, and M.A. Miles, eds. (Wallingford, CABI International), pp. 509-523. 
Vale, G.A., and Torr, S.J. (2005). User-friendly models of the costs and efficacy of tsetse control: application to 
sterilizing and insecticidal techniques. Med Vet Entomol 19, 293-305. 
van Kooten, C., and Banchereau, J. (1997). Immune regulation by CD40-CD40-L interactions. Front Biosci 2, d1-
11. 
Vanhamme, L., Pays, E., McCulloch, R., and Barry, J.D. (2001). An update on antigenic variation in African 
trypanosomes. Trends Parasitol 17, 338-343. 
Vernet, T., Berti, P.J., de Montigny, C., Musil, R., Tessier, D.C., Menard, R., Magny, M.C., Storer, A.C., and 
Thomas, D.Y. (1995). Processing of the papain precursor. The ionization state of a conserved amino acid motif 
within the Pro region participates in the regulation of intramolecular processing. J Biol Chem 270, 10838-10846. 
Vickerman, K. (1969). The fine structure of Trypanosoma congolense in its bloodstream phase. J Protozool 16, 54-
69. 
Wang, S., Longo, F.M., Chen, J., Butman, M., Graham, S.H., Haglid, K.G., and Sharp, F.R. (1993). Induction of 
glucose regulated protein (grp78) and inducible heat shock protein (hsp70) mRNAs in rat brain after kainic acid 




Wang, Y., Kelly, C.G., Singh, M., McGowan, E.G., Carrara, A.S., Bergmeier, L.A., and Lehner, T. (2002). 
Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by 
the peptide binding fragment of heat shock protein 70. J Immunol 169, 2422-2429. 
Wells, G.A., Birkholtz, L.M., Joubert, F., Walter, R.D., and Louw, A.I. (2006). Novel properties of malarial S-
adenosylmethionine decarboxylase as revealed by structural modelling. J Mol Graph Model 24, 307-318. 
Wells, P.W., Emery, D.L., Hinson, C.A., Morrison, W.I., and Murray, M. (1982). Immunization of cattle with a 
variant-specific surface antigen of Trypanosoma brucei: influence of different adjuvants. Infect Immun 36, 1-10. 
Wendling, U., Paul, L., van der Zee, R., Prakken, B., Singh, M., and van Eden, W. (2000). A conserved 
mycobacterial heat shock protein (hsp) 70 sequence prevents adjuvant arthritis upon nasal administration and 
induces IL-10-producing T cells that cross-react with the mammalian self-hsp70 homologue. J Immunol 164, 2711-
2717. 
Williams, D.J., Naessens, J., Scott, J.R., and McOdimba, F.A. (1991). Analysis of peripheral leucocyte populations 
in N'Dama and Boran cattle following a rechallenge infection with Trypanosoma congolense. Parasite Immunol 13, 
171-185. 
Wilson-Welder, J.H., Torres, M.P., Kipper, M.J., Mallapragada, S.K., Wannwmuehler, M.J., and Narasimhan, B. 
(2008). Vaccine adjuvants: current challenges and future approaches. J Pharm Sci, 1-39. 
Wu, S., and Letchworth, G.J. (2004). High efficiency transformation by electroporation of Pichia pastoris pretreated 
with lithium acetate and dithiothreitol. Biotechniques 36, 152-154. 
Wyss, D.F., and Wagner, G. (1996). The structural role of sugars in glycoproteins. Curr Opin Biotechnol 7, 409-416. 
Yasuda, M., Murakami, Y., Sowa, A., Ogino, H., and Ishikawa, H. (1998). Effects of additives on refolding of a 









Nucleotide sequence alignment of the C2 mutants with wild-type full-length 
congopain (CP2). The sequencing of pGEM-T-C2 (H43W) and pGEM-T-C2 (K39F; 
E44P) was done in ILRI sequencing unit and the sequences were compared using 
Sequencher® 4.7 software (Gene Codes Corporation, 2006). 
 
 
 
